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Abstract 
 
Research supports the clinical and societal benefits of antiretroviral treatment 
(ART) for people living with HIV or AIDS (PLWHA). However, factors associated with 
ART adherence and the relationship of ART adherence to total healthcare expenditures 
are not well understood. 
The research data included Florida Medicaid claims for five years (July 2006 
through June 2011). All subjects (n=514) were HIV-positive, adult, non-pregnant, and 
ART naïve for at least 12 months prior to their 24 month measurement period. Each 
subject was categorized as adherent (>90%) or non-adherent (<90%) based upon 
medication possession ratios (MPR). Total expenditures were payments Medicaid made 
to providers and pharmacies. 
Objective 1 modeled the logit probability of a subject being non-adherent to ART 
(versus adherent). Certain factors were expected to have significant negative associations 
with non-adherence to ART, including females, older age group, AIDS diagnosis, 
adherence to antidepressants, severe mental illness, meeting the minimum recommended 
number of outpatient visits, ART regimen type, number of medications in the ART 
regimen, residing in a county with a high median income, and residing in a county with 
an urban population density. The variables expected to have significant positive 
associations included race/ethnicity, substance or alcohol abuse diagnosis, depression or 
 viii 
 
anxiety diagnoses, disease progression from HIV to AIDS, discontinuous Medicaid 
coverage, Medicaid eligibility type, and co-morbidity count levels. 
The Objective 1 results showed that all non-white race/ethnicity categories had at 
least twice the odds of being classified as non-adherent. Also, increasing numbers of 
concurrent ART medications significantly predicted non-adherence; the odds ratio for 
three to five ART medications was 2.04 (95% CI=1.04-4.01, p<.05), and six or more 
prescriptions category odds ratio was 4.58 (95% CI=1.82-11.56, p<.01), as compared to a 
single medication. Finally, a chronic diseases diagnosis was protective against non-
adherence (OR=.46, 95% CI=.26-.84, p<.01), as was adherence to antidepressants 
(OR=.28, 95% CI=.14-.54, p<.01). 
In Objective 2, it was expected that the ART adherence group, the explanatory 
variable, would have significantly less monthly mean total healthcare expenditures, the 
outcome variable. For each of the HIV-positive (n=232) and the AIDS-diagnosed 
(n=270) groups, a generalized linear model predicted the mean total expenditures for the 
ART non-adherence group (<90% MPR) versus the ART adherence group, controlling 
for other factors. For the HIV-positive subjects, the predicted mean total healthcare 
expenditures for the ART non-adherent group was $1,291 (95% CL $840-$2,004); the 
predicted mean for the adherent group was $1,926 (95% CL $1,157-$3,231). The 
difference was statistically significant, but the hypothesis was not supported. The non-
adherent group mean was less than the adherent group (-40%, p<.001). However, for the 
AIDS-diagnosed subjects, there was no statistical difference between the non-adherent 
and adherent groups. The predicted mean for the non-adherent group was $2,279 (95% 
CL $1,572-$3,322), and $2,005 (95% CL $1,387-$2,913) for the adherent group. 
 ix 
 
The findings of this research support the need for translating evidence on 
racial/ethnic disparities in ART adherence, along with behavioral, social, or cultural 
barriers and effective interventions, into policy and practice. Also, certain medication 
management strategies should be implemented to reduce the number of medications in 
ART regimen. Finally, the results of the present study underscores the necessity for 
appropriate financial incentives and purposeful risk-adjusted capitation payment 
structures that would support ART adherence among Medicaid-insured PLWHA. 
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Chapter One: Introduction / Statement of the Problem 
 
Antiretroviral medication therapy (ART) has transformed HIV/AIDS from an 
acute infectious disease with high mortality to a manageable chronic disease for which 
treatment adherence is vital (Dieffenbach & Fauci, 2011). Current research provides 
overwhelming support for the clinical and societal benefit of ART for certain people 
living with HIV or AIDS (PLWHA), as it reduces their viral load and decreases their HIV 
transmission risk (Reynolds et al., 2011). Unfortunately, below optimal adherence to 
ART predicts increased morbidity and mortality (Hogg et al., 2002; Lieb et al., 2002) and 
virologic failure (Maggiolo et al., 2005).  
However, the factors associated with ART adherence are not well understood. In 
spite of a plethora of published studies examining the factors associated with adherence 
to ART, only a small number of determinants are reliably statistically significant across 
studies (Reynolds, 2004). The key correlates most consistently associated with non-
adherence to ART are psychosocial variables, such as low patient self-efficacy, life stress 
or lack of social support and antiretroviral treatment-related factors, such as side-effects, 
inconvenience or regimen complexity (Ammassari et al., 2002). On the other hand, 
demographic factors (e.g., race and income), patient education interventions, psychiatric 
comorbidities (e.g., alcohol abuse, depression), patient-provider relationships are not 
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reliably associated with ART adherence. This research will examine determinants 
associated with ART non-adherence for PLWHA with Medicaid coverage. 
Despite agreements on clinical benefits to treatment, ambiguity surrounds cost 
savings related to ART adherence. Bozzette et al. (2001) and Nachega (2010) found that 
ART adherence was independently related to a reduction in healthcare expenditures, 
while Gardner et al. (2008) and Acurcio et al. (2006) found that improved adherence to 
ART was associated with an increase in total medical expenditures. These conflicting 
results represent a research opportunity for the present study.  
Inconsistent results such as these influence a broader debate of whether adherence 
to recommended care for chronic diseases is associated with decreased expenditures. 
Adding to the chronic disease care cost concern, medication adherence seems to have 
contradictory influences on costs for different diseases. For example, evidence shows that 
adherence to antidepressant medication is significantly related to increased near-term 
future costs (6 months following initiation) (Robinson et al., 2006). Similarly, children 
enrolled in Medicaid that were adherent to asthma medications incurred higher 
expenditures, despite having lower non-drug expenditures (Mattke, Boylston Herndon, 
Cuellar, Hong, & Shenkman, 2010). It has been postulated that the positive relationship 
of chronic disease medication adherence to increased costs may be due to improved 
access to needed services (Riegel, 2000).  
However, other chronic diseases show the opposite association of medication 
adherence to costs. Medicaid expenditures decreased for congestive heart failure patients 
who are adherent to their medication treatment (Esposito, Bagchi, Verdier, Bencio, & 
Kim, 2009). Also, Roebuck et al. (2011) found total savings associated to medication 
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adherence for conditions such as certain vascular conditions, congestive heart failure, 
hypertension, diabetes, and dyslipidemia were due to decreased inpatient costs, relative to 
the medication expenditures. Earlier cost studies regarding diabetes, hypertension, and 
high cholesterol all showed lower total medical costs were linked to higher condition-
specific medication adherence (Sokol, McGuigan, Verbrugge, & Epstein, 2005). These 
authors (2005) observed that savings were primarily due to the cumulative effects of 
sustained adherence over several years. Thus, it is unclear that efforts to assure adherence 
to recommended care for chronic diseases reduces total healthcare expenditures, 
especially in the near-term. 
The relationship of ART adherence to healthcare expenditures has current policy 
significance in Florida. In early 2011, Governor Rick Scott signed into law statewide 
expansion of Florida Medicaid managed care (Florida Statutes, 2011). This policy change 
involves the required enrollment of Medicaid recipients into managed care organizations. 
Through this financing system, managed care organizations are paid a set per member per 
month fee to coordinate the healthcare of their enrollees. While the implementation of a 
pilot program of Medicaid Reform has been successful in many respects (Landry, Lemak, 
& Hall, 2011), all risk-based payment systems suffer from unfortunate realities that are 
difficult or expensive to monitor by regulators (Eisenhardt, 1989). In the worst case, 
potentially unprofitable Medicaid recipients could be subjected to discrimination by 
managed care plans that may want to avoid enrolling them into their plan or to shirk 
expensive care management and/or quality improvement responsibilities that could 
improve their health (Van de Ven & Ellis, 2000). These prohibited behaviors may be 
exacerbated because of the inability of managed care organizations to collect data on the 
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long-term financial benefits of care management (i.e., prevention, treatment adherence) 
due to high membership turn-over typically found in Medicaid managed care (Short, 
Graefe, & Schoen, 2003). 
In response to these Medicaid managed care vulnerabilities, the Agency for 
Health Care Administration (AHCA), Florida’s Medicaid regulator, requires managed 
care organizations to conduct disease management programs (including HIV/AIDS) and 
report quality-related process measures (including ART utilization among enrollees 
diagnosed with AIDS) (Landry et al., 2011; Agency for Health Care Administration, 
2009). Currently, AHCA does not provide bonuses for meeting or exceeding the 
requirements, rather, the results are published for potential enrollees to review. Due to 
membership instability, regulations that offer weak financial incentives may not be 
enough to induce managed care organizations to invest in care management activities that 
will benefit the long-term health of members since the managed care organizations will 
not directly benefit in the near-term. 
This research determined the demographic, geographic, and clinical factors 
associated with ART non-adherence (versus ART adherence). Additionally, this research 
contributed to the evidence regarding the relationship of ART non-adherence to 
healthcare expenditures as compared to those subjects not adherent to ART. The main 
explanatory variable in this part of the research was ART non-adherence, and the 
outcome variables was total healthcare expenditures in a 24 month period.  
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Chapter Two: Review of the Literature 
 
ART adherence  
There is no recognized “gold standard” for measurement of adherence to ART 
(Mills et al., 2006). While researchers acknowledge that measurement of ART adherence 
relies heavily on the assumption that filling prescriptions is strongly correlated with  the 
patients actually taking the medicines (Reynolds, 2004), using pharmacy claims data has 
been found to be valid proxy for medication consumption (Steiner & Prochazka, 1997). 
Many studies measure ART adherence through pharmacy claims records (Grossberg & 
Gross, 2007), and those that investigate a dose-response relationship show significant 
relationship of ART adherence to both virologic failure (Smith, Rublein, Marcus, Brock, 
& Chesney, 2003) and mortality (Nachega et al., 2006). 
There is no consensus among researchers as to the best cut-off for ART adherence 
as a dichotomous measure. In a review of North American and Sub-Saharan African ART 
adherence studies from 1998 to 2006, 26 research teams defined adherence as 100%, 20 
greater than 95%, six as greater than 90%, and six as greater than 80% (Mills et al., 
2006). In the Mills et al. (2006) meta-analysis, large heterogeneity in adherence to ART 
(26% to 86%) existed across studies, accounting for different adherence measure 
thresholds. A pooled proportion of North American patients’ adherence to ART was 55% 
(95% CI, 0.49-0.62). Another study of 244 HIV-infected Medicaid-insured patients 
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showed that 60% of patients were adherent with >80% of their antiretroviral therapy in 
the past week, 43% were >90% adherent, and 29% were 100% adherent (Eldred, Wu, 
Chaisson, & Moore, 1998). In the subsequent multivariable analysis by Eldred et al. of 
the factors associated with ART adherence, the authors defined the values for the 
dependent variable as > 80% equal to adherent. Regarding demarcation of low adherence, 
Kitahata et. al (2004) created the categorical ART low adherence measure at below 70% 
MPR. The study showed significant differences in viral rebound and higher CD4 cell 
counts over 12–24 months, as compared to middle (70% to 90%) and high ART 
adherence groups (>90%). 
Complicating ART adherence measurement, recent data suggest that each 
regimen class may have different adherence-resistance relationships (Bangsberg, Kroetz, 
& Deeks, 2007). For example, a study by Maggiolo et al. (2005) found that when 
comparing NNRTI versus PI-based ART regimens, the level of adherence required to 
prevent of virologic failure was not equal. They found that at similar adherence rates, 
between 76%–99%, PI-based have a higher virologic failure rate than NNRTI-based 
regimens. Similarly, another study found that higher levels of adherence were required of 
PI-based to antiretroviral drug resistance compared to NNRTI-based regimens 
(Bangsberg, 2006). Together, these studies underscore the difficulty in drawing a “bright 
line” of dichotomous ART adherence, though numerous studies have done so in the past. 
When measuring ART adherence in categorical groups, as seen in Nachega et al. 
(2010) and Gardner et al. (2008) research, ART adherence was created by dividing the 
study sample into equal numbered quartiles. In these studies, quartiles were created with 
the highest adherence groups defined as 100% adherent, and the lowest adherence groups 
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measured at > 20%. Both studies analyzed the relationship of healthcare expenditures to 
ART adherence by comparing the lowest quartile expenditures to the highest quartile 
expenditures. 
Key factors associated with ART adherence 
Since the advent of antiretroviral medications in 1996, many researchers have 
investigated the problem of adherence to ART, most focused on identifying associated 
factors. While many factors have been identified by this research, few were reliably 
reproduced across studies (Reynolds, 2004). In fact, a review summarizing the results of 
20 studies scrutinizing ART adherence factors, only a handful of determinants were 
consistently and statistically related to non-adherence: treatment related symptoms and 
side-effects, stress, lack of social or family support, inconvenience and complexity of the 
treatment, and low patient self-efficacy (Ammassari et al., 2002). Other possible key 
determinants of decreased ART adherence include CD4 count, no outpatient visits 
(Gordillo, del Amo, Soriano, & González-Lahoz, 1999; Kleeberger et al., 2001), non-
white race (Kong, Nahata, Lacombe, Seiber, & Balkrishnan, 2012; Lillie-Blanton et al., 
2010; Zhang, Senteio, Felizzola, & Rust, 2013), younger age (Becker, Dezii, Burtcel, 
Kawabata, & Hodder, 2002), male sex, and geography (urban versus rural) (Chesney, 
2000). Also, the specific ART regimen, such as protease inhibitor-boosted versus 
NNRTI, (Altice, Mostashari, & Friedland, 2001; Trotta et al., 2002) and number of 
concurrent medications in regimen, showed an association to adherence, controlling for 
other factors (Bangsberg, Ragland, Monk, & Deeks, 2010; Kleeberger et al., 2001; Lazo 
et al., 2007; Maggiolo et al., 2005). 
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Outpatient care may be related to medication adherence among HIV/AIDS 
patients. Bakken et al. (2000) conceptualized engagement with a healthcare provider 
along multiple dimensions, including perceived access to healthcare provider. Also, 
according to the Primary Care Guidelines for the Management of Persons Infected with 
Human Immunodeficiency Virus, cell counts and low viral loads should be monitored 
every three to four months to monitor for drug toxicity and to assess response to ART 
(Aberg et al., 2009). Finally, Giordano et al. (2007) found that patients had visits to an 
HIV outpatient clinic at least once a quarter over four quarters had lower adjusted hazard 
ratio of mortality, as compared to those patients with three or less quarterly visits in the 
same period. 
Sustained case management interventions, such as education and counseling, have 
been found to improve ART adherence for PLWHA (Katz et al., 2001; Pradier et al., 
2003). For this research, the Project AIDS Waiver (discussed below) provided to some 
qualified Florida Medicaid AIDS patients has produced some evidence suggesting 
expenditure-reducing impact of case management services (Anderson & Mitchell, 1997). 
Also, alcohol abuse (AA), substance abuse (SA), depression, anxiety and 
somatoform diagnoses, antidepressant treatment adherence, and outpatient mental health 
treatment are important associated factors with ART adherence. Studies by Mellins et al. 
(2009), Hendershot et al. (2009) and Hicks et al. (2007) found a significant negative 
association between SA and/or AA and ART adherence. In addition, depression, anxiety 
and somatoform diagnoses are significantly negatively related to ART adherence 
(Horberg et al., 2008; Kleeberger et al., 2001; Tegger et al., 2008). Recent research by 
Horberg et al. (2008), Walkup et al. (2007), Dalessanro et al. (2007) and Yun et al. 
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(2005) found that adherence to antidepressants had a significantly positive relationship to 
ART adherence. Safren et al. (2009) found that outpatient mental health treatment 
increased the likelihood of ART utilization. 
On the other hand, severe mental illness (SMI), including schizophrenia and 
bipolar disorder, may have a positive relationship to ART adherence. Himelhoch et al. 
(2009) found that ART discontinuance was significantly lower for patients with SMI 
diagnoses, versus those without a SMI diagnosis. These results are consistent with 
evidence that providers are more likely to initiate ART for patients diagnosed with 
schizophrenia, if they are also receiving psychiatric care (Himelhoch, Powe, Breakey, & 
Gebo, 2007). It is believed that the positive relationship of SMI and ART adherence may 
be the result of improved care coordination provided to PLWHA in HIV specialty clinics 
(Ohl, Landon, Cleary, & LeMaster, 2008). 
While most research is focused on the association of mental illness comorbidities 
with HIV care, Crawford et al. (2013) found that patients with non-HIV co-occurring 
chronic diagnoses, including cancer, cardiovascular, cerebrovascular, respiratory, 
diabetes, or depression had significantly improved retention in care, as compared to those 
patients without any of those chronic disease diagnoses. Also, Giordano et al. (2007) 
found that PLWHA with comorbid condition had improved retention in HIV care, as 
compared to those without comorbidities. When reporting on retention to HIV care, the 
authors recognized that the relationship between retention in care to survival is mediated 
by adherence to ART. Finally, Webster (2010) in a study of HIV-infected veterans found 
that those subjects with cardiovascular disease had higher ART adherence than those 
without cardiovascular disease. 
 10 
 
Finally, there are multiple options for antiretroviral therapy regimens, and the 
treatment choice is dependent upon an individual patient’s clinical stage, other 
comorbidities and pharmaceuticals, and tolerance for various antiretroviral medication 
side-effects (Volberding, 2008). Research has found that there are varying ART 
adherence rates for different regimens, depending on specific pharmaceutical side-effects, 
number of pills, and complexity (Altice et al., 2001; Kleeberger et al., 2001; Trotta et al., 
2002). For example, Altice et al. (2001) found that a boosted protease inhibitor ART 
regimen was associated with a threefold higher risk for non-adherence, as compared to 
two NRTI combination therapies.    
ART adherence association with total healthcare expenditures 
Bozzette et al. (2001) and Nachega (2010) found that ART adherence was 
independently related to a reduction in expenditures. However, the researchers arrived at 
this conclusion using different study samples, methods and statistical techniques. 
Bozzette et al. (2001) assessed the relationship of ART use to total expenditures in a 28-
month survey that began in January 1996, just as the first protease inhibitors were 
prescribed. Using a U.S. probability sample from 28 cities plus 25 clusters of rural 
counties, the authors interviewed 2,864 HIV-infected adults. Self-reported information 
about use of protease inhibitors or non-nucleoside reverse-transcriptase inhibitors at four 
interviews - June 1996, March 1997, November 1997, and October 1998 - acted as 
independent variables. Pharmaceutical costs were estimated using prices from a national 
retail pharmacy, a federal distributor of drugs, and a hospital buying consortium. 
Antiretroviral medication costs represented 54% of total average costs among the study 
subjects in July 1998. Medical service expenditures were estimated from payments in 
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administrative records or cost-to-charge ratios from a third of hospitals and a quarter of 
outpatient service locations. Total monthly costs per patient for each of the four 
interviews, adjusted for 1996 U.S. dollars, acted as the dependent variables. 
Using this panel data, Bozzette et al. (2001) developed regression models to 
predict total expenditures, adjusting for the dates of each set of interviews, changes in 
clinical status and deaths, and such covariates as insurance coverage (including 
Medicaid), race, clinical stage, age, sex, education, region, risk group (e.g., intravenous 
drug use), and size of HIV practice of the treating physician. The authors found that total 
expenditures decreased from 1996 to 1998 for the sample of HIV patients; the differences 
between the 1997 and 1998 total expenditure estimates, however, were not significant. 
Predictors, such as public insurance coverage, PLWHA seeing physicians that care for 
more than 500 HIV patients, and PLWHA taking protease inhibitors or non-nucleoside 
reverse-transcriptase inhibitors, were related to a decrease in expected per patient 
monthly costs. The authors concluded that ART may reduce total expenditures by 
reducing hospital services in the near-term.  
Nachega (2010) assessed the effect of ART adherence on mean expenditures on 
6,833 HIV-infected South African adults who started ART during the study period. 
Adherence to ART was measured as the number of months with ART claims divided by 
the number of complete months from ART initiation to death, withdrawal, or study end, 
multiplied by 100 (called medication possession ratio). Adherence to ART was the 
categorized into quartiles of the sample, including 1st (20%), 2nd (60%), 3rd (85%), and 
4th (100%) quartiles. ART costs accounted for only 13% of total costs - a relatively low 
percentage compared to other studies discussed in this research. The average monthly 
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healthcare cost per patient per month, the dependent variable, was calculated as the total 
costs for the five-year follow-up period and divided by number of complete months from 
ART initiation to death, withdrawal from program, or study end.  
Using a logit function to account for the probability of nonzero costs, Nachega et 
al. (2010) then used a generalized linear model to predict the mean monthly per patient 
expenditures. Data analysis corrected for the heteroscedasticity of multiple measures per 
patient using Huber-White standard errors. The lowest quartile (20%) adherence variable 
was the reference quartile for the three other quartiles (100%, 85%, and 60%) in the 
analysis. Moving from lowest ART adherence quartile to higher adherence quartiles was 
associated with lower mean monthly healthcare costs suggesting that ART adherence on 
total expenditures exhibited a dose-response relationship. 
On the other hand, both of the Gardner et al. (2008) and Acurcio et al. (2006) 
found that improved adherence to ART was associated with an increase in total mean 
medical expenditures. Gardner et al. (2008) conducted a cross-sectional analysis using 
annualized cost data from 1997 and 2003 from an inner-city Denver hospital and 
associated HIV clinics. The adherence measure was calculated as the average of ART 
doses filled, divided by doses prescribed for the first 180 days after ART initiation. In 
addition to the continuous ART adherence variables, quartiles were created among the 
325 subjects - 1st (100%), 2nd (96.2% - 98.4%), 3rd (82.0% - 91.3%), and 4th (20.2% - 
65.6%). The mean annualized healthcare costs were also divided into quartiles. The costs 
calculated by using billed charges for services converted using Denver Health cost-to-
charge ratios adjusted for inflation to year 2005. The ART expenditure variable was 
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calculated using average wholesale pricing (AWP) for antiretroviral drug costs, 
representing 61% of the total average estimated costs.  
Gardner et al. (2008) conducted two statistical analyses. First, a multivariate 
logistic regression was fit using the highest expenditures quartile (versus other quartiles) 
acting as the dependent variable, ART adherence (percentage) as the continuous 
independent variable, while controlling for CD4+ cell counts, HIV-RNA levels, 
opportunistic illnesses and mortality. The regression results showed that for every 10% 
increase in ART adherence, the odds of a subject’s costs being in the highest quartile 
decreased by 20%. Second, the next analyses conducted were multiple ANOVAs 
comparing log-transformed annualized total medical costs across four adherence 
quartiles. For these comparisons, total medical costs were significantly lower for those 
with less than 65.6% adherence to ART (lowest quartile), as compared with the other 
adherence quartiles.  
Gardner et al. (2008) cautioned not to conclude that ART adherence is expensive, 
despite the positive relationship of ART adherence and total healthcare expenditures. 
Rather, they suggest that the positive relationship may be due to manufacturer pricing of 
the antiretroviral drugs in the United States. However, when they ran the same analysis at 
340B pricing levels - the federal HIV drugs purchasing program that reduced drug costs 
by 38% in this study - the positive relationship of ART adherence to increased costs 
remained. It was only at the generic drug pricing levels (3% of total healthcare costs) that 
the adherence to ART was related to cost savings. While generic formulations of 
antiretrovirals are available in many parts of the world, commercial patents prevent 
marketing most generic antiretroviral drugs in the United States (FDA, 2011).  
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Acurcio et al. (2006) also found that ART adherence significantly increased total 
healthcare expenditures. This cross-sectional study, conducted with 306 previously 
antiretroviral medication-naïve HIV-infected adults in Brazil, analyzed 9 months of 
claims data from the national Sistema Único de Saúde. The adherence to ART was 
measured through interviews asking the patient to self-report adherence in the previous 3 
days. Patients reporting equal to or greater than 95% of the prescribed doses for 3 days 
prior to the first follow-up visit were considered adherent. Total costs were measured 
through Brazilian national health system fee schedule for the year 2002. Inpatient 
expenditures were calculated as average cost of a hospital stay for the admitting 
diagnosis. Antiretroviral medications represented 94.6% of total average cost among the 
adherent patients and 90.0% among the non-adherent patients – the highest proportion of 
antiretroviral pharmaceutical costs among the four studies discussed in this research. 
Acurcio et al. (2006) conducted a multiple linear regression model to estimate the 
contribution that ART adherence and use of protease inhibitors (independent variables) 
had to total healthcare costs (dependent variable), controlling for other covariates, such as 
age, sex, race, marital status, education, individual and family income, private health 
insurance, initial clinical staging, initial CD4+  level. The researchers removed 
statistically insignificant variables (p > 0.05) from the final multiple regression analysis. 
Acurcio et al. (2006) also conducted a binary logit regression that examined the 
relationship of ART adherence to cost effectiveness. In their multiple regression analysis, 
the researcher found that adherence to ART was significantly associated with increased 
total healthcare costs.  
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Antiretroviral therapy background 
Beginning with the introduction of antiretroviral medication in 1987, remarkable 
advances have been made in the treatment of HIV (Dieffenbach & Fauci, 2011). In 
particular, the simplification of regimens for ART-naïve patients (those taking 
antiretroviral medications for the first time) have improved adherence by removing 
barriers such as frequency of dosing, food requirements, and other adverse effects 
(Bangsberg et al., 2010; Maggiolo et al., 2005; Nachega, Mugavero, Zeier, Vitória, & 
Gallant, 2011). The goal of ART is to suppress HIV replication, requiring simultaneous 
use of multiple drugs (Volberding, 2008). Typically, two nucleoside reverse transcriptase 
inhibitors (NRTI) are combined with either a) non-nucleoside reverse transcriptase 
inhibitors (NNRTI) or b) a boosted protease inhibitor (PI). Other less common 
antiretroviral medication classes include integrase strand transfer inhibitors (INSTI), 
chemokine receptor (e.g., CCR5), and fusion inhibitors (e.g., enfuvirtide) (Panel on 
Antiretroviral Guidelines for Adults and Adolescents, 2011). Also, a recent and 
preliminary study described the combination of INSTI and NNRTI drug classes, 
specifically raltegravir (INSTI) and etravirine (NNRTI), and found the combination as 
effective at controlling PLWHA viral load (Calin et al., 2012). In addition, although not 
yet recommended by the Panel on Antiretroviral Guidelines for Adults and Adolescents 
(2011), an alternate ART regimen combines PI and NNRTI in order to exclude NTRIs for 
select patients that may be resistant (Joly, Descamps, & Yeni, 2002; Tebas et al., 2007). 
This therapy choice is called “nucleoside-sparing” (Tebas et al., 2007). The choice of 
ART regimen combinations is dependent upon an individual patient’s clinical stage, other 
comorbidities and drugs, and tolerance for various antiretroviral medication side-effects 
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(Volberding, 2008). ART regimen decisions are relatively simple in early stages of HIV 
progression (so-called first-line regimens), but become more complex due to 
antiretroviral drug resistance and/or drug interactions with other disease treatments 
(Volberding, 2008). 
Successful multiple-drug combinations of ART began in the mid-1990s. Since 
that time numerous swings in the expert opinion regarding the appropriate time begin 
treatment ensued (Wilkin & Gulick, 2008). According to the Panel on Antiretroviral 
Guidelines for Adults and Adolescents (2011), ART should be initiated in all patients 
with a history of an AIDS-defining illness, with a CD4 count less than 350 cells/mm3, 
pregnancy, HIV- associated nephropathy, or hepatitis B virus (HBV) co-infection. 
Despite this, current opinion is split on whether to start ART earlier than at CD4 counts 
<350 cells/mm3. According to the expert opinion of the Working Group of the Office of 
AIDS Research Advisory Council Patients, a panel of the U.S. Department of Health and 
Human Services (2011), there are four cited reasons that opinions have shifted to earlier 
initiation of ART.  
First, at least one study demonstrated survival benefit with initiation of ART at 
CD4 count >500 cells/mm3. Also, if left untreated, HIV infection may be associated with 
comorbidities, such as cardiovascular disease, kidney disease, liver disease, and 
malignancy. Next, new ART regimens are more effective and convenient, but provide 
less side-effects than previous medications. Finally, evidence suggests that ART may 
reduce HIV transmission. Despite these justifications, the remaining 50% of the Panel 
(2011) thought that additional evidence is needed to recommend ART initiation >500 
cells/mm3 pointing to the risks of side-effects associated with antiretroviral drugs, ART 
 17 
 
non-adherence for asymptomatic patients, and potential development of antiretroviral 
drug resistance.  
In July 2006 the FDA approved AtriplaTM, a combination drug with three active 
antiretroviral medications, has been available as a single-tablet regimen (U.S. Food and 
Drug Administration, 2009). AtriplaTM includes a non-nucleoside reverse transcriptase 
inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTI) (Julg & 
Bogner, 2008). AtriplaTM is recommended as an option for simplifying first line regimen 
(U.S. Food and Drug Administration, 2009).  
Generic formulations of antiretroviral drugs are available in the marketplace. 
However, due to legal market protections, some of the generics that meet safety, efficacy, 
and manufacturing quality standards set by the FDA (“tentative approval”) cannot be sold 
in the United States (FDA, 2011). Table 2.1 below lists the generic antiretroviral drugs 
approved by the FDA that are marketed in the United States and whether the generic is 
offered to Florida Medicaid-insured PLWHA through the AHCA Preferred Drug List 
(PDL). 
 
TABLE 2.1: FDA approved generic antiretroviral drugs 
Drug Dose(s) 
FDA 
Approval 
AHCA PDL 
3/6/09 
AHCA PDL 
7/25/11 
Didanosine 10 mg 3/8/2007 No Yes 
Didanosine  125mg 9/24/2008 Yes Yes 
Didanosine  200mg/250mg/400mg  12/3/2004 Yes Yes 
Stavudine 15mg/20mg/30mg/40mg  12/29/2008 Yes Yes 
Stavudine  1mg/mL  12/29/2008 No Yes 
Zidovudine 50 mg/5mL 9/19/2005 Yes Yes 
Zidovudine 60 mg 7/23/2009 No No 
Zidovudine 100 mg 3/27/2006 Yes Yes 
Zidovudine 300 mg 9/19/2005 Yes Yes 
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Healthcare expenditures 
Total healthcare expenditures for Florida Medicaid among PLWHA were a focus 
of this research. Drivers of total healthcare expenditures for PLWA include comorbidities 
(Fakhraei, Kaelin, & Consiver, 2001) and HIV or AIDS disease clinical classification 
(Fleishman, Hsia, & Hellinger, 1994). In addition, Anderson and Mitchell (1997) 
concluded that Florida Medicaid Project AIDS Care (PAC) case management reduced 
total per-capita expenditures, principally because of reduced inpatient costs despite 
substantial increases in pharmaceutical costs. Although PAC waiver enrollees had higher 
drug spending, they represent only a fraction of the higher inpatient costs incurred by 
non-waiver enrollees. In a previous study, Anderson and Mitchell (1997) found that after 
controlling for selection bias and demographic factors, a 22% savings was associated 
with enrollment in the Florida PAC case management program. Finally, Bozzette et al. 
(2001) found that care provided by an HIV/AIDS specialist was significantly related to 
decreased expenditures for PLWHA - perhaps due to efficiencies gained through 
experience caring for PLWHA. 
The relationship of ART adherence and total healthcare expenditure-related 
variables is a main interest of this research. Across all HIV-severity levels, a substantial 
proportion of healthcare costs for HIV/AIDS in the United States can be attributed to 
antiretroviral medication (Bozzette et al., 2001; Gardner et al., 2008; Gebo et al., 2010). 
As discussed above, contradictory evidence has been published on the relationship of 
ART adherence on total healthcare expenditures. Bozette et al. (2001) and Nachega 
(2010) found that ART adherence was related to decreased expenditures, while Gardner 
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et al. (2008) and Acurcio et al. (2006) found ART adherence was related to increased 
costs. Another study (Fleishman, Gebo, et al., 2005) found that expenditures for inpatient 
and outpatient services for patients on ART were not significantly lower than patients not 
on ART. 
Inpatient utilization 
 Inpatient utilization comprises a large proportion of total medical costs in the 
United States. Among a nationally representative annual survey of approximately 15,000 
households (Medical Expenditure Panel Survey) in 2009 found that overall expenditures 
were primarily for inpatient treatment (31.3%), office-based visits (23.5%), and 
prescription medications (20.7%). For chronic conditions, the proportion of 
pharmaceutical costs relative to total medical expenditures (34.8%) outpaced inpatient 
treatment (29.9%) (Conway, Goodrich, Machlin, Sasse, & Cohen, 2011). 
Among New York Medicaid recipients diagnosed with HIV, Laufer et al. (2011) 
found that the 2007 inpatient care expenditures made up 50.2% of total costs for the high-
cost group (those over $100,000 annual total costs; median of $157,209/year), and 26.1% 
of total expenditures for medium-cost recipients (median of $24,800/year). According to 
Krentz and Gill (2010), for AIDS-diagnosed patients, 21% of the total healthcare costs 
were attributable to inpatient services in the first year. After the first year, mean annual 
costs decreased by 25% per year – mostly due to reduced inpatient costs attributed to 
active treatment. In subsequent years, inpatient costs account for less than 10%.  
Upon the introduction of ART in late 1995, inpatient admissions and length of 
stay (Mouton et al., 1997; Torres & Barr, 1997) and inpatient expenditures (Keiser, 
Nassar, Kvanli, et al., 2001b) decreased for PLWHA. Bozzette et al. (2001) and Nachega 
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et al. (2010) found that ART was accompanied by a significant reduction in inpatient 
utilization. Similarly, Fleishman et al. (2005) found that ART use was negatively related 
to inpatient admissions. This reduction in hospital use is consistent with research 
pertaining to increased adherence to medications for other chronic diseases, such as 
diabetes, hypertension, hypercholesterolemia, and congestive heart failure (Sokol et al., 
2005). Interestingly, Bozzette et al. (2001) found that after a decline after 18 months of 
ART hospital costs had increased to baseline levels. The researchers speculated that the 
increase may have been due to ART resistance. Still, consistent with the established 
theme, Bozzette et al. (2001) found that overall healthcare costs decreased in the two 
years after starting ART. 
The Anderson and Aday (1978) behavioral model on the determinants of 
healthcare utilization provides a framework for understanding variables associated with 
inpatient utilization. The behavioral model characterizes factors as predisposing (age, 
sex, race), enabling (travel circumstances) and need-based (perceived disability, 
diagnosis). Disease comorbidities are commonly included in healthcare utilization models 
as need-based drivers of inpatient care. For example, according to one study of the 
general HIV/AIDS population in the United States, HIV and hepatitis C virus (HCV) co-
infection prevalence was found to be 16.1% (Sherman, Rouster, Chung, & Rajicic, 2002). 
Since Gebo et al. (2003) found that patients co-infected with HIV-HCV were more likely 
to experience costly hospital admissions, HCV is a key comorbidity to be considered in 
this research. Also, an AIDS clinical classification (versus non-AIDS HIV), was found to 
be a predictor of hospitalization (Fleishman, Hsia, & Hellinger, 1994). 
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Comorbidities among PLWHA 
Depression, anxiety and somatoform disorder diagnoses are highly prevalent 
among PLWA. Research conducted in the United States in 2001 showed that 
approximately 36% of patients with HIV had major depression and that 15.8% had 
generalized anxiety disorder, and 10.5% suffered from panic attacks (Bing et al., 2001). 
A subsequent study found that 13% had a triple diagnosis: HIV, mood and/or anxiety 
disorders, and drug dependence symptoms and/or heavy drinking (Galvan, Burnam, & 
Bing, 2003).  
Considerable evidence demonstrates that depression, anxiety and somatoform 
diagnoses complicate the adherence to ART (Pence, 2009; Leserman, 2008; Walkup et 
al., 2007). Separate studies that examine depression (Horberg et al., 2008) and anxiety 
(Roux et al., 2009) diagnoses found significant negative association of those diagnoses to 
ART adherence, controlling for covariates.  
However, the relationship between psychiatric illnesses and antiretroviral 
treatment is complex (Ownby, 2010). It is possible that antiretroviral medications that 
impact the central nervous system may cause psychiatric side effects, such as depression 
and anxiety (Treisman & Kaplin, 2002). The non-nucleoside reverse-transcriptase 
inhibitor, efavirenz, has been linked to neuropsychiatric disorders, such as depression, 
mood changes, irritability, nervousness, and anxiety (Fumaz et al., 2005; Rihs et al., 
2006). Case reports compiled by Cespedes and Aberg (2006) indicate that other ART 
component drugs (i.e., Zidovudine, Abacavir, Nevirapine) may be related to 
neuropsychiatric reactions, including depression, agitation, and anxiety. 
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On the other hand, the treatment of depression, anxiety and somatoform disorder 
diagnoses appears to be positively associated with ART adherence. A randomized 
controlled study by Safren et al. (2009) showed that PLWHA that received cognitive 
behavioral therapy in an outpatient setting had an increased likelihood of ART utilization. 
Also, a 2007 study found for those HIV-positive individuals with an antidepressant 
prescription, the odds of current-month antiretroviral adherence were increased by almost 
30% for those with antidepressant use in the prior month, after controlling for other 
factors (Walkup et al., 2007). Research by Horberg et al. (2008) and Yun et al. (2005) 
confirmed that antidepressant utilization improved adherence to ART. 
The presence of a co-occurring mental illness diagnoses has been associated with 
significantly greater healthcare expenditures and utilization for PLWHA (Henk, 
Katzelnick, Kobak, Greist, & Jefferson, 1996; Katon, Lin, Russo, & Unutzer, 2003; 
Koopmans, Donker, & Rutten, 2005; Stein, Cox, Afifi, Belik, & Sareen, 2006; Wittchen, 
2002). Similar studies regarding other chronic diagnoses show increased costs associated 
with mental illness (Egede, Zheng, & Simpson, 2002; Richardson et al., 2006). It is 
thought that these increased costs may not be directly related to mental illness treatment, 
but rather a consequence of increased overall medical service utilization (Simon, 2003).  
Hansen et al. (2002) found that patients with depression or anxiety diagnoses had 
more than three times increased odds for being high-users of non-psychiatric inpatient 
care, as compared with patients without psychiatric diagnoses, controlling for disease 
severity. (Somatoform disorders had more than six times increased odds). Also, there is 
evidence that anxiety or depression are significantly associated with increased inpatient 
utilization (Grabe, Baumeister, John, Freyberger, & Völzke, 2009).   
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Several recent studies have examined the association of non-HIV chronic diseases 
to HIV care and showed that those with one or more non-HIV chronic disease diagnosis 
was associated with improved measures of care, including ART adherence and retention 
in care (Crawford et al., 2013; Giordano et al., 2007; Webster, 2010). Prevalent chronic 
diseases include hypertension COPD, hepatitis C, diabetes, asthma, chronic ischemic 
heart disease, cardiac insufficiency and myocardial infarction, osteoarthritis, chronic 
kidney disease, shingles and peripheral neuropathy (Gingo et al., 2012; Kim et al., 2012; 
Vance, Mugavero, Willig, Raper, & Saag, 2011). 
Hepatitis B (HBV) and C (HCV) co-infection is high among individuals 
diagnosed with HIV or AIDS. Hepatitis and HIV infection share pathways of 
transmission, such as sexual transmission and intravenous drug use (Qurishi et al., 2003). 
According to one study of the general HIV/AIDS population in the United States, HIV-
HCV co-infection prevalence was found to be 16.1%, and among high risk subjects 
(defined by drug use or hemophilia and <100 cells/µl), 100% were infected with HCV 
(Sherman et al., 2002). Also, a study by Braitstein et al. (2006) found that PLWHA co-
infected with HCV were significantly less likely to be adherent to ART (42%) than those 
without HCV (72%). Sub-optimal adherence may be due to hepatic toxicity associated 
with ART (Melvin, Lee, Belsey, Arnold, & Murphy, 2000).  
Florida Medicaid and HIV/AIDS  
According to the latest estimates, prevalence of HIV in the United States is 
approximately 1.1 million individuals (CDC, 2010). As of 2010, Florida had reported 
117,612 cumulative AIDS cases, and is the third highest in cumulative reported AIDS 
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cases the U.S. (CDC, 2010). According to Florida state records, an estimated 6,000 new 
HIV cases are diagnosed each year (Florida Department of Health, 2009).  
According to Kaiser Family Foundation (2009), Medicaid covers more people 
diagnosed with HIV than all other insurance type, and that PLWHA are three to four 
times more likely to be covered by Medicaid than the U.S. population overall. An HIV-
positive status does not necessarily mean that individuals qualify for Medicaid, so they 
must become disabled from the disease to obtain Medicaid coverage (Kaiser Family 
Foundation, 2009). In fact, most individuals diagnosed with HIV who qualify for 
Medicaid are low-income and disabled, and qualify for Medicare Supplemental Security 
Income (SSI) benefits (Kaiser Family Foundation, 2004). Most adults diagnosed with 
HIV/AIDS are eligible for Medicaid because they are both low-income (below 75% of 
the federal poverty level) and permanently disabled, as defined by the U.S. Social 
Security Administration (“Social Security for People Living with HIV/AIDS,” 2005). 
Many that are newly diagnosed with HIV are already enrolled in Medicaid (Kaiser 
Family Foundation, 2009). Individuals that qualify for Medicare, AIDS Drug Assistance 
Programs (ADAP), or commercial insurance were not included as subjects in this 
research. 
Florida Medicaid is administered and financed by the Agency for Health Care 
Administration (AHCA). The Florida Medicaid programs include traditional fee-for-
service (FFS), pre-paid mental health plans (PMHP), primary care case management 
(MediPass). Within the FFS financing strategy, AHCA pays healthcare providers directly 
for the services rendered to Medicaid recipients. AHCA contracts with pre-paid mental 
health plans (PMHP) to coordinate mental health benefits. These PMHPs are paid 
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capitation by AHCA to coordinate mental health services, but all other services are paid 
by AHCA through the FFS claims system. AHCA also contracts with MCOs and similar 
managed care organizations to coordinate care to Medicaid enrollees. As of June 2011, 
these managed care organizations enrolled 46% of the total Medicaid recipients in Florida 
(Agency for Health Care Administration, 2011). For most of Florida Medicaid recipients, 
enrollment into managed care was optional. However, in 2006 AHCA implemented the 
Florida Medicaid Reform pilot in two AHCA geographic regions, Areas 4 and 10, in 
which enrollment into managed care was mandatory. Finally, within the MediPass 
program, primary care providers were paid a small monthly case management capitation 
fee ($3.00), but were reimbursed for services delivered via Medicaid FFS. 
In addition to the financing strategies described above, AHCA also conducts 
various waivers, including a disease management program for Medicaid recipients 
diagnosed with AIDS. The Florida Project AIDS Care waiver (PAC) can be categorized 
as a FFS financing strategy with supplemental disease management funded by AHCA for 
6,000 patients diagnosed with AIDS (Anderson & Mitchell, 2000).  
 
  
 26 
 
 
 
 
Chapter Three: Methods 
 
Among ART-naïve PLWHA enrolled in Florida Medicaid (excluding Medicaid 
managed care enrollees), the objectives of this research were a) to assess the determinants 
of non-adherence to ART and b) to analyze the association of ART non-adherence to 
healthcare expenditures.   
Data 
The data for this research included Florida Medicaid fee-for-service (FFS) claims 
and Prepaid Mental Health Plans (PMHP) encounters for five fiscal years (July 2006 
through June 2011). Managed care encounter data were excluded. Claims data included 
diagnosis codes (ICD-9), procedure codes (CPT), condition codes (V codes), and 
pharmaceutical codes (NDC). In the Medicaid FFS administrative claims set, inpatient 
claims data included up to five diagnoses, and outpatient claims included only one 
diagnosis. The enrollment data included demographics (age, sex, race, and eligibility 
status), third party coverage periods, Medicaid coverage periods, and Medicaid 
disenrollment reason (including death).  
Sampling methods and inclusion criteria 
Identification of HIV-positive individuals for this research was made through an 
algorithm based on specific diagnosis, procedure, and pharmaceutical codes - the same 
algorithm used by Florida Medicaid in the Reform Pilot (Hidalgo, 2009). The algorithm 
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examined claims data for any combination of the procedure codes, NDC drug codes or 
primary diagnosis codes. If there were two or more matches with the relevant procedure, 
diagnosis or drug codes (NDCs) in different months, then the member was classified as 
having HIV. If any of the secondary diagnosis codes, such as opportunistic infections 
(e.g. candidiasis of lung) or other AIDS-related conditions (e.g. Kaposi's Sarcoma) were 
present, then the patient was classified as having an AIDS-diagnosis. Also, subjects 
enrolled into the Project AIDS Care waiver, according to the enrollment data were 
considered as diagnosed with AIDS.   
This research included non-pregnant adults ages 18 through 64 only. Claims for 
patients identified as having been diagnosed with HIV or AIDS were reviewed for at least 
one treatment with antiretroviral therapy (defined below). Subjects were excluded if 
patient was not antiretroviral treatment-naïve for 12 months prior to the 24 month 
measurement period. Treatment naïve was defined as any patient having not initiated 
ART for 12 months prior to the measurement period.  
Recipients with less than six months of FFS activity (i.e., managed care 
financing) were excluded, and subjects with lapses greater than 3 months per year in the 
measurement period were excluded. Medicaid managed care data was not available for 
this research. Any recipient with Medicare coverage were excluded, as the healthcare 
claims were paid though different financing mechanism.   
Individuals with hemophilia or von Willebrand disease, a disease that sometimes 
requires very expensive factor replacement therapy were excluded from Objective 2 of 
this research. Florida Medicaid state policy requires individuals with these diagnoses to 
enroll in a 1915(b) Medicaid waiver disease management program. Florida Medicaid 
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purchases the factor replacement therapy medications from one of the two state 
contracted vendors. This rule applies to individuals in fee-for-service and managed care 
programs (Agency for Health Care Administration, 2012). Two subjects were in the ART 
adherent group (1 HIV, 1 AIDS) and ten in the non-adherent group (1 HIV, and 9 AIDS). 
The following table describes the research selection criteria variables measures in 
more detail. 
TABLE 3.1: Analysis variables 
Measure Measure Statement Level of 
Measurement 
Reference 
Antiretroviral 
medication 
therapy 
(ART_flag) 
An instance of an 
antiretroviral ndc. (see 
Appendix A1). 
Dichotomous, with 
values of 1 if ART 
prescription measure 
is met, and 0 if not.  
Nachega et 
al. (2010); 
Castillo et al. 
(2004) 
ART naïve 
(NAIVE) 
No ART_flag prescription 
refills in reference year. 
Dichotomous, with 
values of 1 if ART 
naïve, and 0 if not. 
Bozzette et 
al. (2001) 
Medication 
possession ratio 
(MPR) 
Filling prescriptions 
strongly correlated with  
medication consumption, 
and using pharmacy claims 
data has been found to be 
valid proxy for medication 
consumption 
MPR was calculated 
as the number of 
days with ART 
prescriptions filled 
divided by the 
number of days in 
measurement period 
(24 months). 
Reynolds 
(2004); 
Steiner & 
Prochazka 
(1997); 
Esposito et al. 
(2009) 
HIV diagnosis Two or more matches with 
the HIV/AIDS procedure, 
diagnosis or drug codes 
(NDCs) in different months 
of the measurement year or 
24 prior months. See 
Appendix Table A1. 
Dichotomous, with 
values of 1 if the 
patient is diagnosed 
with HIV, and 0 if 
not. 
Hidalgo 
(2009) 
AIDS diagnosis An HIV diagnosis AND 
any secondary diagnosis 
codes in the measurement 
year or 24 prior months. 
(See Appendix Table A3.) 
A recipient enrolled in the 
AIDS PAC Waiver was 
defined as AIDS. 
Dichotomous, with 
values of 1 if the 
patient is diagnosed 
with AIDS, and 0 if 
not. 
Hidalgo 
(2009) 
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Continued, TABLE 3.1: Analysis variables   
HIV positive in 
reference year 
(HIV_REF) 
HIV positive in reference 
year, as defined by presence 
of HIV and/or AIDS 
diagnosis variables (above). 
Dichotomous, with 
values of 1 if the 
patient is HIV+ in 
reference year, and 0 
if not HIV+. 
 
Patient death 
(DEATH) 
Flagged as death in 
enrollment file.  
Dichotomous, with 
dummy values of 1 if 
the patient dies for 
each of the 
measurement years, 
and 0 if living. 
 
Project AIDS 
Care waiver 
enrollment or 
case 
management 
services (PAC) 
Case management 
intervention improves ART 
adherence 
Dichotomous; 
Presence of PAC 
flag in AHCA 
enrollment files 
equal to 1; if not 
then equal to 0 
Pradier et al. 
(2003); Katz 
et al. (2001) 
 
Calculating healthcare expenditures 
Healthcare expenditures were calculated as the amount that Medicaid paid to 
providers and pharmacies for services (not charges), as indicated in the administrative 
claims data for FFS and encounters for PMHPs. The analysis was conducted from the 
perspective of Florida Medicaid, and therefore, did not include indirect costs. 
Pharmaceutical pricing is defined below.  
Missing data due to lapses in Medicaid coverage 
Missing data is a challenge when using any public health database (Rubin, 1996). 
The primary source of missing data when analyzing the Medicaid FFS claims and PMHP 
encounter data for this research will be lapses in Medicaid coverage. Estimates from 
Florida Medicaid administrative data reveal that about 7% of recipients with chronic 
conditions (diabetes and depression) have at least a month in lapsed coverage (Hall, 
Harman, & Zhang, 2008; Harman, Hall, & Zhang, 2007). Thus, considering the 
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documented range of Medicaid enrollment churn, it is possible that lapses in Medicaid 
coverage may approach 10% of the subjects for this research. 
Therefore, subjects with enrollment lapses greater than three months in a year 
were excluded, as this research assumed that the subject accessed needed care through 
other sources. Patients with lapses in coverage equal to or less than three months within 
the measurement period were coded with a “discontinuous coverage” dummy variable to 
account for some of the unmeasured effects associated extended lapses in coverage. This 
three month cut-off corresponds to “short” (one to two months) or “moderate” (three to 
six months) lapses in Medicaid coverage, as described by Harman et al. (2007). 
Furthermore, subjects that lose eligibility and do not later regain coverage were excluded, 
as it was assumed that the subject obtained coverage and possibly antiretroviral drugs 
through other sources. Those subjects with gaps in coverage of equal to or less than three 
months were included in the sample. The denominator of the medication possession ratio 
measure was counted the same as those without enrollment lapses, as those individuals 
with short gaps can be reasonably assumed to be non-adherent to ART during the lapse 
period.  
Descriptive statistics 
Descriptive statistics will be calculated for the study subjects. First, baseline 
characteristics for the first ART adherence measurement year (2006) were reported for all 
covariates, such as clinical classification (HIV/AIDS), race, sex, and selected 
comorbidities (e.g., depression, anxiety, hepatitis C). In addition, patient characteristics at 
ART initiation baseline for all variables by ART adherence - both > 90% versus < 90% 
were reported. Comparisons between groups were made between groups using 
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appropriate nonparametric tests (Hirsch, Rosenquist, Best, Miller, & Gilmer, 2009). 
Standard tests, such as t tests and analysis of variance, will not be reported for 
expenditures, as these tests were not appropriate for mean cost comparisons because of 
likely non-normality (Nachega et al., 2010). 
Inferential statistical analysis 
The purposes of this research were to a) determine the effect of independent 
factors on the probability of ART non-adherence and b) model the relationship between 
those not adherent to ART and mean monthly total healthcare expenditures per patient for 
ART-naïve subjects, controlling for covariates described below. Two different objectives 
will be accomplished: 1) determine the factors that influence the probability a patient will 
be non-adherent to ART, and 2) estimate the mean per patient total healthcare 
expenditures for the measurement period. 
Objective 1: Overview 
 Objective 1 assessed the independent determinants of non-adherence to ART 
among Medicaid-insured treatment-naïve PLWHA using retrospective Florida claims 
data.  
Objective 1: Hypotheses 
ART non-adherence will be significantly and negatively associated with counties 
with high median income counties, urban county residence, female sex, age groups, 
AIDS diagnosis, non-adherence to antidepressants, severe mental illness, meeting 
minimum recommended average outpatient visits and ART regimen type; and 
significantly and positively associated with race/ethnicity, substance abuse diagnosis 
and/or alcohol abuse diagnosis, depression or anxiety diagnosis, disease progression from 
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HIV to AIDS, Medicaid eligibility type, discontinuous Medicaid enrollment and co-
morbidity count levels.  
Objective 1: Determinants of ART non-adherence 
 Adherence will be measured by a medication possession ratio of greater than or 
equal to 90%; non-adherence will be less than 90%. A medication possession ratio 
(MPR) is calculated as the number of days with ART prescriptions filled divided by the 
measurement period. Dummy variables will be created for the ART non-adherence 
outcome variable, coded as zero where the patient MPR for the 24 month ART 
measurement period is greater than or equal to 90%, and coded to one otherwise.  
In this objective, a one-equation multi-variable logistic regression model was used 
to predict the effect of each factor’s effect on the odds of a given patient will be non-
adherent to ART. The logistic regression model uses the inverse standard normal 
distribution to predict cumulative probability of a binary outcome (ART adherent versus 
not ART adherent) specified as a function of a set of predictor variables (Molenberghs & 
Verbeke, 2005). The results of the model presented the odds of an explanatory variable 
on non-adherence to ART, when controlling for other independent variables. 
The multivariable logistic regression model is as follows, where Pr is logit 
probability of a subject being non-adherent to antiretroviral therapy (ART): 
Logit Pr(NO_ART) = α + β1age_group1 + β2 age_group2 + β3County_low + β4County_urban  +  β5male_sex 
+ β6black + β7Hispanic_RE + β8Other + β9SSI + β10ENG + β11DEP_ANX + β12AASA + β13PAC + β14SMI + 
β15OPMH + β16MIRx + β17COM1 + β18AIDS + β19CHURN + β20NNRTI + β21Single_ARTClass + β22Rx_N2  +  
β23Rx_N3 + β24Rx_N4 + β25DXP +  ε  (1) 
  
 33 
 
Where the parameters are: 
1. Age_group1 = 18–34 year age group 
2. Age_group2 = 35–49 year age group 
3. County_Low = low median income county 
4. County_Rural = rural county 
5. Male_Sex = male sex  
6. Black = black race, non-Hispanic 
7. Hispanic_RE = Hispanic race and/or ethnicity 
8. Other_Race = race not determined, Native American, Alaskan Native and Asian 
9. SSI = Social Security Income Medicaid eligibility category 
10. ENG = engagement with provider, (> 4 annual outpatient visits mean) 
11. DEP_ANX = depression and/or anxiety diagnosis 
12. AASA = alcohol abuse and/or substance abuse diagnosis 
13. PAC = Project AIDS Care case management waiver or case management procedures 
14. SMI = severe mental illness diagnosis 
15. OPMH = Cognitive behavioral therapy outpatient mental health services 
16. MIRx_yes = 2 or more antidepressant prescription claims 
17. COM1= one or more non-HIV chronic disease diagnosis 
18. AIDS = AIDS-diagnosis status 
19. CHURN = Medicaid enrollment gap in 1 to 3 months within year 
20. NNRTI = non-nucleoside reverse transcriptase inhibitor antiretroviral therapy  
21. Single_ART_class = Antiretroviral medication regimen containing only one drug 
class (e.g., INSTI, nuc-sparing and single ART) 
22. Rx_N2 = two concurrent ARV medicines in first month of ART 
23. Rx_N3 = three to five concurrent ARV medicines in first month of ART 
24. Rx_N4 = six or more concurrent ARV medicines in first month of ART 
25. DxP = Disease progression from HIV to AIDS 
 
The following variables have been identified as related to ART adherence. 
TABLE 3.2: Objective 1 model variables 
Variable Theoretical 
consideration Measurement Reference(s) 
ART adherence 
(ART1) 
Outcome variable. 
No consensus among 
researchers as to the 
best dichotomous 
cut-off for ART 
adherence.  
Dichotomous; 
Medication possession 
ratio (MPR) greater than 
or equal to 90%, then 
coded 1 if the patient is 
adherent to ART, and 0 if 
not adherent. 
Mills et al. 
(2006) 
Sex (SEX) Male sex associated 
with non-adherence 
to ART 
Dichotomous, with value 
of 0 if male and 1 if 
female 
Chesney (2000) 
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Continued, TABLE 3.2: Objective 1 model variables 
Age group 
(AGE) 
Younger age 
associated with non-
adherence to ART 
 
Categorical; Measured 
on July 1 of reference 
year. Age groups, 18–34 
(reference), 35–49, and 
50 years or older 
Becker et al. 
(2002); 
Chesney 
(2000); Laine 
et al. (2000);  
County Median 
Income 
(County_High, 
County_Low) 
Evidence describes 
substantial variation 
in healthcare 
spending 
independently 
associated with 
geography 
Categorical; defined by 
U.S. Census Bureau, 
2005-2009 American 
Community Survey, 
divided into 2 groups by 
median household 
income; lower county 
group is reference; See 
Appendix Table A4 
 
Race and 
Ethnicity 
(RACE) 
Non-white race 
associated with non-
adherence to ART 
Categorical; white 
(reference), black, 
Hispanic race and/or 
ethnicity, Other 
(including Not 
Determined, Native 
American, and Asian); 
dummy variables for 
each category 
Kleeberger 
(2001) 
Supplemental 
Security 
Income-related 
disability (SSI) 
Temporary 
Assistance for 
Needy Families 
(TANF) versus SSI 
Dichotomous; presence 
of SSI eligibility status 
then equal to 1; if not 
then equal to 0 
 
Depression, 
anxiety or 
somatoform 
diagnoses 
(DEP_ANX) 
Depression, anxiety 
or somatoform 
diagnoses associated 
with decreased ART 
adherence 
Dichotomous; presence 
of depression, anxiety or 
somatoform diagnoses 
then equal to 1; if not 
then equal to 0 (see App. 
Table A5) 
Gordillo et al. 
(1999), 
Kleeberger 
(2001), Horberg 
et al. (2008) 
Alcohol abuse 
and/or substance 
abuse (AASA) 
Adherence to ART is 
negatively associated 
with alcohol abuse 
and substance abuse 
Dichotomous; Presence 
of alcohol abuse and/or 
substance abuse 
diagnosis equal to 1; if 
not then equal to 0 (see 
App. Table A5) 
Chesney 
(2000), Hinkin 
et al. (2007) 
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Continued, TABLE 3.2: Objective 1 model variables 
Severe mental 
illness (SMI) 
Increases ART 
adherence, possibly 
through improved 
care coordination 
Dichotomous; Presence 
of 1 or more severe 
mental illness diagnosis 
then equal to 1; if not 
then equal to 0 (see App. 
Table A5) 
Bogart et al. 
(2006) 
 
 
Outpatient 
mental health 
treatment 
(OPMH) 
Mental health 
therapy increased the 
likelihood of ART 
utilization 
 
Dichotomous; > 1 
Cognitive Behavioral 
Health Therapy visits in 
measurement period 
equal to 1; if not then 
equal to 0 
Safren et al. 
(2009)  
Adherence to 
antidepressants 
(MIRx) 
Adherence to 
antidepressant 
medications 
improves adherence 
to ART  
Dichotomous; If 2 or 
more Rx and > 80% 
MPR equal to 1; if not 
then equal to 0  
Horberg et al. 
(2008); Walkup 
et al. (2007); 
Yun et al. 
(2005) 
Co-occurring 
chronic disease 
diagnosis  
Co-occurring chronic 
diseases (e.g., 
diabetes, HCV, 
asthma, renal 
disease, heart 
disease) may 
increase likelihood of 
ART non-adherence 
Dichotomous; Key 
chronic disease 
diagnoses, excluding 
HIV, AIDS, AA, SA, 
SMI, DAS; dummy 
coded as equal to 1 if 
present, zero as reference 
Vance et al. 
(2011) 
AIDS clinical 
classification 
(AIDS) 
Conflicting evidence 
that AIDS (i.e., CDC 
disease stage) is 
associated with ART 
adherence 
Dichotomous; Presence 
of AIDS-defining 
diagnosis or PAC waiver 
enrollment then equal to 
1; if not then equal to 0 
Gifford et al. 
(2000); 
Kleeberger et 
al. (2001)  
 
Gap in 
enrollment 
(CHURN) 
Post-lapse period is 
associated with  
increased 
expenditures 
Medicaid coverage lapse 
greater than or equal to 1 
and less than or equal to 
3 months in a fiscal year 
equal to 1; if not then 
equal to 0. 
Harman, Hall, 
& Zhang  
(2007); Hall, 
Harman, & 
Zhang (2008) 
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Continued, TABLE 3.2: Objective 1 model variables 
Disease 
progression 
(DXP) 
Non-adherence 
strongly positively 
related to disease 
progression from 
HIV to AIDS 
Dichotomous; If HIV 
classification in first 
month of measurement 
year, and then presence 
of AIDS in a subsequent 
month, then equal to 1; if 
not equal to 0 
Bangsberg et al. 
(2001) 
Non-nucleoside 
reverse 
transcriptase 
inhibitor therapy 
(NNRTI)  
ART regimens may 
have varying 
adherence due to 
different complexity 
and side-effects 
2 nucleoside reverse 
transcriptase inhibitors 
(NRTIs) and one 
NNRTI in first month of 
measurement period 
with values of 1, and 0 
if not. 
Panel on 
Antiretroviral 
Guidelines 
(2011); Trotta 
et al. (2002) 
Boosted 
protease therapy 
inhibitor (PI)  
ART regimens may 
have varying 
adherence due to 
different complexity 
and side-effects 
2 nucleoside reverse 
transcriptase inhibitors 
(NRTIs) and a ritonavir-
boosted protease 
inhibitor (PI) in first 
month of measurement 
period with values of 1, 
and 0 if not. 
Panel on 
Antiretroviral 
Guidelines 
(2011); Trotta 
et al. (2002) 
Other ART 
regimen 
(Oth_ART) 
ART regimens may 
have varying 
adherence due to 
different complexity 
and side-effects 
Other ART regimen, 
including single ART 
regimens, Nuc-sparing 
(NNRTI and PI), FI, 
Chemokine receptor 
therapy, or INSTI in 
first month of 
measurement period 
with values of 1, and 0 
if not. 
 
Number of 
concurrent 
antiretroviral 
medications 
(Rx_N1, etc.) 
Increased number of 
antiretroviral 
medications used 
concurrently may be 
related to lower 
adherence 
Categorical; Counts of 
number of concurrent 
antiretroviral 
medications in first 
month; 1 medication as 
reference 
Kleeberger et 
al. (2001); 
Maggiolo et 
al. (2005) 
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See Appendix Table A4 for the U.S. Census Bureau, 2005-2009 American Community 
Survey divided into half by median household income.  The lower income county set is 
the reference category in the model, including Calhoun, Dixie, Putnam, Holmes, 
Highlands, Suwannee, Washington, Levy, Gadsden, Hamilton, Taylor, Jackson, Madison, 
and DeSoto, Hendry, Citrus, Franklin, Gulf, Okeechobee, Hardee, Columbia, Glades, 
Alachua, Liberty, Marion, Bradford, Union, Sumter, Gilchrist, Hernando, Leon, and 
Miami-Dade. The upper income county set includes Escambia, Volusia, Pasco, Jefferson, 
Polk, Charlotte, Lake, Pinellas, Walton, Bay, Baker, Osceola, Indian River, Lafayette, St. 
Lucie, Flagler, Manatee, Sarasota, Brevard, Duval, Hillsborough, Orange, Lee, Broward, 
Wakulla, Martin, Palm Beach, Okaloosa, Santa Rosa, Monroe, Nassau, Collier, 
Seminole, Clay, and St. Johns. The demarcation point for median income for the lowest 
high median income county is $43,326, Volusia County’s median income. Also in 
Appendix Table A4 are the notations of the counties by population density (urban and 
rural). Based on the 2010 U.S. Census data, there were 30 counties defined as rural in 
Florida, as defined by a density of less than 100 persons per square mile. 
Objective 1: Expectations 
 The dichotomous outcome variable was ART non-adherence (MPR< 90%) versus 
ART adherence (MPR>90%). Certain factors were expected to significantly and 
negatively associated with the probability that the patient would be non-adherent to ART, 
including county median income (high versus low), rural county population density, male 
sex, age groups, AIDS diagnosis, adherence to antidepressants, severe mental illness, 
PAC Waiver enrollment or case management services, meeting minimum recommended 
average outpatient visits, ART regimen type, and number of medications in the ART 
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regimen. Positive significant independent variables included race/ethnicity, disease 
progression from HIV to AIDS, substance abuse diagnosis, alcohol abuse diagnosis, 
depression, anxiety or somatoform disorder diagnosis, Medicaid eligibility type, 
Medicaid discontinuous coverage, and co-morbidity count levels. 
Objective 2: Overview 
The second objective is to assess the mean total healthcare expenditures in the 
twenty-four month measurement period between those PLWHA subjects in the ART 
adherence group (>90%) versus those in the non-adherence group (<90%), controlling for 
demographic, geographic, insurance and clinical factors.  
Objective 2: Hypothesis 
The mean total healthcare expenditures (Q) for the multi-year period among those 
PLWHA in the ART adherence group will be less than those in the low ART adherence 
group. More formally, 
H0: Q ART Adherence > Q ART non-Adherence 
HA: Q ART Adherence   Q ART non-Adherence 
Regression analysis estimated the expected per patient mean monthly total 
healthcare expenditures in the measurement period. To account for the likely skewness of 
the outcome variable, a generalized linear model (GLM) with a log link function and 
gamma distribution will be utilized (Manning & Mullahy, 2001). GLM prevented the 
need to transform the skewed expenditure data, and subsequently to retransform the 
predicted expenditures back into dollar figures (Manning & Mullahy, 2001). GLM with 
log-link and gamma distribution is the statistical method employed by Nachega et al. 
(2010) in their study regarding the relationship of ART to healthcare expenditures.  
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Total healthcare expenditures were calculated using Florida Medicaid FFS claims 
and PMHP encounters in the 24 month period. Total healthcare expenditures per patient 
per month were determined by adding expenditures for inpatient, outpatient, antiretroviral 
medication, non-antiretroviral outpatient pharmacy, emergency department utilization, 
outpatient mental health, inpatient mental health, and outpatient surgeries. Home health 
care, hospice care, nursing home care, and radiological examinations were excluded. 
Inpatient expenditures were defined as total per diem expenditures reflected on the 
Medicaid claim. In Florida Medicaid, hospitals bill AHCA a pre-determined schedule of 
rates per day. As a category, inpatient expenditures excluded behavioral health inpatient 
expenditures.  
For monthly pharmaceutical expenditure calculation, filled pharmacy claims from 
all years used the expenditures listed on the Medicaid pharmaceutical claims minus the 
29.1% rebate for drugs on the Florida Medicaid Preferred Drug List (PDL) and AWP 
minus 16.4% rebate for non-PDL drugs (Florida Statute, 2008). It is important to note 
that federally granted participants in the 340B program may purchase pharmaceuticals at 
significant discounts, as compared to other organizations (Public Health Service Act, 
1992). Pricing of pharmaceuticals is important to inferences of the ART adherence 
impact on healthcare expenditures. In fact, Gardner et al. (2008) found that the positive 
relationship of ART adherence to increased total expenditures did not exist when 
pharmaceutical pricing was modeled at significantly discounted generic drug pricing, 
reported as 3% of total healthcare expenditures. 
Fakhraei et al. (2001) created a comorbidity-based payment methodology for 
Maryland Medicaid enrollees with HIV/AIDS whereby the certain diagnoses that were 
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associated with total healthcare costs. Each diagnosis was categorized according to the 
relative effect on total expenditures. Despite the categorization of diseases, the diagnoses 
in the Fakhraei co-morbidities-based payment methodology were individually additive to 
costs (as opposed to hierarchical). That is, multiple diagnoses are counted within each 
diagnostic classification or multiple diagnoses within different groups. Objective 2 
follows the practice of counting the number of diagnoses. See Appendix Table A6 for the 
list of all relevant diagnoses and the frequency among subjects in this research 
Objective 2: Model variables  
The following variables have been identified as related to ART adherence. 
TABLE 3.3: Objective 2 model variables 
Variable Theoretical 
consideration 
Measurement Reference(s) 
Total healthcare 
expenditures 
(Q) 
Ambiguity surrounds 
total cost savings 
related to ART 
adherence. 
Continuous; Expenditures 
for inpatient, outpatient, 
antiretroviral medication, 
non-antiretroviral 
outpatient pharmacy, 
emergency department, 
outpatient mental health, 
inpatient mental health, 
laboratory studies, 
radiological examinations, 
and outpatient surgeries  
Bozzette et 
al. (2001); 
Nachega 
(2010); 
Gardner et al. 
(2008); 
Acurcio et al. 
(2006) 
ART adherence 
(ART1) 
Outcome variable. No 
consensus among 
researchers as to the 
best dichotomous cut-
off for ART 
adherence 
Dichotomous; Medication 
possession ratio (MPR) 
greater than or equal to 
90%, then coded 1 if the 
patient is adherent to 
ART, and 0 if not 
adherent. 
Mills et al. 
(2006) 
Age group 
(AGE) 
Predisposing factor: 
Increased age a well-
established factor 
associated with 
increased healthcare 
utilization 
Categorical; with dummy 
variables for each age 
groups, 18–34 (reference), 
35–49, and 50 years or 
older 
Anderson 
and Newman 
(2005); 
Fleishman et 
al. (2005) 
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Continued, TABLE 3.3: Objective 2 model variables 
County Median 
Income 
(County_High, 
County_Low) 
Evidence describes 
substantial variation 
in healthcare 
spending 
independently 
associated with 
geography 
Categorical; defined by 
U.S. Census Bureau, 
2005-2009 American 
Community Survey, 
divided into 2 groups by 
median household 
income; lower county 
group is reference; See 
Appendix Table A5 
 
County Density 
(CountyR, 
County U) 
Evidence describes 
substantial variation 
in healthcare 
spending 
independently 
associated with 
geography 
Categorical; geographic 
compose of rural and 
urban, as defined by the 
U.S. Census Bureau; See 
Appendix Table A5 
 
Sex 
(SEX_male) 
Predisposing factor: 
Sex an established 
determinant 
associated with 
healthcare utilization 
Dichotomous, with value 
of 0 if male and 1 if 
female 
Anderson 
and Newman 
(2005); 
Fleishman et 
al. (2005) 
Race/ethnicity 
(RACE) 
Predisposing factor: 
Non-white race 
associated with 
increased healthcare 
utilization 
Categorical; White 
(reference), black, 
Hispanic, other; dummy 
variables for each 
category  
Anderson 
and Newman 
(2005); 
Fleishman et 
al. (2005) 
Supplemental 
Security 
Income-related 
disability (SSI) 
Temporary 
Assistance for Needy 
Families (TANF) 
versus SSI 
Dichotomous; presence of 
SSI eligibility status then 
equal to 1; if not then 
equal to 0 
 
Depression, 
anxiety or 
somatoform 
diagnoses 
(DEP_ANX) 
Increased costs may 
be due to increased 
medical service 
utilization, not mental 
illness treatment 
Dichotomous; presence of 
depression or anxiety then 
equal to 1; if not then 
equal to 0 
Simon 
(2003) 
Alcohol abuse 
(AA) and/ 
Substance 
abuse (SA) 
Increased costs may 
be a consequence of 
increased overall 
medical service 
utilization, not mental 
illness treatment 
Dichotomous; Presence of 
1 alcohol and/or substance 
abuse diagnosis equal to 
1; if not then equal to 0 
(see Appendix Table A5) 
Simon 
(2003) 
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Continued, TABLE 3.3: Objective 2 model variables 
Severe Mental 
Illness (SMI) 
Increased costs may 
be due to increased 
overall medical 
service utilization, 
not mental illness 
treatment 
Dichotomous; Presence of 
1 or more severe mental 
illness diagnosis (see 
Appendix Table A5) 
Simon 
(2003) 
 
Adherence to 
antidepressants 
(MIRx) 
Conflicting evidence 
of adherence to 
antidepressant 
medications on 
healthcare utilization 
> 2 months of 
antidepressant medication 
and 
> 80% adherence equal to 
1; if not then equal to 0  
Cantrell et. al 
(2006); 
Robinson et 
al. (2006) 
Co-morbidities 
(COM0=0, 
COM1=1, 
COM2=2 or 
more) 
Need-based driver of 
health services 
utilization 
Categorical; Counts of 
key comorbidity 
diagnoses excluding HIV, 
AIDS, AA, SA, SMI; zero 
comorbidities as reference  
see Appendix 
Table A6 
AIDS clinical 
classification 
(AIDS) 
Need-based driver of 
health services 
utilization 
Presence of AIDS-
defining diagnosis equal 
to 1; if not then equal to 0 
Fleishman, 
Hsia, & 
Hellinger 
(1994) 
Discontinuous 
Medicaid 
coverage 
(CHURN) 
Post-lapse period is 
associated with  
increased 
expenditures 
Dummy variable for each 
measurement year. 
Medicaid coverage lapse 
greater than 3 months in a 
fiscal year equal to 1; if 
not then equal to 0. 
Harman, 
Hall, & 
Zhang  
(2007); Hall, 
Harman, & 
Zhang (2008) 
Generic drug as 
a part of ART 
regimen (GEN) 
Generic drug pricing 
can influence ART 
adherence impact on 
expected 
expenditures 
Dichotomous; If a generic 
drug (see Table 1) is 
included in plurality of 
ART refills then coded as 
1, and 0 if not. 
Gardner et al. 
(2008) 
 
Objective 2: Expectations 
The relatively smaller mean monthly total healthcare expenditures for those 
PLWHA in the ART adherence group versus the ART non-adherence group is based on 
the expectation that, despite the significantly higher antiretroviral pharmacy expenditures, 
the ART adherence group will have significantly less inpatient expenditures than the 
ART non-adherence group. 
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Chapter Four: Results 
 
Final inclusion and exclusion criteria 
The data for this research included Florida Medicaid fee-for-service (FFS) claims 
and Prepaid Mental Health Plans (PMHP) encounters for five fiscal years (July 2006 
through June 2011). Identification of HIV-positive individuals for this research was made 
through the algorithm discussed in the methods section above (Hidalgo, 2009). No 
subjects were pregnant nor had Medicare eligibility.  
For those that had enrollment gaps of no more than 3 months at the end of a 
measurement year, procedures were taken to evaluate whether the subject “churned” back 
on to Medicaid later in the non-measurement period (n=66, 12.6%). These subjects were 
noted in the model with a discontinuous enrollment (“churn”) variable. Those that had 
gaps of less than four months, but did not return to Medicaid, were removed.   
All subjects were ART medication-naïve (no antiretroviral therapy medication 
claims) for at least 12 months prior to the first month of the subsequent 24 month 
measurement period. Figure 5.1 illustrates how the 24 month measurement periods vary 
for each subject. For example, of the 514 subjects, 14 individuals (2.7%) initiated ART 
on July 1, 2006 and ended on June 30, 2008. In the next month, 15 subjects’ 24 month 
measurement period started on August 1, 2006 and ended on July 31, 2008.  
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Figure 4.1: Frequency of Subjects from Antiretroviral Initiation Month to End of Study in 
Twenty-Four Month Measurement Period (n=514) 
First Month Last Month
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The ART adherence groups were analyzed for difference in means of the start 
date of the subjects’ measurement period. Given that the ART initiation dates and 
resultant 24 measurement periods vary by subject (see Figure 4.1), potential systematic 
changes to Medicaid payments over time have the potential to render any differences in 
total healthcare expenditures between adherence and non-adherence groups biased. 
Therefore, it was necessary to test whether the 24 month measurement periods for the 
two groups of interest, ART adherent (>90% MPR) and non-adherent (<90% MPR), 
spanned significantly different periods in time.  
The mean ART start date for the HIV-positive group combined was October 2, 
2007 (n=270). For the HIV-positive group, there was a 33 day difference in ART 
initiation between the ART adherence group and the non-ART adherence group. Based 
on a two sample t-test procedure of the groups’ antiretroviral start dates, no significant 
statistical difference existed between mean start dates for the groups (t= -1.25, p=0.2137).  
The mean ART start date for the AIDS-positive group combined was May 18, 
2008 (n=232). Based on a two sample t-test procedure of the groups’ antiretroviral start 
dates, no significant statistical difference between mean start dates for the groups (t= .70, 
p=0.4825).  
Figure 4.2 shows that the median antiretroviral start month was January 2008; the 
mode start date was July 2007. 
  
Figure 
Data cleaning 
Florida Medicaid contracts with
activities for some AIDS-
managed care) payment system, called the Florida Medicaid Project AIDS Care (PAC). 
Unfortunately, the data for PAC waiver enrollment was not included in the files for fiscal 
years 2009 through 2011. Figure 
procedure codes and PAC enrollment declined in later years of the measurement study. 
As a result of this data issue, a variable that controlled for these services was not included 
in the research models. 
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4.2: First month of ART (n=514) 
 a company to conduct disease management
diagnosed individuals enrolled in the fee-for-service (non
4.3 demonstrates how claims for case management 
 
 
-
  
Figure 4.3: Project AIDS Care enrollment or case management 
Codes regarding provider specialty code were only included for less than 5% of 
the sampled claims; therefore, an HIV specialist and infectious disease 
variable that controlled for expertise of a treating physician was not included in the 
research models. 
Cognitive therapy has been found to be an important factor (Safren et al., 2009) in 
improving adherence to ART. In the Medicaid data obta
lacked procedure codes for most of the outpatient claims. Therefore, an outpatient mental 
health variable that controlled for the impact of cognitive therapy was not included in the 
research models. 
Lab data (LOINC) were included 
data (July 2006-June 2008
below, the impact of the missing expenditure data would not bias either the high 
adherence group or the low adherence grou
Also, Table 4.1 shows that the values for lab claims 
high adherence (>90% M
47 
services claims by year 
physician type 
ined from AHCA, the files 
in the data set for the early fiscal years of the 
), but not later years (July 2008-June 2011). As discussed 
p, therefore, the data were kept in the analysis. 
were small and comparable between 
PR) and non-adherence groups (<90 MPR), on average.
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TABLE 4.1: Descriptive statistics for monthly laboratory 
expenditures in 24 month measurement period (n=435) 
  n mean sd minimum maximum 
< 90% MPR 326 $35.13 $61.39 $0.00 $627.28 
> 90% MPR 109 $34.26 $46.28 $0.00 $166.88 
 
In addition, as shown in Table 4.2, among laboratory utilizers (n=249), there was little 
difference in the mean expenditures between ART adherence groups. 
TABLE 4.2: Descriptive statistics for monthly laboratory 
expenditures for subjects averaging greater than $0 in 24 month 
measurement period (n=249) 
  n mean sd minimum maximum 
< 90% MPR 188 $60.92 $70.50 $0.24 $627.28 
> 90% MPR 61 $61.22 $46.66 $0.24 $166.88 
 
 None of the 514 subjects were diagnosed with somatoform disorder. As such, this 
diagnosis was removed from the variable that included diagnoses of depression and 
anxiety. 
As demonstrated by Gardner et al. (2008), discounted generic antiretroviral drug 
pricing significantly impacts the relationship of adherence to ART to the total 
expenditures, as the generics may be less than 10% of the prices of non-generic ART 
medications. Among the sample of this research, only five individuals were prescribed 
generic medications, as noted in Table 4.3. As a result of the small sample size, subjects 
taking generic ART were not included as a model variable. 
Among those subjects that filled generic ART medications, the generics were a 
minority of the other antiretroviral drugs (1.7% to 26.7%), as shown in Table 4.3. 
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TABLE 4.3: Descriptive statistics for Medicaid-insured previously ART-naïve 
PLWHA whose antiretroviral therapy (ART) includes generic medications (n=5) 
Subject Generic ART Frequency Total ART Prescriptive Fills 
% of Subject's ART 
Prescriptions 
Subject 1 Zidovudine 30 mg 10 40 25.0% 
Subject 2 Zidovudine 30 mg 8 30 26.7% 
Subject 3 Zidovudine 30 mg 1 60 1.7% 
Subject 4 Zidovudine 30 mg 10 79 12.7% 
Subject 5 Didanosine 250 mg  14 104 13.5% 
 
Additionally, those subjects with generic ART claims were all found in the non-adherent 
group (<90% MPR). Table 4.4 shows that the mean MPR for the five subjects was 33%.  
TABLE 4.4: Descriptive statistics for medication possession ratio among 
Medicaid-insured PLWHA whose antiretroviral therapy (ART) included 
generic medications (n=5) 
  n mean sd minimum maximum 
Medication possession ratio 5 0.33 0.15 0.16 0.53 
 
Finally, the mean total expenditures for the five subjects using generic 
medications was $2,461, although there was substantial variation, as Table 4.5 shows. 
Nonetheless, the mean for this generic antiretroviral medication group was 30% higher 
than the mean for the subjects in the non-adherent group (<90%) as a whole ($1,886).  
TABLE 4.5: Descriptive statistics for total healthcare expenditure among 
Medicaid-insured previously ART-naïve PLWHA whose antiretroviral 
therapy (ART) included generic medications (n=5) 
n mean sd minimum maximum 
Total healthcare expenditures 5 $2,461 $2,666 $344 $6,790 
 
While a fully automated de-duplication was processed on the entire claims file, 
some duplicate inpatient claims remained in the system. In some instances, hospitals 
submitted two claims for the same date span, but for slightly different amounts. Under 
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Medicaid claims payment policy, payments were made on a per diem basis, so duplicate 
claims for the same days were disallowed. In these cases, the duplicates were removed. 
Objective 1: Descriptive results  
Objective 1 assessed the independent determinants of non-adherence to ART 
among treatment-naïve PLWHA using retrospective Florida Medicaid claims data. As 
discussed above, the final sample for this objective was 514 individuals. All subjects 
were ART treatment naïve for 12 months prior to the 24 months measurement period. 
Each subject was categorized into one of two groups according to their 
medication possession ratio (MPR), a measure of their adherence to ART, as discussed in 
the Methods section above.  
TABLE 4.6: Frequency of previously ART-naïve Medicaid-
insured PLWHA in antiretroviral therapy "adherence" and 
"non-adherence" categories as measured by possession ratio 
(MPR) in 24 month measurement period (n=514) 
  n   % 
> 90% MPR 109   21% 
< 90% MPR 405   79% 
All subjects 514   100% 
 
As shown in Table 4.6 above, 109 subjects had an MPR of 90% or greater and 
were categorized as adherent; 405 subjects were below 90% MPR and were categorized 
as non-adherent. Among the 514 PLWHA in the study, 21% were adherent to ART over 
the 24 month measurement period, and 79% were non-adherent during that time span. 
As shown in Table 4.7, the mean MPR for the adherent group was 96%, but only 
46% for the non-adherent group. Overall, the mean MPR for PLWHA in the study was 
56%.  
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TABLE 4.7: Descriptive statistics for Medicaid-insured medication naïve 
PLWHA by adherence and non-adherence categories (n=514) 
  
n mean sd minimum maximum 
All subjects 514 0.56 0.31 0.004 1 
> 90% MPR 109 0.96 0.04 0.90 1 
< 90% MPR 405 0.46 0.25 0.004 0.89 
 
  Subjects’ ages were measured based on their age on July 1st of their ART 
treatment naïve year. The overall mean age for all subjects was 39.2 years. Subjects in 
this research were divided into three groups: 1) 18 to 34 years, 2) 35 to 49 years, and 3) 
50 to 64 years. The allocation and proportion of the 514 subjects were categorized in each 
age group as follows 167 (32.5%) in ages 18-34, 267 (53.7%) in ages 35-49, and 80 
(15.6%) in ages 50-64.  
 
TABLE 4.8: Descriptive statistics for age on July 1st of subjects' 
reference year (n=514) 
  
n mean sd minimum maximum 
All subjects 514 39.2 9.89 18 61 
> 90% MPR 405 39.1 10.18 18 61 
< 90% MPR 109 39.8 8.74 21 57 
 
 
As shown in Table 4.8 above, the mean ages by adherence group equals 39.1 
years and 39.8 for the adherent (>90%) and non-adherent (<90%) groups, respectively. 
The distribution of MPR by age groups are presented in Table 4.9 below. On average, the 
younger age group has a lower MPR than the two older groups of individuals. 
  
  
  
TABLE 4.9: Medication possession ratio (MPR) among previously ART
 
 
Florida Medicaid gathers race and ethnicity as a part of the eligibility and 
enrollment process. Among 514 subjects in this 
majority (58.8%) reported their race as black
Hispanic race or ethnicity, and 8% 
Figure 4.4: ART Adherence category by race/ethnicity (n=514)
All 18 - 34
> 90% MPR
< 90% MPR
All 35 - 49
> 90% MPR
< 90% MPR
All 50 - 64
> 90% MPR
< 90% MPR
TABLE 4.9: Medication possession ratio (MPR) among previously 
ART-naïve Medicaid-insured PLWHA by age groups (n=514)
52 
-naïve Medicaid-insured PLWHA by age groups (n=514)  
research, Figure 4.4 shows that the 
, 20% reported as white, 13.2% reported as 
other race, or not determined.  
n mean sd minimum maximum
167 0.49 0.32 0.00
32 0.95 0.04 0.90
135 0.38 0.25 0.004
267 0.60 0.29 0.04
59 0.97 0.03 0.90
208 0.50 0.24 0.04
80 0.58 0.31 0.04
18 0.98 0.03 0.90
62 0.47 0.26 0.04
Age Group 3: 50-64 (n=80)
Age Group 1: 18-34 (n=167)
Age Group 2: 35-49 (n=267)
 
 
 
1.00
1.00
0.86
1.00
1.00
0.89
1.00
1.00
0.86
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Table 4.10 shows the relative proportion of blacks were non-adherent to ART in 
the measurement period.  
TABLE 4.10: Adherent (>90%) and non-adherent 
(<90%) proportions by race and ethnicity for 
Medicaid-insured previously antiretroviral naïve 
PLWHA (n=514) 
  White Black Other Hispanic 
> 90% MPR 35% 18% 12% 21% 
< 90% MPR 65% 82% 88% 79% 
 
Table 4.11 shows the distribution of MPR by adherence category by race and ethnicity 
categories.  
TABLE 4.11: Medication possession ratio (MPR) by race and ethnicity for Medicaid-insured previously antiretroviral naïve PLWHA (n=514) 
 
 
There are two main eligibility categories in Florida Medicaid – Temporary 
Assistance for Needy Families (TANF) and Social Security Income (SSI) (Agency for 
n mean std dev minimum maximum
All 103 0.63 0.32 0.04 1.00
> 90% MPR 36 0.96 0.04 0.90 1.00
< 90% MPR 67 0.45 0.25 0.04 0.86
All 302 0.53 0.31 0.004 1.00
> 90% MPR 54 0.96 0.04 0.90 1.00
< 90% MPR 248 0.44 0.26 0.004 0.89
All 41 0.54 0.28 0.04 0.99
> 90% MPR 5 0.96 0.02 0.95 0.99
< 90% MPR 36 0.48 0.25 0.04 0.86
All 68 0.62 0.26 0.08 1.00
> 90% MPR 14 0.97 0.04 0.90 1.00
< 90% MPR 54 0.53 0.21 0.08 0.86
TABLE 4.11: Medication possession ratio (MPR) by race 
and ethnicity for Medicaid-insured previously antiretroviral 
naïve PLWHA (n=514)
Other races
White
Black 
Hispanic race and ethnicity
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Health Care Administration, 2013a, 2013b). The income limit for a family of two (i.e., 
child and adult) to qualify for Florida Medicaid in 2013 was $1,138 per month for 
eligibility under SSI rules and $1,293 per month under TANF eligibility rules. The assets 
limits of approximately $2,000 in 2010 were also applicable for Medicaid eligibility. It is 
important to note that for the Medicaid population in Florida, the relative affluence of a 
county population at large does not reflect the individual Medicaid enrollee’s financial 
resources. In fact, the income among all subjects is held relatively constant, in that low 
income and assets are a requirement for Medicaid eligibility.  
 Table 4.12 shows that a majority of subjects (76%) were eligible for Medicaid 
through the SSI program. The MPR means for both Medicaid eligibility categories was 
56%.  
TABLE 4.12: Medication possession ratio (MPR) by Medicaid 
eligibility category for PLWHA (n=514) 
  n mean sd minimum maximum 
TANF Medicaid Eligibility (n=123) 
All 123 0.56 0.31 0.004 1.00 
< 90% MPR 97 0.45 0.25 0.00 0.86 
> 90% MPR 26 0.96 0.04 0.90 1.00 
SSI Medicaid Eligibility (n=391) 
All 391 0.56 0.31 0.03 1.00 
< 90% MPR 308 0.46 0.25 0.03 0.89 
> 90% MPR 83 0.96 0.03 0.90 1.00 
 
Table 4.13 shows that similar proportions were divided among the ART adherent 
and non-adherent categories. A chi-square test confirmed no significant difference in 
frequencies between SSI-eligible subjects that were adherent compared to non-adherent, 
nor any differences between TANF-eligible subjects in adherent versus non-adherent 
categories (χ2=.0004, p=.98). 
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TABLE 4.13: Medicaid eligibility categories by type and adherence category 
among previously ART-naïve Medicaid-insured PLWHA (n=514) 
  < 90% (n=405)   > 90% (n=109)   Total 
  n %   n %   n % 
Temporary Assistance for 
Needy Families (TANF) 
97 24.0%   26 23.9%   123 23.9% 
Social Security Income (SSI) 308 76.0%   83 76.1%   391 76.1% 
 
Due to Agency for Health Care Administration data use agreement designed to 
protect patient identity, county of residence is the smallest geographic identifier available 
in the demographic files provided for this study. The U.S. Census Bureau defines an 
urban county as containing a density equal to or greater than 100 people per square mile 
(U.S. Census Bureau, 2013b). In Florida, there were 38 counties (56%) classified as 
urban. A large majority of PLWHA subjects reside in urban counties (n=470, 91.4%), as 
compared to rural counties (n=44, 8.6%). This proportion was approximately the same as 
the 2013 Florida population living in urban counties (91.2%) but higher than the U.S. 
urban population as a whole (81%) (U.S. Census Bureau, 2013b). In addition, the 
proportion of PLWHA in the United States is predominantly urban (Vyavaharkar, 
Glover, Leonhirth, & Probst, 2013). Table 4.14 shows the distribution of MPR for subject 
in counties by rural and urban population density.  
According to the U.S. Census Bureau, 2005-2009 American Community Survey 
(2013a), the median household median income for Florida counties in 2010 was $43,326. 
That is, half of the counties’ median incomes were below this amount and half were 
above this amount. Table 4.15 below shows that subjects residing in high income 
counties had lower mean than subjects residing in low income counties. See Appendix 
Table A4 for the complete listing of counties.  
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TABLE 4.14: Frequency and distribution of medication 
possession ratio (MPR) by county population density for 
Medicaid-insured previously ART naïve PLWHA (n=514) 
  n mean sd minimum maximum 
Rural Counties  (< 100 persons per square mile) 
All 44 0.63 0.34 0.04 1.00 
> 90% MPR 15 0.96 0.04 0.90 1.00 
< 90% MPR 29 0.46 0.29 0.04 0.86 
Urban counties (> 100 persons per square mile) 
All 470 0.56 0.30 0.004 1.00 
> 90% MPR 94 0.96 0.04 0.90 1.00 
< 90% MPR 376 0.46 0.25 0.004 0.89 
 
TABLE 4.15: Frequency and distribution of medication 
possession ratio (MPR) by county median household income 
category for Medicaid-insured PLWHA (n=514) 
  n mean sd minimum maximum 
Low Median Household Income (< $43,326) 
All 192 0.60 0.31 0.04 1.00 
< 90% MPR 141 0.47 0.25 0.04 0.88 
> 90% MPR 51 0.96 0.04 0.90 1.00 
High Median Household Income (> $43,326) 
All 322 0.54 0.30 0.004 1.00 
< 90% MPR 264 0.45 0.25 0.004 0.89 
> 90% MPR 58 0.96 0.04 0.90 1.00 
 
 Table 4.16 shows the frequency of subjects residing in urban/rural and upper 
household income counties/lower household income counties. Few individuals in the 
sample (n=15, 2.9%) reside in low income rural counties. 
TABLE 4.16: Frequency of subjects residing in counties by median income 
(high versus low) and population density (urban versus rural) attributes 
(n=514) 
  Urban   Rural   Total 
  n %   n %   n 
Low median income counties 307 59.7%   15 2.9%   322 
High median income counties 163 31.7%   29 5.6%   192 
Total 470 91.4%   44 8.6%   514 
 
  
As illustrated in Figure 
low median income counties 
Figure 4.5
Among the 514 subjects in Objective 1, 234 were HIV
and 280 were diagnosed with AIDS (
fewer subjects diagnosed as HIV in the sample popul
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individuals categorized as adherent (>90%) than AIDS-diagnosed subjects, although 
there is no statistical difference (χ2=2.55, p=.11). 
TABLE 4.17: Proportion of HIV or AIDS disease status by 
adherence and non-adherence categories for Medicaid-
insured previously ART naïve PLWHA (n=514) 
    HIV   AIDS   Total 
    n %   n %   n 
> 90% MPR   57 24.4%   52 18.6%   109 
< 90% MPR   177 75.6%   228 81.4%   405 
 
The differences in adherence to ART between subjects with HIV and AIDS is illustrated 
in the overall mean MPR shown in Table 4.18. There is no statistical difference between 
the mean MPR for AIDS-diagnosed subjects (55%) compared to HIV-positive 
individuals (58%) (χ2=82.97, p=.54).  
TABLE 4.18: Medication possession ratio (MPR) by HIV or AIDS disease 
status for Medicaid-insured previously ART naïve PLWHA (n=514) 
  n mean sd minimum maximum 
HIV 
All 234 0.58 0.32 0.004 1.00 
> 90% MPR 177 0.46 0.27 0.004 0.88 
< 90% MPR 57 0.96 0.04 0.90 1.00 
AIDS 
All 280 0.55 0.30 0.04 1.00 
> 90% MPR 228 0.45 0.24 0.04 0.89 
< 90% MPR 52 0.96 0.04 0.90 1.00 
 
Primary care guidelines for the management of PLWHA recommend that cell 
counts and low viral loads be monitored every 3 to 4 months to monitor for drug toxicity 
and to assess response to ART (Aberg et al., 2009). To engage in outpatient care at the 
recommended frequency in the 24 month measurement period, subjects should have at 
least eight outpatient claims. Table 4.19 shows that over half of the 514 patients (n=277, 
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53.9%) had eight or more outpatient claims. Only six subjects had no outpatient claims 
during the 24 month measurement period; 61 subjects had 60 or more outpatient claims. 
TABLE 4.19: Total and proportion of outpatient visits 
in 24 month measurement period among Medicaid-
insured previously ART-naïve PLWHA (n=514) 
 Outpatient visits n % 
Zero outpatient visits 6 1.2% 
1 to 2 203 39.5% 
3 to 7 28 5.4% 
8 to 19 74 14.4% 
20 to 39 93 18.1% 
40 to 59  49 9.5% 
60 and more 61 11.9% 
 
An increased number of antiretroviral medications used concurrently may be 
related to lower ART adherence (Kleeberger et al., 2001; Maggiolo et al., 2005). Among 
this sample, over 62% filled three to five ART medications in their first month of ART. 
Among those subjects that filled only one ART medication prescription (n=106), 91 
subjects (86%) filled AtriplaTM, a combination drug with three active medications, 
including a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside 
reverse transcriptase inhibitors (Julg & Bogner, 2008). There is a bivariate significant 
difference between non-adherence (n=57, 14%) and adherent groups of (n=34, 31%) 
subjects taking AtriplaTM as a single drug (2=17.27, p<0.001). The remaining 15 
subjects filled prescription from single classes of drugs, such as integrase strand transfer 
inhibitors (INSTI).  
As shown in Table 4.20, a lower proportion of AIDS-diagnosed subjects filled 
only a single antiretroviral medication (ARV), as compared to those without an AIDS 
diagnosis. A higher proportion of AIDS-diagnosed subjects (21.4%) filled six or more 
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concurrent medications in the first month of ART initiation, as compared to those without 
an AIDS diagnosis (10.3%). 
TABLE 4.20: Number of concurrent ARV medications filled in the 
first month of ART initiation by HIV or AIDS status among 
previously ART-naïve Medicaid-insured PLWHA (n=514) 
    HIV (n=234)   AIDS (n=280) 
  
Total 
    n %   n % 
  
n 
1 (reference) 
  
63 26.9% 
  
43 15.4% 
  
106 
2 
  
44 18.8% 
  
41 14.6% 
  
85 
3 to 5 
  
103 44.0% 
  
136 48.6% 
  
239 
6 or more 
  
24 10.3% 
  
60 21.4% 
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The most common ART regimen among the 514 subjects was boosted protease 
inhibitors (50.6%), followed by NNRTI regimen (41.8%). Of the 39 subjects (7.6%) in 
the single ART drug class category, 11 took INSTI class medications, 2 were on a 
“nucleoside-sparing” regimen. A “nuc-sparing” regimen is designed to solve certain side-
effects associated with ART by removing NNRTI class of medications (Tebas et al., 
2007). The remaining 26 subjects filled a single drug class in their first month of ART 
(four of these subjects filled multiple prescriptions in the same class). Drug regimens 
were measured in the first month of the measurement period. Additional drug classes 
could have been added to the single drug regimen, or the regimen could have changed 
over the 24 month measurement period.  
While the burden associated with adverse drug reactions (ADR) associated with 
ART has lessened with the development of new drugs, no ADR-free ART regimens exist 
(Johnson, Dilworth, Taylor, & Neilands, 2010). There were common ADR associated 
with ART, such as symptoms involving digestive system (Johnson et al., 2010; Wohl et 
al., 2006), abnormal glucose levels of the blood, lactic acidosis (Wohl et al., 2006), 
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lipodystrophy, visual disturbances, anorexia (Ammassari et al., 2001), dyslipidemia, 
dizziness and skin disorders (Rudorf, 2005).  
TABLE 4.21: ART-related adverse drug reactions among Medicaid-insured previously antiretroviral-naïve PLWHA by adherence categories (n=514) 
 
As shown in Table 4.21 above, the most prevalent diagnosis category among 
commonly identified ADR involved the digestive system (51.6%), such as nausea, 
diarrhea, and vomiting. The other common ADR was dyslipidemia, an abnormal amount 
of lipids (e.g., cholesterol and/or fat) in the blood. Dyslipidemia has been shown to be 
associated with advanced HIV disease in the absence of ART and a consequence of ART 
medications (Wohl et al., 2006). Among the 514 subjects in this research, dyslipidemia 
was more prevalent in the ART adherent group (56.0%) than in the non-adherent group 
(35.8%); a bivariate comparison of the proportions between the groups (<90% versus 
>90%) was significant for dyslipidemia (p<0.01). All other bivariate comparisons of 
ADR were non-significant. 
Among common chronic diseases among HIV-positive individuals, there was no 
significant differences between ART non-adherent and ART adherent groups, as shown 
Total
n % n % χ2
Symptoms involving digestive 
system (e.g., nausea and diarrhea) 209 51.6% 56 51.4% 265
Dyslipidemia 145 35.8% 61 56.0% ** 206
Dizziness 44 10.9% 15 13.8% 59
Visual disturbances 26 6.4% 11 10.1% 37
Skin disorders (e.g., rashes and 
dyschromia) 29 7.2% 6 5.5% 35
Lactic acidosis 23 5.7% 2 1.8% 25
Abnormal glucose 14 3.5% 5 4.6% 19
Lipodystrophy 11 2.7% 3 2.8% 14
Anorexia 11 2.7% 3 2.8% 14
TABLE 4.21: ART-related adverse drug reactions among Medicaid-insured previously 
antiretroviral-naïve PLWHA by adherence categories (n=514)
< 90% > 90%
*** < 0.001; ** <0.01; * <0.05 
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in Table 4.22. Over 69% of subjects had at least one comorbidity. Interestingly, there was 
a significant bivariate difference between those with at least one chronic disease and 
meeting the average recommended minimum number of outpatient visits (2=4.57, 
<.05). However, it is unclear as to the direction of this relationship – outpatient visits 
leading to diagnoses or diagnoses causing more outpatient visits. 
TABLE 4.22: Chronic diseases among Medicaid-insured previously antiretroviral-naïve PLWHA by adherence categories (n=514) 
 
Finally, among the 514 subjects, 269 (52%) were diagnosed with HIV in the first 
month of ART initiation. During the 24 month measurement period, 35 of those subjects 
(13%) were diagnosed with an AIDS-defining illness.  
Objective 1: Unadjusted logistic regression results 
Table 4.23 shows variable proportions organized by ART adherent (>90% MPR) 
and ART non-adherent (<90% MPR) categories. Also, Table 4.23 shows the unadjusted 
logistic regression analysis for the model variables testing for differences between 
adherent (>90% MPR) and non-adherent (<90%) groups.  
 
Total
n % n % χ2
Hypertension 176 43.5% 54 49.5% 230
COPD 103 25.4% 33 30.3% 136
Hepatitis C 99 24.4% 23 21.1% 122
Diabetes 85 21.0% 21 19.3% 106
Asthma 65 16.0% 23 21.1% 88
Chronic ischemic heart disease, 
cardiac insufficiency and MI 48 11.9% 14 12.8% 62
Osteoarthritis 40 9.9% 15 13.8% 55
Chronic kidney disease 39 9.6% 7 6.4% 46
Shingles 24 5.9% 4 3.7% 28
Peripheral Neuopathy 23 5.7% 3 2.8% 26
*** < 0.001; ** <0.01; * <0.05 
TABLE 4.22: Chronic diseases among Medicaid-insured previously 
antiretroviral-naïve PLWHA by adherence categories (n=514)
< 90% > 90%
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TABLE 4.23: Descriptive statistics for Medicaid-insured previously antiretroviral-naïve PLWHA by non-adherent (<90%) and adherent (>90%) categories (n=514) 
 
n % n % χ2 n %
Age groups
18–34 135 33.3% 32 29.4% 167 32.5%
35–49 208 51.4% 59 54.1% 267 51.9%
50 years or older (reference) 62 15.3% 18 16.5% 80 15.6%
Sex
Male 124 30.6% 43 39.4% 167 32.5%
Female (reference) 281 69.4% 66 60.6% 347 67.5%
Race/Ethnicity **
White race, non-Hispanic (reference) 67 16.5% 36 33.0% 103 20.0%
Black race, non-Hispanic 248 61.2% 54 49.5% 302 58.8%
Other race, non-Hispanic 36 8.9% 5 4.6% 41 8.0%
Hispanic race and/or ethnicity 54 13.3% 14 12.8% 68 13.2%
Counties by Median Income *
Low Median Income 141 34.8% 51 46.8% 192 37.4%
High Median Income 264 65.2% 58 53.2% 322 62.6%
Population density *
Rural 29 7.2% 15 13.8% 44 8.6%
Urban 376 92.8% 94 86.2% 470 91.4%
Medicaid Eligiblity Category
TANF 97 24.0% 26 23.9% 123 23.9%
SSI 308 76.0% 83 76.1% 391 76.1%
Eligibility for Medicaid
Continuous Enrollment (reference) 348 85.9% 100 91.7% 448 87.2%
Gap 1 to 3 months within one year 57 14.1% 9 8.3% 66 12.8%
ART regimen **
Boosted protease inhibitor 221 54.6% 39 35.8% 260 50.6%
NNRTI 155 38.3% 60 55.0% 215 41.8%
Other antiretroviral classes 29 7.2% 10 9.2% 39 7.6%
Number of concurrent ARV medications ***
1 (reference) 66 16.3% 40 36.7% 106 20.6%
2 67 16.5% 18 16.5% 85 16.5%
3 to 5 197 48.6% 42 38.5% 239 46.5%
6 or more 75 18.5% 9 8.3% 84 16.3%
Meeting minimum outpatient recommendations
< 4 annual outpatient visits mean 189 46.7% 48 44.0% 237 46.1%
> 4 annual outpatient visits mean 216 53.3% 61 56.0% 277 53.9%
< 90% (n=405) > 90% (n=109) Total
TABLE 4.23: Descriptive statistics for Medicaid-insured previously antiretroviral-
naïve PLWHA by non-adherent (<90%) and adherent (>90%) categories (n=514)
*** < 0.001; ** <0.01; * <0.05 
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 In Table 4.23 above, race/ethnicity had significantly different proportion of 
adherence groups (χ2=14.65, p<0.01). Geographic factors were also significantly 
different between adherent and non-adherent groups - median income county residence 
(χ2=5.16, p<0.05) and rural/urban county residence (χ2=4.30, p<0.05). Among ART 
related factors, regimen types (χ2=12.34, p<0.01), and the number of concurrent ARV 
medications (χ2=23.46, p<0.01) were significantly different between adherent and non-
adherent groups. As for clinical factors, chronic disease diagnosis (χ2=4.12, p<0.05), 
more/less than 2 antidepressant prescription claims (χ2=3.90, p<0.05), and adherence to 
antidepressants (χ2=15.73, p<0.001) were statistically different by adherence groups. The 
Objective 1 bivariate analysis indicated no statistical differences between adherent and 
non-adherent categories for age groups, sex, Medicaid eligibility category, discontinuous 
n % n % χ2 n %
HIV/AIDS status
HIV (reference) 177 43.7% 57 52.3% 234 45.5%
AIDS 228 56.3% 52 47.7% 280 54.5%
Disease Progression 28 12.3% 7 13.5% 35 12.5%
Non-HIV chronic disease diagnoses *
No other chronic disease diagnosis 133 32.8% 25 22.9% 158 30.7%
1 or more non-HIV chronic diagnosis 272 67.2% 84 77.1% 356 69.3%
Mental Illness Comorbidities
Depression and/or anxiety diagnosis 107 26.4% 28 25.7% 135 26.3%
Substance abuse and/or alcohol abuse 42 10.4% 9 8.3% 51 9.9%
Severe mental illness 50 12.3% 15 13.8% 65 12.6%
Antidepressant Regimen *
Less than 2 antidepressant 214 52.8% 46 42.2% 260 50.6%
2 or more antidepressant prescription 191 47.2% 63 57.8% 254 49.4%
Adherent to antidepressants ***
<80% antidepressant MPR 126 66.0% 26 41.3% 152 29.6%
>80% antidepressant MPR 65 34.0% 37 58.7% 102 19.8%
< 90% (n=405) > 90% (n=109) Total
Continued, TABLE 4.23: Descriptive statistics for Medicaid-insured previously 
antiretroviral-naïve PLWHA by non-adherent (<90%) and adherent (>90%) categories 
*** < 0.001; ** <0.01; * <0.05 
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enrollment in Medicaid, HIV/AIDS status, meeting recommended minimum number of 
average outpatient visits, depression and/or anxiety diagnosis, substance abuse and/or 
alcohol abuse, and severe mental illness. 
Objective 1: Model diagnostics 
Multiple independent variables were analyzed for their association with ART non-
adherence, including demographic, diagnoses, insurance, and healthcare service 
utilization factors. Logistic regression was used to predict a binary dependent variable - 
non-adherence to ART (versus adherence to ART). All model independent variables 
contain complete separation of groups (no overlaps of categories). 
Moderate multicollinearity (0.54) exists between NNRTI antiretroviral regimen 
and 3 to 5 concurrent medications drugs in the regimen. Other multicollinearity exists 
between variables in mutual exclusive categories (e.g., chronic disease levels). No 
variance inflation scores were above 2.6, also indicating a lack of multicollinearity. 
The logistic regression models used in this research were adequate for unbiased 
estimation, based on simulation of sample size adequacy run by Vittinghoff & 
McCulloch (2007) showing that 10 outcomes per independent variable rule of thumb may 
be too conservative. The full logistic regression model for this research contains over 21 
outcomes per independent variable (n=514 / IVs=24). Also, Hosmer and Lemeshow 
(2004) recommend a sample size for logistic regression of greater than 400, a 
requirement satisfied by the sample size of 514. Also, there were no linearity of logit 
issues nor any outlier problems. Finally, the requirement that no more than 20% of the 
expected counts of 5 or less for the chi-square contingencies was satisfied (Cochran, 
1954).  
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Hosmer-Lemeshow goodness-of-fit assessment tests the null hypothesis that there 
was no difference between the observed and predicted values of the dependent variable of 
non-adherence to ART (Hosmer & Lemeshow, 2004). For the full logistic model 
described below, the null hypothesis was not rejected (χ2=4.04, p=0.85), so the model fits 
the data. The reduced logistic regression model also fits the data (χ2=12.37, p=0.14). 
Also, the more parsimonious model improves the Akaike’s Information Criterion (AIC), 
naturally, as AIC penalizes for the addition of parameters (Hosmer & Lemeshow, 2004). 
The full model AIC equals 504.51; the reduced model AIC equals 493.90. 
One method for evaluating a logistic regression model fit is to determine the 
influence of outliers on the prediction through a plot of the residual deviances (Pardoe & 
Cook, 2002). Analysis of the residual deviation was plotted in Figure 4.7 showing that 
the full logistic regression model fits reasonably well. The circles on the top represent the 
prediction of the low adherence group, and the circles on the bottom represent the 
prediction of the high adherence group Figure 4.7 shows that the prediction error was 
more pronounced for the ART adherent (>90%) group illustrated below the line in red, 
but that the residuals fall within ± 3 standard deviations. 
 
Figure 4.7: Model Fit Chart of Deviance Residual 
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Objective 1: Logistic model results 
Objective 1 full model. Objective 1 assessed the independent determinants of 
non-adherence to ART among Medicaid-insured previously treatment-naïve PLWHA. 
Given that the dependent variable (non-adherence versus adherence) was dichotomous, a 
multivariable logistic regression model was built.  
In the full logistic regression model shown in Table 4.23 below, individuals 
classified as black race, non-Hispanic ethnicity were found to have over 2.3 times the 
odds (OR=2.31, 95% CI=1.28-4.18, p<.01) of being classified as non-adherent to ART 
(<90% MPR), as compared to their white counterparts. The other race classification 
subjects (Asian, American Indian, Alaskan Native, or not determined) were also 
significantly more likely to be non-adherent to ART compared to whites (OR=3.13, 
CI=1.03-9.48, p<.05). In the full model, subjects reported as Hispanic race and/or 
ethnicity were also statistically significantly associated with being classified as non-
adherent to ART (OR 2.37, CI=1.05-5.34, p<.05).  
As compared to individuals taking a single antiretroviral medication, individuals 
filling three to five ART medications had over twice the odds of non-adherence 
(OR=2.04, 95% CI=1.04-4.01, p<.05); and subjects with six or more ART medications 
were 4.58 times the odds of being non-adherent (95% CI=1.82-11.56, p<.01), as 
compared to those taking only a single ART medication. The number of concurrent 
medications in the ART regimen was a moderator for regimen types included in the 
model. When the number of concurrent medications were removed from the model, those 
taking NNRTI-based regimens have 53% higher odds of being adherent, as compared to 
protease inhibitor based regimens (OR=.47, 95% CI=.29-.76, p<.01). Adverse drug 
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reactions (ADR), lessens the effect size of the number of concurrent medications in ART 
variables, but does not change their significance in the model. Also, existence of ADR do 
not impact regimen type when number of concurrent ART medications were removed 
from the model. 
TABLE 4.24: Full logistic regression model predicting non-adherence (<90% MPR) to antiretroviral therapy among previously ART-naïve Medicaid-insured PLWHA (n=514) 
 
Effect Odds Ratio χ2
Age Groups
18-34 0.808 0.363 1.799
35-49 0.826 0.416 1.639
50 years or older (reference) - - -
Sex
Female (reference) - - -
Male 0.682 0.401 1.159
Race and Ethnicity
White (reference) - - -
Black race non-hispanic 2.309 1.276 4.179 **
Other race, non-hispanic 3.128 1.031 9.484 *
Hispanic race and/or ethnicity 2.367 1.049 5.341 *
Counties by Median Income
Low Median Income - - -
High Median Income 1.892 0.876 4.088
Population density
Rural - - -
Urban 1.623 0.988 2.668
Eligibility for Medicaid
Continuous Enrollment - - -
Gap 1 to 3 months in a year 1.74 0.781 3.874
Medicaid Eligiblity Category
TANF - - -
SSI 1.535 0.822 2.869
ART Regimen
Boosted protease inhibitor - - -
Non-nucleoside reverse transcriptase inhibitor 0.694 0.383 1.257
Other antiretroviral classes (INSTI, nucleocide 
sparing and single ART) 0.824 0.32 2.122
Number of Concurrent ARV Medicines
1 (reference) - - -
2 1.889 0.892 4.004
3 to 5 2.04 1.037 4.013 *
6 or more 4.58 1.815 11.556 **
95% Confidence Limits
Table 4.24: Full logistic regression model predicting non-adherence (<90% MPR) to 
antiretroviral therapy among previously ART-naïve Medicaid-insured PLWHA (n=514)
*** < 0.001; ** <0.01; * <0.05 
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As compared to those subjects with no chronic disease diagnoses, subjects with 
one or more non-HIV chronic disease (see Table 4.21) have 54% higher odds of 
adherence to ART (OR=.46, 95% CI=.26-.84, p<.01). The association of chronic disease 
one or more non-HIV chronic disease to ART adherence persisted with the inclusion of 
the “meeting minimum recommended average outpatient visits” variable in the model. 
Meeting minimum recommended average outpatient visits was defined as meeting the 
minimum recommended outpatient care visits requirement (mean of greater than or equal 
to 4 annually). In addition, the significance and effect size of non-HIV chronic disease to 
ART adherence persisted when outpatient utilization was measured on a continuous scale 
(not included here). 
Finally, among those subjects with two or more antidepressant medication refills, 
those that were adherent to their antidepressants (greater than or equal to 80% medication 
Effect Odds Ratio χ2
Meeting minimum outpatient recommendations
< 4 annual outpatient visits mean (reference) - - -
> 4 annual outpatient visits mean 0.748 0.436 1.283
HIV/AIDS Status
HIV (reference) - - -
AIDS
Disease Progression 0.975 0.366 2.602
Non-HIV chronic disease diagnoses
No other chronic disease diagnosis - - -
1 or more non-HIV chronic disease diagnosis 0.464 0.257 0.836 **
Mental Illness Comorbidities
Depression or anxiety diagnosis 1.308 0.706 2.423
Substance abuse and/or alcohol abuse 1.127 0.46 2.763
Severe mental illness 1.682 0.766 3.691
Antidepressant Regimen
Less than 2 antidepressant prescription claims - - -
2 or more antidepressant prescription claims 0.821 0.473 1.422
<80% antidepressant MPR - - -
>80% antidepressant MPR 0.276 0.142 0.537 **
95% Confidence Limits
Continued, Table 4.24: Full logistic regression model predicting non-adherence (<90% MPR) 
to antiretroviral therapy among previously ART-naïve Medicaid-insured PLWHA (n=514)
*** < 0.001; ** <0.01; * <0.05 
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possession ratio) have 72% greater odds of adherence to ART than those non-adherent to 
antidepressants (OR=.28, 95% CI=.14-.54, p<.01). 
Objective 1 reduced model. In the reduced model shown in Table 4.25, 
individuals classified as black race, non-Hispanic ethnicity were found to have twice the 
odds (OR=2.00, 95% CI=1.16-3.45, p<.01) of being classified as non-adherent to ART, 
as compared to whites.  
TABLE 4.25: Reduced logistic regression model predicting non-adherence (<90% MPR) to antiretroviral therapy among previously ART-naïve Medicaid-insured PLWHA (n=514) (n=514) 
 
Also in Table 4.25 above, the reduced logistic model results show that the other 
race classification had 3.32 times higher odds of being non-adherent to ART (OR=3.32, 
CI=1.14-9.67, p<.05). Hispanic race and/or ethnicity had a non-significant association to 
non-adherence to ART. Individuals living in urban counties in Florida had over two times 
Effect Odds Ratio χ
2
Race and Ethnicity
White (reference) - - -
Black race non-Hispanic 2.00 1.16 3.45 *
Other race, or not determined, non-Hispanic 3.32 1.14 9.67 *
Hispanic race and/or ethnicity 2.02 0.94 4.33
Population density
Rural - - -
Urban 2.19 1.05 4.56 *
Number of Concurrent ARV Medicines
1 (reference) - - -
2 2.39 1.20 4.76 *
3 to 5 2.88 1.67 4.95 **
6 or more 6.68 2.88 15.49 ***
Non-HIV chronic disease diagnoses
No other chronic disease diagnosis - - -
1 or more non-HIV chronic diagnosis 0.57 0.33 0.96 *
Antidepressant Regimen (2 or more claims)
<80% antidepressant MPR - - -
>80% antidepressant MPR 0.38 0.22 0.64 **
*** < 0.001; ** <0.01; * <0.05 
95% Confidence 
Limits
Table 4.25: Reduced logistic regression model predicting non-adherence (<90% MPR) to 
antiretroviral therapy among previously ART-naïve Medicaid-insured PLWHA (n=514)
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higher odds of being classified in the low ART adherence group (OR=2.19, 95% 
CI=1.01-2.64, p<.05), as compared to those living in rural counties. High/low median 
income county of residence was made non-significant by inclusion of the rural counties 
variable. 
As compared to individuals taking a single antiretroviral therapy medication, 
individuals taking two ART medications were found to have over 2.3 times the odds 
(OR=2.39, 95% CI=1.20-4.76, p<.05) of being classified as non-adherent to ART (<90% 
MPR). Additionally, subjects filling three to five ART medications had almost 2.9 times 
the odds of non-adherence (OR=2.88, 95% CI=1.67-4.95, p<.01); and subject with six or 
more ART medications were 6.7 times as likely to be non-adherent (OR=6.68, 95% 
CI=2.88-15.49, p<.001), as compared to those taking only a single ART. When the 
number of concurrent medications were removed from the reduced model, those taking 
NNRTI-based regimens have 57% higher odds of being adherent, as compared to 
protease inhibitor based regimens (95% CI=.26-.69, p<.01). Adverse drug reactions 
lessens the effect size of the number of concurrent medications in ART variables, but 
does not change their significance in the model. Also, existence of ADR do not impact 
regimen type variable significance in the model when numbers of concurrent ART 
medications were removed. 
Also, non-HIV chronic diseases play a statistically significant part of predicting 
non-adherence to ART. As compared to those with no chronic disease diagnoses, subjects 
with at least one chronic disease diagnosis were 43% less likely to be classified as non-
adherent to ART (OR=0.57, 95% CI=.33-.96, p<.05). The existence of one or more ADR 
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lessens the coefficient of non-HIV chronic diseases, but does not change the significance 
in the model. 
Finally, subjects with two or more antidepressant medication refills do not have 
significantly different odds of non-adherence to ART, as compared to those with one or 
less antidepressant medication refills. However, among subjects with two or more 
antidepressant medication refills, those with greater than or equal to 80% medication 
possession ratio were 62% less likely to be classified as non-adherent (OR=0.38, 95% 
CI=.22-.64, p<.01). 
Objective 2: Descriptive results 
Objective 2 modeled the mean monthly total healthcare expenditures for the 
measurement period of those PLWHA in the ART non-adherent group (<90%) as 
compared to the ART adherent group (>90%), controlling for demographic, clinical and 
healthcare utilization factors. The Objective 2 sample of 502 subjects by HIV and AIDS 
disease status and adherence group is shown in Table 4.26.  
TABLE 4.26: Proportion of HIV or AIDS disease status by adherence 
and non-adherence categories for Medicaid-insured previously ART 
naïve PLWHA (n=502) 
    HIV (n=232)   AIDS (n=270)   Total Total 
    n %   n %   n % 
> 90% MPR   56 52.3%   51 47.7%   107 21.3% 
< 90% MPR   176 44.6%   219 55.4%   395 78.7% 
 
The mean total healthcare expenditures for Florida Medicaid among PLWHA was 
the outcome variable of Objective 2. The unadjusted mean monthly per subject total 
healthcare expenditures for the 24 month period for the overall sample (n=502) was 
$1,875. Figure 4.7 shows the mean unadjusted monthly total healthcare expenditures for 
the non-adherent group (n=395) was $1,847; the unadjusted mean monthly total 
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healthcare expenditures for the adherent group (n=107) was $1,976. An examination of 
the expenditure components confirms that the adherent group had higher mean ART 
pharmacy costs ($849 versus $445), but lower mean inpatient costs ($324 versus $745), 
as compared to the non-adherent group. 
 
Figure 4.8: Unadjusted mean monthly total healthcare expenditures by 
ART adherence category 
Table 4.27 lists the mean total healthcare expenditures by category and the 
relative proportions for the non-adherent and adherent groups and the overall means. TABLE 
4.27: Unadjusted mean monthly total healthcare expenditures by category among Medicaid-insured ART-naïve PLWHA and antiretroviral therapy adherence category (n=502) 
 
$418 $502
$745
$324
$184
$279
$445 $849
$56
$21
$0
$500
$1,000
$1,500
$2,000
$2,500
Non-adherent (n=395) Adherent (n=107)
Outpatient Inpatient Rx (Non-ART) ART Rx BH Inpatient
mean % mean % mean %
Outpatient $418 22.6% $502 25.4% $436 23.3%
Inpatient $745 40.3% $324 16.4% $655 34.9%
Rx (Non-ART) $184 10.0% $279 14.1% $205 10.9%
ART Rx $445 24.1% $849 43.0% $531 28.3%
BH Inpatient $56 3.0% $21 1.1% $48 2.6%
Non-adherent (<90% 
MPR; n=232)
Adherent MPR 
(>90% MPR; n=107) Total
TABLE 4.27: Unadjusted mean monthly total healthcare expenditures by 
category among Medicaid-insured ART-naïve PLWHA and antiretroviral therapy 
adherence category (n=502)
$1,847 $1,976 
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As shown in Figure 4.9, the mean monthly total healthcare expenditures vary 
greatly between HIV-positive ($1,439) and AIDS-diagnosed subjects ($2,250). The 
unadjusted mean monthly ART pharmacy expenditures for HIV-positive were $497 and 
$560 for AIDS-diagnosed subjects. The unadjusted mean monthly inpatient expenditures 
for HIV-positive were $318, and $944 for AIDS-diagnosed subjects. 
 
 
Figure 4.9: Unadjusted mean monthly total healthcare expenditures by 
HIV/AIDS status by ART adherence category 
 
Figure 4.10 shows that the lowest unadjusted mean monthly total healthcare 
expenditure group was non-adherent HIV-positive individuals ($1,280), and the highest 
was the non-adherent AIDS-diagnosed subjects ($2,017). Separate linear regression 
models for the HIV-positive and AIDS diagnosed groups were developed.  
$401 $467
$318
$944
$162
$241
$497
$560
$61
$38
$0
$500
$1,000
$1,500
$2,000
$2,500
HIV (n=232) AIDS (n-270)
Outpatient Inpatient Rx (Non-ART) ART Rx BH Inpatient
$1,439 
$2,250 
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Figure 4.10: Unadjusted mean monthly total healthcare expenditures by 
ART adherence category 
Table 4.28 and Table 4.29 show the unadjusted mean monthly healthcare 
expenditures and the relative proportion for HIV-positive and AIDS-diagnosed subjects, 
respectively. The unadjusted mean monthly inpatient expenditures for non-adherent 
AIDS-diagnosed subjects ($1,084) were almost three times the mean expenditures for the 
adherent AIDS-diagnosed group ($341). The unadjusted mean ART expenditures for the 
AIDS-diagnosed adherent group ($946) was about twice the mean expenditures for the 
non-adherent AIDS group ART expenditures ($470).  
TABLE 4.28: Monthly expenditures by category for HIV-positive 
subjects by adherence category (n=232) 
  
Non-adherent (<90%; 
n=176)   
Adherent (>90%; 
n=56) 
  mean %   mean % 
Outpatient $329 25.7%   $628 32.4% 
Inpatient $322 25.1%   $309 15.9% 
Rx (Non-ART) $147 11.5%   $210 10.8% 
ART Rx $413 32.2%   $761 39.3% 
BH Inpatient $70 5.5%   $30 1.6% 
Total $1,280 100%   $1,938 100% 
 
$329
$628 $490 $365
$322
$309
$1,084
$341
$147
$210
$215
$354$413
$761
$470
$946
$70
$30
$44
$11
$0
$500
$1,000
$1,500
$2,000
$2,500
<90% MPR HIV 
(n=176)
>/90% MPR HIV 
(n=56)
<90% MPR AIDS 
(n=219)
>/90% MPR AIDS 
(n=51)
Outpatient Inpatient Rx (Non-ART) ART Rx BH Inpatient
$1,938
$2,304
$2,017
$1,280 
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TABLE 4.29: Monthly expenditures by category for AIDS-
diagnosed subjects by adherence category (n=270) 
  
Non-adherent (<90%; 
n=219)   
Adherent (>90%; 
n=51) 
  mean %   mean % 
Outpatient $490 21.3%   $365 18.1% 
Inpatient $1,084 47.1%   $341 16.9% 
Rx (Non-ART) $215 9.3%   $354 17.5% 
ART Rx $470 20.4%   $946 46.9% 
BH Inpatient $44 1.9%   $11 0.6% 
Total $2,304 100%   $2,017 100% 
 
Covariate factors by adherence group, including demographic, geographic, 
Medicaid eligibility, and comorbidities are shown below. Table 4.30 shows the sample 
characteristics for the HIV-positive group by non-adherence and non-adherence.  
TABLE 4.30: Descriptive statistics for HIV-positive Medicaid-insured subjects by ART medication possession ratio adherence categories (n=232) 
 
 
n % n % n %
Subjects 176 75.9% 56 24.1% 232 100%
Age groups
18–34 73 41.5% 17 30.4% 90 38.8%
35–49 73 41.5% 29 51.8% 102 44.0%
50 years or older (reference) 30 17.0% 10 17.9% 40 17.2%
Sex
Male 54 30.7% 17 30.4% 71 30.6%
Female  (reference) 122 69.3% 39 69.6% 161 69.4%
Race/Ethnicity
White race non-hispanic 26 14.8% 17 30.4% 43 18.5%
Black race non-hispanic 115 65.3% 31 55.4% 146 62.9%
Other race or Not Determined, 
non-Hispanic 
10 5.7% 2 3.6% 12 5.2%
Hispanic race and/or ethnicity 25 14.2% 6 10.7% 31 13.4%
TABLE 4.30: Descriptive statistics for HIV-positive Medicaid-insured subjects 
by ART medication possession ratio adherence categories (n=232)
< 90% MPR > 90%MPR Total
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TABLE 4.30: Descriptive statistics for HIV-positive Medicaid-insured subjects by ART medication possession ratio adherence categories (n=232) 
 
Table 4.31 shows the characteristics for the AIDS-diagnosed subjects. 
TABLE 4.31: Descriptive statistics for AIDS-diagnosed Medicaid-insured subjects by ART medication possession ratio adherence categories (n=270) 
 
n % n % n %
Geographic Areas - High and Low 
Median Income
Low 64 36.4% 26 46.4% 90 38.8%
High 112 63.6% 30 53.6% 142 61.2%
Geographic Areas - Rural and 
Urban Counties
Rural 15 8.5% 9 16.1% 24 10.3%
Urban 161 91.5% 47 83.9% 208 89.7%
Eligibility category 
SSI 127 72.2% 42 75.0% 169 72.8%
TANF (reference) 49 27.8% 14 25.0% 63 27.2%
Discontinuous coverage (up to 3 
months ineligibility per year) 27 15.3% 4 7.1%
31
13.4%
Mental Illness Comorbidities
Depression and/or anxiety 41 23.3% 15 26.8% 56 24.1%
Alcohol abuse and/or substance 
abuse 12 6.8% 4 7.1%
16 6.9%
Severe mental illness 22 12.5% 7 12.5% 29 12.5%
Co-morbidity diagnoses counts
No comorbidities (reference) 58 33.0% 22 39.3% 80 34.5%
1 51 29.0% 11 19.6% 62 26.7%
2 or more 67 38.1% 23 41.1% 90 38.8%
Continued, TABLE 4.30: Descriptive statistics for HIV-positive Medicaid-
insured subjects by ART medication possession ratio adherence categories 
(n=232)
< 90% MPR > 90%MPR Total
n % n % n %
Subjects 219 81.1% 51 18.9% 270 100%
Age groups
18–34 59 26.9% 14 27.5% 73 27.0%
35–49 129 58.9% 29 56.9% 158 58.5%
50 years or older (reference) 31 14.2% 8 15.7% 39 14.4%
TABLE 4.31: Descriptive statistics for AIDS-diagnosed Medicaid-insured subjects by 
ART medication possession ratio adherence categories (n=270)
< 90% MPR Total> 90%MPR
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n % n % n %
Sex
Male 66 30.1% 24 47.1% 90 33.3%
Female (reference) 153 69.9% 27 52.9% 180 66.7%
Race/Ethnicity
White race, non-Hispanic  
(reference) 40 18.3% 18 35.3% 58 21.5%
Black race, non-Hispanic 128 58.4% 22 43.1% 150 55.6%
Other race or Not Determined, 
non-Hispanic 
24 11.0% 3 5.9% 27 10.0%
Hispanic race and/or ethnicity 27 12.3% 8 15.7% 35 0.1296
Geographic Areas - High and Low 
Median Income
Low 71 32.4% 24 47.1% 95 35.2%
High 148 67.6% 27 52.9% 175 64.8%
Geographic Areas - Rural and 
Rural 12 5.5% 6 11.8% 18 6.7%
Urban 207 94.5% 45 88.2% 252 93.3%
Eligibility category 
SSI 171 78.1% 39 76.5% 210 77.8%
TANF (reference) 48 21.9% 12 23.5% 60 22.2%
Discontinuous coverage (up to 3 
months ineligibility per year) 27 12.3% 5 9.8% 32 11.9%
Mental Illness Comorbidities
Depression and/or anxiety 
diagnosis
61 27.9% 13 25.5% 74 27.4%
Alcohol abuse and/or substance 
abuse
30 13.7% 5 9.8% 35 13.0%
Severe mental illness 28 12.8% 7 13.7% 35 13.0%
Co-morbidity diagnoses counts
No comorbidities (reference) 42 19.2% 11 21.6% 53 19.6%
1 36 16.4% 13 25.5% 49 18.1%
2 or more 141 64.4% 27 52.9% 168 62.2%
Continued, TABLE 4.31: Descriptive statistics for AIDS-diagnosed Medicaid-insured 
subjects by ART medication possession ratio adherence categories (n=270)
< 90% MPR Total> 90%MPR
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Objective 2: Model diagnostics 
Objective 2 of this research predicted mean monthly total healthcare expenditures 
in the 24 month measurement for subjects in the ART adherence and non-adherence 
groups, controlling for demographic, geographic, Medicaid eligibility and clinical factors.  
Healthcare expenditures are typically positively skewed with a very long right tail 
and non-normally distributed (Manning, Basu, & Mullahy, 2003). The HIV mean 
healthcare expenditures in this research were no exception, as the skewness was 3.00, and 
the kurtosis was 10.6. The Kolmogorov-Smirnov test of goodness-of-fit confirms the 
non-normality (p<0.001).  
 
 
Figure 4.11: Non-normal distribution of total 
healthcare expenditure for the HIV-positive group 
 
Figure 4.11 illustrates the non-normal shape of the distribution of the total 
healthcare expenditure (Q) for the HIV-positive group. The AIDS-diagnosed group mean 
healthcare expenditures distribution also was skewed and non-normal (3.02) and kurtotic 
(10.9) The Kolmogorov-Smirnov test of goodness-of-fit confirms the non-normality 
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(p<0.001). Figure 4.10 shows the distribution more closely follows a gamma distribution 
curve. Note extreme variance illustrated in the histogram in Figure 4.10, also true for the 
AIDS model. While the unadjusted mean for the HIV-positive mean monthly total 
expenditure was $1,439, and the median was only $974. The AIDS model mean was 
$2,250, and the median was $1,341. These differences between the mean and the median 
indicate the importance of high value outliers in the model distributions.  
To account for the skewed distribution and wide variation in expenditures, recent 
health economics literature modeling health care expenditures using a generalized linear 
model with a gamma distribution and a log link variance function (Clark, Yampolskaya, 
& Robst, 2011; Manning et al., 2003; Manning, Basu, Mullahy, & Manning, 2002; 
Manning, 2012; Moran, Solomon, Peisach, & Martin, 2007; Mullahy, 1998, 2009; 
Nachega et al., 2010; Robst, 2009, 2012). An alternate method of estimation in order to 
correct for skewness is through lognormal transformation of the healthcare expenditure 
dependent variable (Manning & Mullahy, 2001). Although transforming the expenditures 
can cause problems with interpretation and retransformation bias (Manning et al., 2002), 
ordinary least squares (OLS) can be modeled with the resultant normally distributed 
dependent variable.  
Manning and Mullahy (2001) recommend procedures to determine which 
approach (GLM versus OLS) is more appropriate. First, the log-scale residuals should be 
obtained by estimating the expenditure dependent variable using GLM. In order for a 
GLM model to be appropriate, the coefficient of kurtosis of the log-scale residuals should 
be less than three. In the cases of the HIV and AIDS models, the log-scale residuals 
  
coefficient of kurtosis was less than three (1.22 and .29, respectively). Thus, a GLM 
model was preferred over OLS.
Figure 4.12 shows that the residua
were slightly heteroscedastic
Although not a focus of this study, 
heteroscedasticity would impact the 
precision of the coefficients and cause 
problems of assessing the relative 
importance of various factors in the 
model in predicting the expenditure outcome variable 
Objective 2: Model results
A regression analysis estimated the expected per patient mean monthly total 
healthcare expenditures, as measured on a continuous scale. As discussed above, given 
the disparity in mean total he
the AIDS-diagnosed group show
2) AIDS. Both of the models were specified with the same parameters. 
Objective 2 multivariate 
(GLM) with a log link function and gamma distribution was employed 
Mullahy, 2001). The model 
ART adherence group and 
geographic, clinical, and Medicaid eligibility factors. 
total healthcare expenditures (Q) for the 
less than those in the ART non
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ls 
. 
(Moran et al., 2007)
 
althcare expenditures between the HIV-positive group and 
n in Figure 4.8, two models were specified: 1) HIV and 
 
regression HIV model. A generalized linear model 
(Manning & 
predicted the mean monthly total healthcare expenditures for 
non-adherence group, controlling for demographic, 
It was hypothesized that the mean 
in the ART adherence group (>90%) would be 
-adherence group (<90%).  
Figure 4.12: Predicted residuals 
.  
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As shown in Table 4.32 below, the results indicate that, controlling for other 
factors, the null hypothesis was not rejected for the HIV-positive group. Interpretation of 
the estimate for the non-adherent group was reported as relative to the reference group 
and computed as e- 1. The non-adherent group has significantly lower expected total 
healthcare expenditures (-40%, p<.001) than the ART adherent group.  
 
TABLE 4.32: Generalized Linear Model (gamma, log link) for total healthcare costs in 24 month period among Medicaid-insured previously antiretroviral therapy 
(ART) naïve HIV-positive subjects (n=232) 
ART adherence
< 90% MPR -0.52 0.11 -0.29 -0.74 <.001 *** -0.40
> 90% MPR (reference) - - - - -
Age groups
18–34 -0.11 0.15 0.18 -0.41 0.4489 -0.11
35–49 -0.02 0.14 0.26 -0.30 0.9015 -0.02
50 years or older (reference) - - - - -
Sex
Male -0.05 0.11 0.17 -0.27 0.6374 -0.05
Female  (reference) - - - - -
Race/Ethnicity
White race, non-Hispanic 
(reference) - - - - -
Black race non-Hispanic 0.11 0.13 0.37 -0.14 0.3845 0.12
Other race, or not determined,  
non-Hispanic 0.15 0.25 0.63 -0.34 0.5554 0.16
Hispanic race and/or ethnicity 0.12 0.18 0.46 -0.23 0.5134 0.12
*** < 0.001; ** <0.01; * <0.05 
TABLE 4.32: Generalized Linear Model (gamma, log link) for total healthcare costs in 
24 month period among Medicaid-insured previously antiretroviral therapy (ART) naïve 
HIV-positive subjects (n=232)
Parameter Estimate Std Error 95% Confidence 
Limits
P 
value
eβ  - 1
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The mean predicted per person mean monthly expenditures for the non-adherent group 
was $1,291 (95% CL $840-$2,004); the mean predicted per person mean monthly 
expenditures for the adherent group was $1,926 (95% CL $1,157-$3,231). 
High & Low Median Income 
Counties
Low 0.29 0.10 0.50 0.09 0.0045 ** 0.34
High - - - - -
Rural and Urban Counties
Rural 0.07 0.16 0.38 -0.25 0.6805 0.07
Urban - - - -
Eligibility category 
SSI 0.14 0.12 0.37 -0.09 0.223 0.15
TANF (reference) - - - -
Discontinuous coverage (up to 3 
months ineligibility in year) -0.07 0.10 0.13 -0.27 0.4795 -0.07
Mental Illness Comorbidities
Depression and/or anxiety 
diagnosis 0.37 0.12 0.62 0.13 0.0025 ** 0.45
Alcohol abuse and/or 
substance abuse 0.34 0.21 0.75 -0.07 0.1057 0.41
Severe mental illness 0.10 0.17 0.43 -0.23 0.5373 0.11
Other co-morbidity levels 
(counts)
0 (reference) - - - - -
1 0.11 0.12 0.36 -0.13 0.355 0.12
2 or more 0.85 0.12 1.08 0.62 <.001 *** 1.34
*** < 0.001; ** <0.01; * <0.05 
Continued, TABLE 4.32: Generalized Linear Model (gamma, log link) for total 
healthcare costs in 24 month period among Medicaid-insured previously antiretroviral 
therapy (ART) naïve HIV-positive subjects (n=232)
Parameter Estimate Std Error 95% Confidence 
Limits
P 
value
eβ  - 1
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Figure 4.13: HIV-positive model adjusted mean total 
healthcare expenditures (n=232) 
Also, the model indicated that those living in low median income counties had 
significantly higher expected mean monthly total healthcare expenditures for the 
measurement period (34%, p<.01). Also, subjects diagnosed with depression and/or 
anxiety had significantly higher expected mean monthly total healthcare expenditures 
(45%, p<.01), compared to those without a depression and/or anxiety diagnosis. Finally, 
the HIV-positive subjects with 2 or more comorbidities had significantly higher expected 
mean total monthly healthcare expenditures for the 24 month measurement period, as 
compared to those subjects with no comorbidity diagnoses (134%, p<.001). 
Objective 2 multivariate regression AIDS model. As with the HIV-positive 
model above, regression analysis for the AIDS-diagnosed group estimated the expected 
per patient mean monthly total healthcare expenditures in the 24 month measurement 
(n=270). Using GLM with a log link function and gamma distribution, the model 
predicted the difference the mean monthly total healthcare expenditures for ART 
adherence group and non-adherence group, controlling for relevant factors. It was 
$1,291
$1,926
$0
$500
$1,000
$1,500
$2,000
$2,500
Non-adherent(<90%; n=176) Adherent (>90%; n=56)
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hypothesized that the mean total healthcare expenditures (Q) for the ART adherence 
group would be less than those in the ART non-adherence group.  
As shown in Table 4.33 below, the null hypothesis was not rejected. Controlling 
for other model factors, there was no significant difference between the expected mean 
monthly total healthcare expenditures ART non-adherent group and the ART adherent 
group among the AIDS-diagnosed subjects. The mean predicted per person mean 
monthly expenditures for the non-adherent group was $2,279 (95% CL $1,572-$3,322); 
the mean predicted per person mean monthly expenditures for the adherent group was 
$2,005 (95% CL $1,387-$2,913).  
TABLE 4.33: Generalized Linear Model (gamma, log link) for total healthcare costs in 24 month period among Medicaid-insured previously antiretroviral therapy 
(ART) naïve AIDS-diagnosed subjects (n=270) 
 
 
ART adherence
< 90% MPR -0.12 0.1103 0.10 -0.33 0.29 -0.11
> 90% MPR (reference) - - - -
Age groups
18–34 -0.18 0.1449 0.10 -0.46 0.22 -0.16
35–49 -0.03 0.1252 0.22 -0.28 0.81 -0.03
50 years or older (reference) - - - -
Sex
Male -0.10 0.095 0.08 -0.29 0.27 -0.10
Female  (reference) - - - -
Race/Ethnicity
White race, non-Hispanic 
(reference) - - - -
Black race non-Hispanic -0.06 0.1129 0.16 -0.28 0.57 -0.06
Other race, or not determined,  
non-Hispanic -0.05 0.1608 0.27 -0.36 0.76 -0.05
Hispanic race and/or ethnicity -0.01 0.1525 0.29 -0.31 0.95 -0.01
*** < 0.001; ** <0.01; * <0.05 
TABLE 4.33: Generalized Linear Model (gamma, log link) for total healthcare costs in 
24 month period among Medicaid-insured previously antiretroviral therapy (ART) naïve 
AIDS-diagnosed subjects (n=270)
Parameter Estimate Std Error 95% Confidence 
Limits
P 
value
eβ  - 1
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Also shown in Table 4.33 above, those living in low median income counties had 
significantly higher expected total healthcare expenditures (37%, p<.01). Additionally, 
subjects diagnosed with severe mental illness (SMI) had significantly higher expected 
total healthcare expenditures (52%, p<.01). Finally, the AIDS-diagnosed subjects with 2 
or more comorbidities had significantly higher expected mean monthly total healthcare 
expenditures for the 24 month measurement period, as compared to those subjects with 
no comorbidity diagnoses (191%, p<.001).   
High & Low Median Income 
Counties
Low 0.31 0.091 0.49 0.13 0.001 ** 0.37
High - - - -
Rural and Urban Counties
Rural -0.25 0.1744 0.09 -0.60 0.15 -0.22
Urban - - - -
Eligibility category 
SSI 0.07 0.1192 0.31 -0.16 0.54 0.08
TANF (reference) - - -
Discontinuous coverage (up to 3 
months ineligibility in year) 0.05 0.0969 0.24 -0.14 0.60 0.05
Mental Illness Comorbidities
Depression and/or anxiety 
diagnosis -0.01 0.0975 0.18 -0.20 0.92 -0.01
Alcohol abuse and/or substance 
abuse 0.15 0.1316 0.41 -0.11 0.26 0.16
Severe mental illness 0.42 0.128 0.67 0.17 0.001 ** 0.52
Other co-morbidity levels (counts)
0 (reference) - - - -
1 0.27 0.1396 0.54 -0.01 0.05 0.31
2 or more 1.07 0.1148 1.29 0.84 <0.001 *** 1.91
*** < 0.001; ** <0.01; * <0.05 
Continued, TABLE 4.33: Generalized Linear Model (gamma, log link) for total 
healthcare costs in 24 month period among Medicaid-insured previously antiretroviral 
therapy (ART) naïve AIDS-diagnosed subjects (n=270)
Parameter Estimate Std Error 95% Confidence 
Limits
P 
value
eβ  - 1
 87 
 
 
 
 
Chapter Five: Conclusions and Recommendations 
 
Objective 1: Discussion 
When antiretroviral medication therapy (ART) is available to PLWHA, 
HIV/AIDS becomes a chronic disease. Poor ART adherence predicts increased morbidity 
and mortality (Hogg et al., 2002; Lieb et al., 2002), virologic failure (Maggiolo et al., 
2005) and increases HIV transmission risk (Reynolds et al., 2011). Unfortunately, the 
results of Objective 1 confirm that most subjects were non-adherent to ART (78.7%), and 
that the determinants associated with non-adherence among vulnerable populations were 
multifaceted. 
Using retrospective Medicaid administrative claims, Objective 1 of this research 
examined the factors associated with ART non-adherence among previously 514 non-
pregnant, non-elderly ART naïve Medicaid-insured adults diagnosed with HIV or AIDS. 
A closer examination of the PLWHA sample characteristics revealed subjects similar to 
Florida Medicaid enrollment as a whole. Females made up over 64% of non-elderly adult 
Florida Medicaid enrollment, and under 35 year old adult population was over 50% of the 
total (Florida Agency for Health Care Administration, 2013). In this sample, the largely 
young and female proportions (one-third under 35 and two-thirds female) represent the 
typical Medicaid-eligible population, rather than the older and male-dominated U.S. 
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population of PLWHA (where 51% were under the age of 44 years and only 24.3% were 
female) (Centers for Disease Control and Prevention, 2012). 
Furthermore, Florida Medicaid was disproportionately comprised of blacks 
(28%), as compared to the general U.S. population (13%) (Florida Agency for Health 
Care Administration, 2013; U.S. Census Bureau, 2013a). Also, blacks account for greater 
proportion of HIV prevalence in the U.S. (44%) than any other racial category (Centers 
for Disease Control and Prevention, 2012). The high proportion of blacks in this sample 
(59%) was consistent with the large proportion enrolled in Medicaid and disproportionate 
share that have been diagnosed with HIV in the United States. Not surprisingly, a large 
majority of subjects live in urban counties (91%). This sample characteristic sets a 
context for the subjects of being economic disadvantaged. 
Finally, Florida Medicaid eligibility for non-elderly adults have been split roughly 
in half among Temporary Assistance for Needy Families (TANF), a program for low-
income families with children, and Supplemental Security Income (SSI), a program for 
low-income, disabled persons (Agency for Health Care Administration, 2013a, 2013b; 
Florida Agency for Health Care Administration, 2013). In this sample, however, over 
76% of the subjects were eligible for Medicaid through the SSI program. This Medicaid 
eligibility characteristic indicates that a majority of the subjects were sick enough for 
their doctors to certify that they too sick to work (“Social Security for People Living with 
HIV/AIDS,” 2005). 
As described above, among the 514 subjects in the study, 21.3% were adherent 
(>90% MPR) to ART, and the overall mean adherence was 56%. The adherence to ART 
in this research was similar to the pooled mean of 55% (95% CI, 0.49-0.62) produced by 
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Mills et al. (2006) meta-analysis. Another large study of 3,788 Medicaid-insured 
subjects, found that 26% of the subjects were 80% adherent to ART, and the overall 
adherence mean was 53% (Becker, 2002). Thus, the proportion of adherent subjects and 
overall mean adherence percentage among the sample used in this research was similar to 
another large Medicaid-insured study cohort.  
According to the results of the full and partial logistic regression models, race and 
ethnicity were important factors associated with non-adherence to ART. While race and 
ethnicity have not been universally found to be related to non-adherence to ART in the 
published literature (Mills et al., 2006), among other ART adherence studies examining 
Medicaid-insured or low-income subjects, race and ethnicity were significant predictors 
of non-adherence (Kong et al., 2012; Lillie-Blanton et al., 2010; Zhang et al., 2013). 
Other social factors, including racism, may be at play in low income populations that 
render race and ethnicity a significant factor in ART adherence. It may be that 
interactions of various stigmas, including Medicaid insurance coverage, racial 
discrimination and HIV-status, play in ART non-adherence among low-income 
individuals (Bogart, Wagner, Galvan, & Klein, 2010).  
Also, this research found a strong relationship between the number of concurrent 
of ART medications filled in the first month and non-adherence ART. Although other 
ART adherence studies have found association with the number concurrent of ART 
medications (Bangsberg et al., 2010; Kleeberger et al., 2001; Lazo et al., 2007; Maggiolo 
et al., 2005), others show no relationship to non-adherence (Moore et al., 2011; Singh et 
al., 1999). Despite the inconsistent findings in the literature, the number of concurrent 
medications appears to be important, especially among vulnerable populations, such as 
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Medicaid and/or insured low-income populations (Bangsberg et al., 2010). In fact, the 
results of this research showed the strength of association increases as the number of 
medication increases – from over two times for two medications to almost seven times 
the odds in the reduced model, as compared to a single medication fill.  
In addition, understanding the role non-HIV chronic disease comorbidities plays 
in ART adherence may be able to improve the treatment of PLWHA. The results of 
Objective 1 show that those with one or more non-HIV chronic disease diagnosis was 
negatively associated with non-adherence to ART, consistent with other studies 
(Crawford et al., 2013; Giordano et al., 2007; Webster, 2010). It is possible that chronic 
care practices by providers and/or self-management efforts by patients for other chronic 
diseases apply to ART adherence practices (Swendeman, Ingram, & Rotheram-Borus, 
2009).  
On the other hand, the opposite also may true. It may be possible that providers 
focus on sicker patients, and consequently, were inattentive to patients without 
comorbidities (Crawford et al., 2013). However, results from the present study showed 
that the association of a chronic disease diagnosis to ART non-adherence remained 
negatively significant even after controlling for measures of outpatient utilization. This 
result suggests that the effect may not be associated to volume of care provided, but 
rather related to the quality of that care. 
Considering the determinants to ART adherence broadly, the interplay of 
important unmeasured variables may be related to both non-HIV chronic disease and 
ART adherence may be at work. Perhaps absent in the model were variables measuring 
barriers to health seeking behaviors. Indeed, the most consistent association to non-
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adherence to ART across published studies have been those factors related to barriers to 
health seeking behaviors, such as low patient self-efficacy, life stress, and lack of social 
support (Ammassari et al., 2002), which were mot measured in the present study.  
Furthermore, the significance of adherence to antidepressant medications variable 
in the full and reduce models underscores the importance of possible unmeasured 
psychosocial variables. Specifically, the results showed that among those with an anxiety 
and/or depression diagnosis, adherence to antidepressant medications was positively 
related to ART adherence. It may be that the same behavioral factors that are associated 
with adherence to antidepressants are related with adherence to ART. 
In addition to unmeasured factors, the negative association of non-HIV chronic 
diseases to ART non-adherence may be confounded with adverse drug reactions (ADR). 
The inclusion of an ADR count variable in the model mediated the significance of the 
chronic disease variable’s significant negative association to non-adherence. There are a 
few relationships between covariates that should be considered. Most directly, ART 
adherence may lead to ADR diagnoses. For example, this research found significantly 
higher dyslipidemia (an abnormal level of lipids in the blood) in the ART adherent 
subjects, as compared to the non-adherent group (p<0.001). It can be reasonably 
concluded that dyslipidemia is an effect of increased ART (as opposed to the 
dyslipidemia increasing ART adherence). However, no differences between adherence 
groups were found for other ADR diagnoses, such as nausea and dizziness. One could 
conclude that nausea could be both a consequence of ART adherence and a cause of ART 
non-adherence (Capili & Anastasi, 1998). 
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Next, diagnoses classified as ADR in this research, such as nausea, dizziness, 
abnormal glucose and dyslipidemia, may be associated with chronic diseases 
independently of HIV-infection and ART. Strong association of dyslipidemia is seen in 
heart disease (Lehto et al., 1997), chronic kidney disease (Tsimihodimos, Mitrogianni, & 
Elisaf, 2011) and diabetes (Goldberg, 2001). Also, abnormal glucose has been found to 
be highly prevalent in coronary heart diseases (Bartnik et al., 2004).  
Lastly, the interplay of the three factors (ADR, ART adherence, and chronic 
disease) is further complicated by the influence of HIV-infection on chronic disease. For 
example, some cardiovascular complications, such as cardiomyopathy and pericarditis, 
are associated with HIV infection (Sudano et al., 2006). Also, the impact of HIV-
infection of osteoporosis was seen in HIV-positive subjects prior to the introduction of 
ART, although later found to be exasperated by protease inhibitor-based ART 
(Montessori, Press, Harris, Akagi, & Montaner, 2004).  
In the full model, the type of ART-regimen (PI, NNRTI, etc.) was found not to 
predict non-adherence to ART, consistent with other studies in literature (Ammassari et 
al., 2002). Although NNRTI resulted in significantly higher odds of non-adherence, as 
compared to PI regimens, in a version of the models, the statistical association did not 
exist when the number of concurrent ART medications was included in the model.  
Unexpectedly, mental illness comorbidities, such as depression and/or anxiety, 
severe mental illness, and alcohol abuse and/or substance abuse were not significant 
predictors of ART non-adherence in the full model. These results were surprising, since 
many studies these show strong associations of mental illness comorbidities to ART non-
adherence among many different populations and settings (Hendershot et al., 2009; Hicks 
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et al., 2007; Himelhoch et al., 2009; Horberg et al., 2008; Kleeberger et al., 2001; Mellins 
et al., 2009; Tegger et al., 2008).  
Also unexpected was the non-significance of the AIDS-diagnosis compared to the 
HIV-positive group in predicting ART non-adherence. According to Nieuwkerk et al. 
(2000), ART may benefit symptomatic individuals with HIV or AIDS, but ART may 
have a negative impact on asymptomatic HIV-positive subjects due to side effects and 
other burdens. Future research may be able to discriminate between asymptomatic HIV 
and symptomatic HIV subjects in order to illuminate any association of HIV infection 
disease severity with non-adherence to ART.  
Objective 1: Recommendations 
Based on the results of Objective 1, three policies are recommended. First, race 
and ethnicity factors were important factors associated with non-adherence in the present 
study and other published results on Medicaid-insured PLWHA (Kong et al., 2012; 
Lillie-Blanton et al., 2010; Zhang et al., 2013). Identification of these disparities has led 
to research uncovering the barriers to ART adherence for non-white PLWHA, such as co-
occurring stigmas associated with low-income, race, and HIV infection (Bogart et al., 
2010). Also, extensive ART adherence interventions guidelines have been promulgated 
based on a total of 325 randomized control trials and pilot studies (Thompson et al., 
2012). Therefore, researchers should focus on the translation of evidence on racial/ethnic 
disparities, cultural and behavioral barriers, and effective interventions to enable 
healthcare providers to improve ART adherence Medicaid-insured PLWHA. Translation 
and dissemination of these lines of research into practice is particularly salient from a 
policy perspective, as the Section 5307 of the Affordable Care Act authorized cultural 
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competency training for healthcare providers, but such Health Professions Education 
grants have yet to receive funding (National Association of County & City Health 
Officials, 2013). 
Next, in light of the association of comorbid chronic conditions with ART 
adherence, state policymakers should continue to support HIV chronic disease 
management. In Florida, statewide Medicaid disease management programs have been 
effective in reducing avoidable healthcare utilization and expenditures for patients with 
chronic illness (Mitchell & Anderson, 2000) and improve survival among PLWHA 
(Anderson & Mitchell, 2004). However, in the past, these programs have been conducted 
separately through the fee-for-service Medicaid program. The recent change to 
mandatory Medicaid managed care places the statewide AIDS disease management 
program in jeopardy. State Medicaid programs should continue the effective policy of 
contracting with competent disease management vendors that recognize the interplay of 
comorbid chronic conditions with HIV care management and ART adherence. 
Finally, the relationship of the number of concurrent ART medications in a 
regimen to ART adherence, suggests that policies related to regimen simplification would 
be prudent (Nachega et al., 2011). State Medicaid programs and managed care 
organizations often employ preferred drug lists (PDL) to control costs and ensure access 
(Ovsag, Hydery, & Mousa, 2008). Also, there are certain pharmaceutical “prior approval” 
strategies that are employed to change physician prescribing behaviors. For example, step 
therapy programs require certain drugs to be tried before other (usually more expensive) 
prescription medications are allowed to be filled at the pharmacy. This principle can be 
applied to changing physician prescribing patterns with the focus on increasing 
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medication adherence, rather than cost control (Parks & Surles, 2004). All PDL and prior 
approval policies should be conducted with Pharmacy and Therapeutics Committee and 
physician oversight. Policies to simplify first-line regimens utilizing specialized ART 
PDLs and prior approval processes could be implemented to improve ART adherence.  
Objective 1: Future research  
Substantial synthesis of ART adherence and the translation to effective 
interventions has been offered by previous research (Simoni, Amico, Smith, & Nelson, 
2010). Missing, however, are comparative effectiveness research (CER) regarding ART 
adherence among the Medicaid-insured. Among the 62 medication adherence CER 
studies found in a recent literature review by Simoni, et al. (2010), only one looked at 
PLWHA (in combination with depression), and none examined the Medicaid-insured 
population specifically. Especially considering the increased funding for CER offered by 
ACA, researchers should focus efforts on understanding the comparable effectiveness of 
interventions for improving ART adherence among the Medicaid-insured. 
Also, through the development of this research, data revealed that 130 subjects 
diagnosed with AIDS did not initiate ART within the multiyear period of claims. This 
alarming development warrants further investigation. These individuals were AIDS-
diagnosed, had adequate eligibility and enrollment, obtained other healthcare services, 
but did not fill ART pharmaceutical claims. It is important to learn what factors were 
associated with ART initiation among Medicaid-insured AIDS diagnosed subjects. 
Objective 1: Limitations 
Although Objective 1 was carefully planned and conducted, certain limitations 
exist that may affect the results and interpretation. First, the restrictive inclusion and 
 96 
 
exclusion criteria caused the sample to be small, although statistically valid. The reasons 
for the small sample were threefold. First, a large portion of HIV-positive individuals in 
the Agency for Health Care Administration (AHCA) administrative files were dually 
eligible for Medicare and Medicaid. In these instances, Medicare would pay the majority 
of the claims, and, therefore, these subjects were excluded from the sample. Next, the 
requirement of 12 months of Medicaid enrollment with no ART claims excluded a 
substantial portion of subjects. By limiting the sample to antiretroviral treatment naïve 
subjects, comparisons could be made to the other studies with similar sampling strategies 
(Acurcio et al., 2006; Bozzette et al., 2001; Gardner et al., 2008; Nachega et al., 2010). 
Third, this research aimed to extend the measurement period as long as possible without 
sacrificing overall sample size. Twenty-four months, while still short-term in relation to a 
lifelong chronic disease, balanced treatment duration with adequate sample size 
considerations. 
While using pharmacy claims data has been found to be valid proxy for 
medication consumption (Steiner & Prochazka, 1997), three issues relating to 
measurement of ART adherence using MPR should be considered. First, discontinuous 
eligibility was measured as though the subject was without ART during the lapse period. 
Discontinuous eligibility was not found not be a significant predictor of non-adherence to 
ART in the present study. Next, researchers acknowledge that measurement of ART 
adherence relies heavily on the assumption that filling prescriptions is strongly correlated 
with the patients actually taking the medicines (Reynolds, 2004). Finally, consensus 
among researchers has not been formed regarding the best cut-off for ART adherence as a 
dichotomous measure (Mills et al., 2006). Among the Medicaid-insured PLWHA 
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subjects in this study, the 90% MPR cut-off aimed to balance clinical validity and sample 
size considerations. 
Also, the exclusive use of administrative data presents certain limitations for this 
research. First, the retrospective design of this study means that no causal conclusions 
about the relationship of the factors to ART adherence can be made. Also, physician 
prescribing information remains unknown. More specifically, there may be instances 
when prescriptions were written and not filled by the patient. Alternatively, the absence 
of ART medication refills could actually be strategic treatment interruption ordered by 
the physician, not true ART non-adherence. Also, administrative data presents challenges 
impacting the thoroughness of the present research. Certain variables were not 
represented in the claims, such as provider types, Project AIDS Care enrollment, and 
cognitive behavioral therapy procedure codes. Furthermore, data restrictions applied by 
the Florida Agency for Health Care Administration for privacy protection reasons 
prevented use of zip codes in the measurement of factors related to geography.  
Finally, the exclusive use of claims data precludes the ability to measure 
important psychosocial issues related to ART adherence, such as subjects’ inclination 
toward health seeking behaviors. Stronger conclusions regarding the association of 
race/ethnicity and regimen-related factors could have been made if supplemented by 
information relating perception of provider engagement, stigma, patient self-efficacy, and 
available social support.  
Objective 1: Conclusion 
Although these limitations exist, Objective 1 demonstrated that a large majority of 
Medicaid-insured PLWHA were non-adherent to ART. Also, the logistic modeling 
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provides evidence of the significant relationship between ART adherence and 
race/ethnicity, multiple concurrent ART medication regimens, chronic disease diagnoses, 
and antidepressant adherence. These were important contributions to the understanding of 
ART adherence among vulnerable populations.  
Objective 2: Discussion 
Uncertainty abounds regarding the association of ART adherence to total 
healthcare expenditures. The results of Objective 2 of this research were mixed regarding 
association of ART adherence with reduced total healthcare expenditures among 
previously ART naïve Medicaid-insured PLWHA in a 24 month period. Non-adherent 
HIV-positive subjects had significantly lower costs, but expenditures for non-adherent 
AIDS-diagnosed subjects were not statistically different than those ART adherent 
subjects.  
Two similar studies to this research found that ART adherence was independently 
related to a reduction in healthcare expenditures (Bozzette et al., 2001; Nachega et al., 
2010), while two others showed that improved adherence to ART was associated with an 
increase in total expenditures (Acurcio et al., 2006; Gardner et al., 2008). Inconsistent 
results such as these fuel the broader debate of whether adherence to recommended care 
for chronic diseases is associated with decreased expenditures. In the short-term, 
adherence to medications for certain chronic diseases is significantly related to increased 
future costs – as reported by Robinson et al. (2006) for antidepressant medications and by 
Mattke et al. (2010) for asthma medications. More often than not, though, published 
research indicates decreased total healthcare costs associated with medication adherence. 
This is true in research by Esposito (2009) on  congestive heart failure patients, Roebuck 
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et al. (2011) for a variety of conditions, such as certain vascular conditions, congestive 
heart failure, hypertension, diabetes, and dyslipidemia, and Sokol et al. (2005) results on 
diabetes, hypertension, and high cholesterol and medication adherence.  
The results of the descriptive statistics for AIDS-diagnosed subjects illustrated in 
Figure 4.9 showed that unadjusted mean ART-related expenses for those subjects 
adherent to ART were $267 less than the increased inpatient expenses associated with 
being ART non-adherent. This suggested a beneficial trade-off between ART costs and 
inpatient costs. However, in the multivariate model with AIDS-diagnosed patients, the 
increased expenditures from ART may not be fully recovered by decreases in inpatient 
costs, controlling for other factors. Considering all factors, the predicted $274 mean 
savings for ART adherent group, compared to the non-adherent group, is not statistically 
significant. The reason for this is likely due to the variability in total healthcare 
expenditures associated with AIDS diagnosis 
However, for HIV-diagnosed subjects not yet diagnosed with AIDS with an 
increase in ART expenditures, the concomitant reduction in inpatient costs did not 
materialize. The unadjusted mean ART expenditures were almost twice as high for the 
adherent group ($761) as the non-adherent group ($413). The unadjusted mean inpatient 
expenditures for the adherent group was $309, and the non-adherent groups was only 
$322. Unfortunately, the cost saving benefit of ART may emerge once a HIV-positive 
individual becomes sick enough to be diagnosed with AIDS.  
Furthermore, the expected total healthcare expenditures for the PLWHA subjects 
reveal an incentive problem for managed care organizations (MCOs) operating in the 
under the Medicaid managed care program. In the Florida Medicaid managed care 
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program, AHCA pays the organizations a separate per member per month capitation 
payment for the HIV and AIDS categories. For example, the 2010 monthly capitation 
payment for an enrollee into a health plan from Jacksonville, Florida diagnosed with HIV 
would be approximately $1,634 per month and approximately $2,398 per month for an 
enrollee diagnosed with AIDS (Agency for Health Care Administration, 2010). The 
managed care plans are responsible for all of the healthcare costs for their members. The 
statewide expected mean monthly expenditures for HIV-positive individuals adherent to 
ART was $1,926 - more than the capitation rate. However, expected mean monthly 
expenditures for the ART non-adherent HIV-positive individuals was $1,291 – less than 
the capitation rate. The expected mean monthly expenditures for AIDS-diagnosed 
individuals were below the capitation rate for both ART adherent and non-adherent 
groups ($2,005 and $2,279, respectively). 
While likely an unintended policy consequence, under this payment scenario, a 
profit seeking managed care organization would have the incentive to 1) discourage 
potentially unprofitable Medicaid recipients diagnosed with HIV from enrolling or 
remaining enrolled in their health plan, or 2) fail to invest in the care management 
services for potentially appropriate ART adherence for the HIV diagnosed members until 
their disease progresses to AIDS where the capitation rate would be sufficient to cover 
the cost of care. Considering the evolution of treatment guidelines to recommend earlier 
ART initiation (Dieffenbach & Fauci, 2011), the current financing approach for non-
AIDS HIV-positive managed care enrollees may be insufficient. 
Finally, the pricing of pharmaceuticals is important to inferences regarding the 
impact of ART adherence on healthcare expenditures. In fact, ART medication prices 
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greatly influenced the results of other studies examining ART adherence association to 
total healthcare expenditures. For example, in Gardner et al. (2008), the authors found an 
increase in overall costs when the ART was priced at the average wholesale price (61% 
of total expenditures). However, when changing the ART price calculation from actual 
proportion of total expenditures (61% of total expenditures) to generic medications prices 
(3% of total expenditures), the relationship flipped – increased ART adherence was 
associated lower total costs. Also, the decreased total expenditures associated with 
increased ART adherence found in the Nachega et al. (2010) South African study may 
have been due to the fact that ART was priced at only 13% of total costs. According to 
the authors, the much lower prices were negotiated through international pharmaceutical 
access programs that are unavailable to U.S. purchasers. 
 As described in the methodology section above, the ART pharmaceuticals for this 
research were priced at the claim dollar amount minus a statutorily mandated 29.1% 
rebate for drugs on the Florida Medicaid Preferred Drug List (Florida Statute, 2008). It is 
important to note that federally qualified entities in the 340B program may purchase 
pharmaceuticals at even greater discounts (Public Health Service Act, 1992). Laws 
prohibit duplicate discounts from both Medicaid rebates and 340B pricing. When 
Gardner et al. (2008) modeled the ART costs at 340b pricing levels (38% lower than the 
average wholesale prices), the researchers found that increased ART adherence was still 
associated with increased total costs. In the present research, the additional 8.9% discount 
for 340B pricing would not have changed the results. 
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Objective 2: Recommendations 
In early 2011, Florida Governor Rick Scott signed into law a requirement that all 
Medicaid-eligible patients enrolls into managed care organizations (MCOs) (Florida 
Statutes, 2011). This policy change was driven by a promise of cost savings to the State 
of Florida projected by the MCO industry (Hatter, 2013). However, the law was passed, 
in part at least, because MCOs boast about their ability to deliver improved care 
(America’s Health Insurance Plans, 2008; Hatter, 2013).  
Recognizing the need to encourage improved quality of care among MCOs, the 
Florida Medicaid agency (AHCA) requires MCOs to report quality of care measures, 
including HIV-related measures such as the ratio of patients diagnosed with AIDS 
prescribed ART (Agency for Health Care Administration, 2009). This approach is similar 
to the set of quality measures used by 90% of the managed care industry, the Healthcare 
Effectiveness Data Information Set (HEDIS) (NCQA, 2009). Such process-based 
measures have been shown to be statistically related to health status and quality of life 
outcomes (Bradley et al., 2006; Kahn et al., 2007).  
There is evidence that MCOs can impact quality of care through certain care 
management activities, such as medication adherence, cancer screening, and diabetes care 
(Baker & Hopkins, 2010). These efforts are implemented separately from, but in 
coordination with, direct healthcare providers. However, MCOs may not perform care 
management as expected. As an example, for patients diagnosed with HIV or AIDS, 
research on Medicaid managed care versus Medicaid fee-for-service shows little 
difference in levels of ART use, hospitalization, or mortality, after adjusting for severity 
(Zingmond, Ettner, & Cunningham, 2007). 
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The reasons for this lack of performance may be two fold, at least. First, as seen 
in the results of Objective 2 of this research, certain quality of care measures have been 
shown to be statistically related to increased near-term future total healthcare costs. Next, 
even though care management efforts may produce a return on their investment in the 
long-term, high membership turn-over (Short et al., 2003) may negate the cost savings 
related care management activities in the near-term (Ofman et al., 2004). Due to the 
uncertain return on investment in the near-term and membership instability, simply 
requiring MCOs to report quality measures to the public may not be enough to induce 
MCOs to invest in care management activities that will benefit the long-term health of 
members.  
In order to reverse the incentives to ration some recommended care, such as 
expensive pharmaceuticals, in favor of unlikely, but costly and undesirable services, such 
as inpatient, and emergency room visits, incentive bonuses for performance on adherence 
to ART should be implemented. Such incentive-based contracts would be intended to 
stimulate MCOs to improve quality so they can achieve higher payments (Benjamin & 
Garza, 2009). Many payors use incentive-based contracts to retrospectively reward 
MCOs based on quality of care process measures in the form of bonuses, fines or tiered 
payments (Maio, Goldfarb, Carter, & Nash, 2003). Based on the results of this study, an 
incentive bonus would be most strongly recommended for the HIV-positive group that 
has initiated ART. 
Finally, AHCA currently pays MCOs two separate risk-adjusted capitation 
payments for the HIV and AIDS diagnoses. The current HIV/AIDS risk adjustment 
payment presents an unfortunate incentive problem. Perversely, under the current 
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payment scheme, if a member’s illness intensifies, a MCO’s risk-adjusted payment would 
increase. Since the capitation rate for AIDS-diagnosed patients is so much higher and 
potentially more profitable, a MCO would have a disincentive to invest in drug adherence 
programs that ensure that members diagnosed with HIV do not progress to AIDS 
diagnosis. In effect, this penalizes the MCOs that prevent disease and rewards those that 
fail to invest in the health of their enrollees.  
To mitigate these problems, it is recommended that payors, such as Medicaid, 
create risk adjustment payments made to MCOs based on more detailed HIV comorbidity 
diagnoses. The more accurately a comorbidity-based risk adjustment payment model 
predicts the future healthcare costs of a member, the less incentive the MCO has to 
positively or negatively select enrollees. HIV/AIDS is an ideal disease state for which to 
develop a risk-adjusted payment methodology because HIV/AIDS is disease for which 
risk selection occurs (Glazer & McGuire, 2000) and high cost and high variability exist 
(Hill & Gebo, 2007).  
Objective 2: Future research 
This research demonstrates that multiple comorbidity diagnoses were positively 
associated with total healthcare expenditures. Future research aimed at developing an 
improved HIV/AIDS risk adjustment payment system that prevents risk selection and 
promotes quality of care. Since HIV/AIDS has become a chronic disease with the advent 
of effective ART and PLWHA are developing comorbidities associated with aging at a 
rate even higher than in the general population (Crawford et al., 2013; Giordano et al., 
2007; Webster, 2010). Any newly developed HIV/AIDS risk-adjustment model should 
recognize these comorbidity factors. Diagnosis based risk-adjustment models have been 
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developed for Medicaid enrollees (Ettner, Frank, McGuire, & Hermann, 2001; Kronick, 
Gilmer, Dreyfus, & Lee, 2000; Robst, 2009) and for HIV/AIDS (Fakhraei, Kaelin, & 
Conviser, 2001) and could provide the basis for future risk-adjusted payment systems. 
Also, this research measured the ART adherence and total healthcare expenditures 
in the near-term – only 24 months. Future research should examine the medium and long-
term association of ART adherence on total healthcare expenditures. This potential 
research is particularly salient for two reasons. First, because HIV/AIDS has become a 
chronic disease, and as the prevalence increases, the long-term financial impact to our 
health system becomes more important to understand. Second, the effectiveness of ART 
does not come without problems. It is important to understand how the costs change over 
time, considering issues such as ART resistance and ART-related ADR. 
Objective 2: Limitations 
Objective 2 has certain limitations that may impact the results and conclusions 
regarding the relationship of ART adherence to healthcare expenditures. First, this study 
exclusively examined secondary data which are often subject to inaccuracies related to 
coding, especially for claims payment values. Given the relative small samples included 
in the models, possible mistakenly coded large claims values could have impacted the 
conclusions. Nevertheless, these kinds of data remain the best source of information on 
healthcare utilization for the Medicaid population.  
Also, for subjects with discontinuous Medicaid coverage of 3 months or less in a 
year, the lapses in coverage lowers ART MPR. While subjects can be reasonably 
assumed to be non-adherent to ART in interrupted eligibility months without Medicaid, 
there is no way to know whether the subjects accessed ART or other services. Studies 
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have shown that when patients return to Medicaid there may be slightly increased 
expenditures for the immediate period following the lapse (Hall et al., 2008; Harman et 
al., 2007). Thus, it is unknown the exact impact that the discontinuous enrollment has on 
overall expenditures. The Objective 2 models showed that the discontinuous eligibility 
was not a significant predictor of total healthcare expenditures for the HIV-positive and 
AIDS-diagnosed subjects. 
Finally, it is important to note that this is not cost-benefit study, but rather an 
examination of the direct healthcare costs from the perspective of Medicaid. Certainly, 
there is benefit of ART adherence to the patient and to society. Previous literature 
provides overwhelming support for ART adherence by decreasing HIV transmission risk 
(Reynolds et al., 2011), improving mortality (Lieb et al., 2002) and increasing quality of 
life (Hogg et al., 2002). Nonetheless, the focus of this research was on direct healthcare 
expenditures for the health insurer. 
Objective 2: Conclusion 
Although these limitations exist, Objective 2 underscores the challenges with 
financial incentives pervasive in the U.S. healthcare system. Much of patient care is 
controlled by organizations, such as Medicare Accountable Care Organizations or 
Medicaid managed care organizations, which promote their ability to decrease healthcare 
costs by improving care management practices. Unfortunately, while medication 
adherence for many chronic diseases is cost-saving in the near-term, others may not be. 
In circumstances where the financial benefit is ambiguous or only realized in the long-
term, organizations may have the financial incentive to shirk care management 
responsibilities or avoid unprofitable patients. Therefore, as policymakers consider 
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transferring the financial risk to organizations for patient care, perverse payment 
incentives should be fully understood, and efforts should be made to assure quality for 
vulnerable populations. 
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Appendix A: HIV/AIDS Pharmaceutical National Drug Codes 
TABLE A1: HIV/AIDS Pharmaceutical National Drug Codes 
NDC Code Drug Name Drug Generic Name HIC3 Class 
00003362212 REYATAZ 300 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
00003362312 REYATAZ 100 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
00003362412 REYATAZ 150 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
00003363112 REYATAZ 200 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
00004024451 INVIRASE 500 MG 
TABLET 
SAQUINAVIR 
MESYLATE 
W5C PI 
00004024515 INVIRASE 200 MG 
CAPSULE 
SAQUINAVIR 
MESYLATE 
W5C PI 
00004024648 FORTOVASE 200 MG 
SOFTGEL CAP 
SAQUINAVIR W5C PI 
00006057062 CRIXIVAN 100 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
00006057142 CRIXIVAN 200 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
00006057143 CRIXIVAN 200 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
00006057301 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
00006057318 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
00006057340 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
00006057342 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
00006057354 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
00006057362 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
00006057465 CRIXIVAN 333 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
00074194063 NORVIR 80 MG/ML 
SOLUTION 
RITONAVIR W5C PI 
00074663322 NORVIR 100 MG 
SOFTGEL CAP 
RITONAVIR W5C PI 
00074663330 NORVIR 100 MG 
SOFTGEL CAP 
RITONAVIR W5C PI 
00074949202 NORVIR 100 MG RITONAVIR W5C PI 
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CAPSULE 
00074949254 NORVIR 100 MG 
CAPSULE 
RITONAVIR W5C PI 
00173067200 AGENERASE 150 MG 
CAPSULE 
AMPRENAVIR/VIT
AMIN E 
W5C PI 
00173067900 AGENERASE 50 MG 
CAPSULE 
AMPRENAVIR/VIT
AMIN E 
W5C PI 
00173068700 AGENERASE 15 MG/ML 
ORAL SOLN 
AMPRENAVIR/VIT
AMIN E/PROP GLY 
W5C PI 
00173072100 LEXIVA 700 MG 
TABLET 
FOSAMPRENAVIR 
CALCIUM 
W5C PI 
00173072700 LEXIVA 50 MG/ML 
SUSPENSION 
FOSAMPRENAVIR 
CALCIUM 
W5C PI 
16590006418 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
16590006430 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
16590006460 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
16590006490 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
35356006706 LEXIVA 700 MG 
TABLET 
FOSAMPRENAVIR 
CALCIUM 
W5C PI 
35356006760 LEXIVA 700 MG 
TABLET 
FOSAMPRENAVIR 
CALCIUM 
W5C PI 
35356006806 REYATAZ 150 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
35356006860 REYATAZ 150 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
35356011406 REYATAZ 300 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
35356011430 REYATAZ 300 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
35356011701 VIRACEPT 625 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
35356013830 NORVIR 100 MG 
SOFTGEL CAP 
RITONAVIR W5C PI 
35356013918 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
35356013960 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
35356020760 REYATAZ 200 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
49999043103 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
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52959028930 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
52959050712 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
52959050718 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
52959050724 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
52959050730 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
54569424200 INVIRASE 200 MG 
CAPSULE 
SAQUINAVIR 
MESYLATE 
W5C PI 
54569424201 INVIRASE 200 MG 
CAPSULE 
SAQUINAVIR 
MESYLATE 
W5C PI 
54569424202 INVIRASE 200 MG 
CAPSULE 
SAQUINAVIR 
MESYLATE 
W5C PI 
54569424203 INVIRASE 200 MG 
CAPSULE 
SAQUINAVIR 
MESYLATE 
W5C PI 
54569433500 NORVIR 100 MG 
CAPSULE 
RITONAVIR W5C PI 
54569454300 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
54569454301 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
54569454302 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
54569454303 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
54569454304 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
54569454305 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
54569454306 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
54569456300 FORTOVASE 200 MG 
SOFTGEL CAP 
SAQUINAVIR W5C PI 
54569456301 FORTOVASE 200 MG 
SOFTGEL CAP 
SAQUINAVIR W5C PI 
54569461300 NORVIR 80 MG/ML 
SOLUTION 
RITONAVIR W5C PI 
54569479200 NORVIR 100 MG 
CAPSULE 
RITONAVIR W5C PI 
54569481300 AGENERASE 150 MG 
CAPSULE 
AMPRENAVIR/VIT
AMIN E 
W5C PI 
54569553000 REYATAZ 150 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
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54569553200 REYATAZ 200 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
54569555000 LEXIVA 700 MG 
TABLET 
FOSAMPRENAVIR 
CALCIUM 
W5C PI 
54569565600 NORVIR 100 MG 
SOFTGEL CAP 
RITONAVIR W5C PI 
54569566400 INVIRASE 500 MG 
TABLET 
SAQUINAVIR 
MESYLATE 
W5C PI 
54569862000 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
54569862001 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
54868369900 INVIRASE 200 MG 
CAPSULE 
SAQUINAVIR 
MESYLATE 
W5C PI 
54868369901 INVIRASE 200 MG 
CAPSULE 
SAQUINAVIR 
MESYLATE 
W5C PI 
54868369902 INVIRASE 200 MG 
CAPSULE 
SAQUINAVIR 
MESYLATE 
W5C PI 
54868378200 NORVIR 100 MG 
CAPSULE 
RITONAVIR W5C PI 
54868378201 NORVIR 100 MG 
SOFTGEL CAP 
RITONAVIR W5C PI 
54868378202 NORVIR 100 MG 
CAPSULE 
RITONAVIR W5C PI 
54868378203 NORVIR 100 MG 
SOFTGEL CAP 
RITONAVIR W5C PI 
54868394700 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
54868411000 FORTOVASE 200 MG 
SOFTGEL CAP 
SAQUINAVIR W5C PI 
54868411300 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
54868485400 REYATAZ 200 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
54868485700 REYATAZ 150 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
54868495400 LEXIVA 700 MG 
TABLET 
FOSAMPRENAVIR 
CALCIUM 
W5C PI 
54868506100 VIRACEPT 625 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
54868583800 REYATAZ 300 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
55175520807 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
55175520901 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
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55289047727 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
55887023030 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
55887023060 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
55887023090 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
58016069900 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
58016069930 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
58016069960 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
58016069990 CRIXIVAN 400 MG 
CAPSULE 
INDINAVIR 
SULFATE 
W5C PI 
60760001018 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
60760001063 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
63010001027 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
63010001030 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
63010001190 VIRACEPT POWDER NELFINAVIR 
MESYLATE 
W5C PI 
63010002770 VIRACEPT 625 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
68030728401 VIRACEPT 250 MG 
TABLET 
NELFINAVIR 
MESYLATE 
W5C PI 
68258914201 REYATAZ 150 MG 
CAPSULE 
ATAZANAVIR 
SULFATE 
W5C PI 
35356007306 VIREAD 300 MG 
TABLET 
TENOFOVIR 
DISOPROXIL 
FUMARATE 
W5I NRTI 
35356007330 VIREAD 300 MG 
TABLET 
TENOFOVIR 
DISOPROXIL 
FUMARATE 
W5I NRTI 
54569533400 VIREAD 300 MG 
TABLET 
TENOFOVIR 
DISOPROXIL 
FUMARATE 
W5I NRTI 
54868466900 VIREAD 300 MG 
TABLET 
TENOFOVIR 
DISOPROXIL 
FUMARATE 
W5I NRTI 
61958040101 VIREAD 300 MG 
TABLET 
TENOFOVIR 
DISOPROXIL 
W5I NRTI 
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FUMARATE 
68258900301 VIREAD 300 MG 
TABLET 
TENOFOVIR 
DISOPROXIL 
FUMARATE 
W5I NRTI 
00003196401 ZERIT 15 MG CAPSULE STAVUDINE W5J NRTI 
00003196501 ZERIT 20 MG CAPSULE STAVUDINE W5J NRTI 
00003196601 ZERIT 30 MG CAPSULE STAVUDINE W5J NRTI 
00003196701 ZERIT 40 MG CAPSULE STAVUDINE W5J NRTI 
00003196801 ZERIT 1 MG/ML 
SOLUTION 
STAVUDINE W5J NRTI 
00004022001 HIVID 0.375 MG 
TABLET 
ZALCITABINE W5J NRTI 
00004022101 HIVID 0.750 MG 
TABLET 
ZALCITABINE W5J NRTI 
00054005221 ZIDOVUDINE 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
00081010793 RETROVIR IV 
INFUSION VIAL 
ZIDOVUDINE W5J NRTI 
00081010855 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
00081010856 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
00081011318 RETROVIR 10 MG/ML 
SYRUP 
ZIDOVUDINE W5J NRTI 
00087661443 VIDEX 100 MG PACKET DIDANOSINE/SODI
UM CITRATE 
W5J NRTI 
00087661543 VIDEX 167 MG PACKET DIDANOSINE/SODI
UM CITRATE 
W5J NRTI 
00087661643 VIDEX 250 MG PACKET DIDANOSINE/SODI
UM CITRATE 
W5J NRTI 
00087663241 VIDEX 2 GM PEDIATRIC 
SOLN 
DIDANOSINE W5J NRTI 
00087663341 VIDEX 4 GM PEDIATRIC 
SOLN 
DIDANOSINE W5J NRTI 
00087665001 VIDEX 25 MG TABLET 
CHEWABLE 
DIDANOSINE/CALC
IUM CARB/MAG 
W5J NRTI 
00087665101 VIDEX 50 MG TABLET 
CHEWABLE 
DIDANOSINE/CALC
IUM CARB/MAG 
W5J NRTI 
00087665201 VIDEX 100 MG TABLET 
CHEWABLE 
DIDANOSINE/CALC
IUM CARB/MAG 
W5J NRTI 
00087665301 VIDEX 150 MG TABLET 
CHEWABLE 
DIDANOSINE/CALC
IUM CARB/MAG 
W5J NRTI 
00087666515 VIDEX 200 MG TABLET 
CHEWABLE 
DIDANOSINE/CALC
IUM CARB/MAG 
W5J NRTI 
00087667117 VIDEX EC 125 MG CAP DIDANOSINE W5J NRTI 
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SA 
00087667217 VIDEX EC 200 MG CAP 
SA 
DIDANOSINE W5J NRTI 
00087667317 VIDEX EC 250 MG CAP 
SA 
DIDANOSINE W5J NRTI 
00087667417 VIDEX EC 400 MG CAP 
SA 
DIDANOSINE W5J NRTI 
00093553006 ZIDOVUDINE 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
00173010793 RETROVIR IV 
INFUSION VIAL 
ZIDOVUDINE W5J NRTI 
00173010855 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
00173010856 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
00173011318 RETROVIR 10 MG/ML 
SYRUP 
ZIDOVUDINE W5J NRTI 
00173047001 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
00173047100 EPIVIR 10 MG/ML ORAL 
SOLN 
LAMIVUDINE W5J NRTI 
00173050100 RETROVIR 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
00173066100 ZIAGEN 300 MG 
TABLET 
ABACAVIR 
SULFATE 
W5J NRTI 
00173066101 ZIAGEN 300 MG 
TABLET 
ABACAVIR 
SULFATE 
W5J NRTI 
00173066400 ZIAGEN 20 MG/ML 
SOLUTION 
ABACAVIR 
SULFATE 
W5J NRTI 
00173071400 EPIVIR 300 MG TABLET LAMIVUDINE W5J NRTI 
00378504091 STAVUDINE 15 MG 
CAPSULE 
STAVUDINE W5J NRTI 
00378504191 STAVUDINE 20 MG 
CAPSULE 
STAVUDINE W5J NRTI 
00378504291 STAVUDINE 30 MG 
CAPSULE 
STAVUDINE W5J NRTI 
00378504391 STAVUDINE 40 MG 
CAPSULE 
STAVUDINE W5J NRTI 
00555058801 DIDANOSINE 200 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
00555058901 DIDANOSINE 250 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
00555059001 DIDANOSINE 400 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
31722050960 ZIDOVUDINE 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
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31722051560 STAVUDINE 15 MG 
CAPSULE 
STAVUDINE W5J NRTI 
31722051660 STAVUDINE 20 MG 
CAPSULE 
STAVUDINE W5J NRTI 
31722051760 STAVUDINE 30 MG 
CAPSULE 
STAVUDINE W5J NRTI 
31722051860 STAVUDINE 40 MG 
CAPSULE 
STAVUDINE W5J NRTI 
35356006530 EPIVIR 300 MG TABLET LAMIVUDINE W5J NRTI 
35356006624 EPIVIR 10 MG/ML ORAL 
SOLN 
LAMIVUDINE W5J NRTI 
35356007460 ZERIT 40 MG CAPSULE STAVUDINE W5J NRTI 
35356007506 ZIAGEN 300 MG 
TABLET 
ABACAVIR 
SULFATE 
W5J NRTI 
35356007560 ZIAGEN 300 MG 
TABLET 
ABACAVIR 
SULFATE 
W5J NRTI 
35356018630 VIDEX EC 400 MG CAP 
SA 
DIDANOSINE W5J NRTI 
35356020530 EMTRIVA 200 MG 
CAPSULE 
EMTRICITABINE W5J NRTI 
35356025930 DIDANOSINE 400 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
35356028560 ZERIT 30 MG CAPSULE STAVUDINE W5J NRTI 
49999011906 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
49999011960 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
49999038618 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
50962045010 RETROVIR 10 MG/ML 
SYRUP 
ZIDOVUDINE W5J NRTI 
50962045205 RETROVIR 10 MG/ML 
SYRUP 
ZIDOVUDINE W5J NRTI 
52959038706 RETROVIR 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
52959050802 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
52959050804 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
52959050806 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
52959050808 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
52959050814 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
52959050815 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
52959050860 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
52959050906 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
52959050912 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
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52959050918 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
52959050920 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
52959050924 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
52959050928 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
52959050930 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
54569177200 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
54569177201 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
54569177202 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
54569177203 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
54569177204 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
54569177205 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
54569365700 VIDEX 100 MG TABLET 
CHEWABLE 
DIDANOSINE/CALC
IUM CARB/MAG 
W5J NRTI 
54569387700 HIVID 0.750 MG 
TABLET 
ZALCITABINE W5J NRTI 
54569387701 HIVID 0.750 MG 
TABLET 
ZALCITABINE W5J NRTI 
54569405300 ZERIT 30 MG CAPSULE STAVUDINE W5J NRTI 
54569405400 ZERIT 40 MG CAPSULE STAVUDINE W5J NRTI 
54569405401 ZERIT 40 MG CAPSULE STAVUDINE W5J NRTI 
54569422100 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
54569422101 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
54569422102 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
54569431300 VIDEX 100 MG TABLET 
CHEWABLE 
DIDANOSINE/CALC
IUM CARB/MAG 
W5J NRTI 
54569431301 VIDEX 100 MG TABLET 
CHEWABLE 
DIDANOSINE/CALC
IUM CARB/MAG 
W5J NRTI 
54569433300 EPIVIR 10 MG/ML ORAL 
SOLN 
LAMIVUDINE W5J NRTI 
54569433400 RETROVIR 10 MG/ML 
SYRUP 
ZIDOVUDINE W5J NRTI 
54569448500 HIVID 0.375 MG 
TABLET 
ZALCITABINE W5J NRTI 
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54569451400 VIDEX 4 GM PEDIATRIC 
SOLN 
DIDANOSINE W5J NRTI 
54569453800 RETROVIR 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
54569488300 ZIAGEN 300 MG 
TABLET 
ABACAVIR 
SULFATE 
W5J NRTI 
54569490500 VIDEX 200 MG TABLET 
CHEWABLE 
DIDANOSINE/CALC
IUM CARB/MAG 
W5J NRTI 
54569517600 VIDEX EC 400 MG CAP 
SA 
DIDANOSINE W5J NRTI 
54569538700 ZERIT 1 MG/ML 
SOLUTION 
STAVUDINE W5J NRTI 
54569539000 ZIAGEN 20 MG/ML 
SOLUTION 
ABACAVIR 
SULFATE 
W5J NRTI 
54569541200 ZERIT 15 MG CAPSULE STAVUDINE W5J NRTI 
54569548000 ZERIT 20 MG CAPSULE STAVUDINE W5J NRTI 
54569550100 EPIVIR 300 MG TABLET LAMIVUDINE W5J NRTI 
54569550400 VIDEX EC 250 MG CAP 
SA 
DIDANOSINE W5J NRTI 
54569552100 EMTRIVA 200 MG 
CAPSULE 
EMTRICITABINE W5J NRTI 
54569564200 DIDANOSINE 250 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
54569564300 DIDANOSINE 400 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
54868197400 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
54868197402 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
54868197403 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
54868249901 HIVID 0.375 MG 
TABLET 
ZALCITABINE W5J NRTI 
54868250001 HIVID 0.750 MG 
TABLET 
ZALCITABINE W5J NRTI 
54868250002 HIVID 0.750 MG 
TABLET 
ZALCITABINE W5J NRTI 
54868250200 VIDEX 100 MG TABLET 
CHEWABLE 
DIDANOSINE/CALC
IUM CARB/MAG 
W5J NRTI 
54868250401 RETROVIR 10 MG/ML 
SYRUP 
ZIDOVUDINE W5J NRTI 
54868335200 ZERIT 40 MG CAPSULE STAVUDINE W5J NRTI 
54868335201 ZERIT 40 MG CAPSULE STAVUDINE W5J NRTI 
54868335300 ZERIT 20 MG CAPSULE STAVUDINE W5J NRTI 
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54868336000 ZERIT 15 MG CAPSULE STAVUDINE W5J NRTI 
54868344800 ZERIT 30 MG CAPSULE STAVUDINE W5J NRTI 
54868369300 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
54868369302 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
54868452200 ZIAGEN 300 MG 
TABLET 
ABACAVIR 
SULFATE 
W5J NRTI 
54868452201 ZIAGEN 300 MG 
TABLET 
ABACAVIR 
SULFATE 
W5J NRTI 
54868466600 VIDEX EC 400 MG CAP 
SA 
DIDANOSINE W5J NRTI 
54868485300 EMTRIVA 200 MG 
CAPSULE 
EMTRICITABINE W5J NRTI 
54868541600 EPIVIR 300 MG TABLET LAMIVUDINE W5J NRTI 
54868546400 DIDANOSINE 250 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
54868559500 VIDEX EC 250 MG CAP 
SA 
DIDANOSINE W5J NRTI 
55045220701 HIVID 0.750 MG 
TABLET 
ZALCITABINE W5J NRTI 
55045354901 ZIDOVUDINE 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
55175449401 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
58016068900 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
58016068930 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
58016068960 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
58016068990 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
58016069000 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
58016069018 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
58016069030 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
58016069060 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
58016069090 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
58016079500 EPIVIR 300 MG TABLET LAMIVUDINE W5J NRTI 
58016079530 EPIVIR 300 MG TABLET LAMIVUDINE W5J NRTI 
58016079560 EPIVIR 300 MG TABLET LAMIVUDINE W5J NRTI 
58016079590 EPIVIR 300 MG TABLET LAMIVUDINE W5J NRTI 
58016086400 RETROVIR 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
 139 
 
58016086430 RETROVIR 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
58016086460 RETROVIR 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
58016086490 RETROVIR 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
58864046230 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
58864046260 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
58864046293 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
61958060101 EMTRIVA 200 MG 
CAPSULE 
EMTRICITABINE W5J NRTI 
61958060201 EMTRIVA 10 MG/ML 
SOLUTION 
EMTRICITABINE W5J NRTI 
62584004611 DIDANOSINE 250 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
62584004621 DIDANOSINE 250 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
62584004811 DIDANOSINE 400 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
62584004821 DIDANOSINE 400 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
63304092060 ZIDOVUDINE 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
65862002460 ZIDOVUDINE 300 MG 
TABLET 
ZIDOVUDINE W5J NRTI 
65862004824 ZIDOVUDINE 50 MG/5 
ML SYRUP 
ZIDOVUDINE W5J NRTI 
65862010701 ZIDOVUDINE 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
65862031030 DIDANOSINE 125 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
65862031130 DIDANOSINE 200 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
65862031230 DIDANOSINE 250 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
65862031330 DIDANOSINE 400 MG 
DR CAPSULE 
DIDANOSINE W5J NRTI 
67253010910 ZIDOVUDINE 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
67253096124 ZIDOVUDINE 50 MG/5 
ML SYRUP 
ZIDOVUDINE W5J NRTI 
68030605901 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
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68030606001 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
68030606401 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
68030606501 RETROVIR 100 MG 
CAPSULE 
ZIDOVUDINE W5J NRTI 
68258910801 EPIVIR 150 MG TABLET LAMIVUDINE W5J NRTI 
68258912601 ZERIT 20 MG CAPSULE STAVUDINE W5J NRTI 
00009376103 RESCRIPTOR 100 MG 
TABLET 
DELAVIRDINE 
MESYLATE 
W5K NNRT
I 
00009757601 RESCRIPTOR 200 MG 
TABLET 
DELAVIRDINE 
MESYLATE 
W5K NNRT
I 
00054390558 VIRAMUNE 50 MG/5 ML 
SUSP 
NEVIRAPINE W5K NNRT
I 
00054464721 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
00054464725 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
00054864725 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
00056047030 SUSTIVA 50 MG 
CAPSULE 
EFAVIRENZ W5K NNRT
I 
00056047330 SUSTIVA 100 MG 
CAPSULE 
EFAVIRENZ W5K NNRT
I 
00056047492 SUSTIVA 200 MG 
CAPSULE 
EFAVIRENZ W5K NNRT
I 
00056051030 SUSTIVA 600 MG 
TABLET 
EFAVIRENZ W5K NNRT
I 
00597004601 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
00597004660 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
00597004661 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
00597004724 VIRAMUNE 50 MG/5 ML 
SUSP 
NEVIRAPINE W5K NNRT
I 
35356006990 SUSTIVA 200 MG 
CAPSULE 
EFAVIRENZ W5K NNRT
I 
35356007106 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
35356007160 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
35356007224 VIRAMUNE 50 MG/5 ML 
SUSP 
NEVIRAPINE W5K NNRT
I 
35356011506 SUSTIVA 600 MG 
TABLET 
EFAVIRENZ W5K NNRT
I 
35356011530 SUSTIVA 600 MG EFAVIRENZ W5K NNRT
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TABLET I 
54569456100 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
54569456101 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
54569456200 RESCRIPTOR 100 MG 
TABLET 
DELAVIRDINE 
MESYLATE 
W5K NNRT
I 
54569461100 SUSTIVA 200 MG 
CAPSULE 
EFAVIRENZ W5K NNRT
I 
54569512200 RESCRIPTOR 200 MG 
TABLET 
DELAVIRDINE 
MESYLATE 
W5K NNRT
I 
54569537400 SUSTIVA 600 MG 
TABLET 
EFAVIRENZ W5K NNRT
I 
54569560200 RESCRIPTOR 200 MG 
TABLET 
DELAVIRDINE 
MESYLATE 
W5K NNRT
I 
54868384400 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
54868384401 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
54868452000 RESCRIPTOR 200 MG 
TABLET 
DELAVIRDINE 
MESYLATE 
W5K NNRT
I 
54868466800 SUSTIVA 600 MG 
TABLET 
EFAVIRENZ W5K NNRT
I 
54868586400 INTELENCE 100 MG 
TABLET 
ETRAVIRINE W5K NNRT
I 
55289039203 VIRAMUNE 200 MG 
TABLET 
NEVIRAPINE W5K NNRT
I 
59676057001 INTELENCE 100 MG 
TABLET 
ETRAVIRINE W5K NNRT
I 
63010002036 RESCRIPTOR 100 MG 
TABLET 
DELAVIRDINE 
MESYLATE 
W5K NNRT
I 
63010002118 RESCRIPTOR 200 MG 
TABLET 
DELAVIRDINE 
MESYLATE 
W5K NNRT
I 
68258902001 SUSTIVA 600 MG 
TABLET 
EFAVIRENZ W5K NNRT
I 
68258902101 SUSTIVA 200 MG 
CAPSULE 
EFAVIRENZ W5K NNRT
I 
00173059500 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
00173059502 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
00173069100 TRIZIVIR TABLET ABACAVIR/LAMIV
UDINE/ZIDOVUDIN
E 
W5L NRTI 
00173069120 TRIZIVIR TABLET ABACAVIR/LAMIV W5L NRTI 
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UDINE/ZIDOVUDIN
E 
00173074200 EPZICOM TABLET ABACAVIR 
SULFATE/LAMIVU
DINE 
W5L NRTI 
16590006106 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
23490708706 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
35356010906 EPZICOM TABLET ABACAVIR 
SULFATE/LAMIVU
DINE 
W5L NRTI 
35356010930 EPZICOM TABLET ABACAVIR 
SULFATE/LAMIVU
DINE 
W5L NRTI 
35356011606 TRIZIVIR TABLET ABACAVIR/LAMIV
UDINE/ZIDOVUDIN
E 
W5L NRTI 
35356011660 TRIZIVIR TABLET ABACAVIR/LAMIV
UDINE/ZIDOVUDIN
E 
W5L NRTI 
49999006206 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
49999006210 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
49999006260 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
52959054602 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
52959054603 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
52959054604 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
52959054606 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
52959054608 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
52959054610 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
52959054614 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
52959054615 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
52959054620 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
52959054628 COMBIVIR TABLET LAMIVUDINE/ZIDO W5L NRTI 
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VUDINE 
54569452400 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
54569452401 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
54569452402 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
54569452403 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
54569519100 TRIZIVIR TABLET ABACAVIR/LAMIV
UDINE/ZIDOVUDIN
E 
W5L NRTI 
54569559400 EPZICOM TABLET ABACAVIR 
SULFATE/LAMIVU
DINE 
W5L NRTI 
54868411400 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
54868411406 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
54868560000 EPZICOM TABLET ABACAVIR 
SULFATE/LAMIVU
DINE 
W5L NRTI 
55175520706 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
55289038904 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
55289038906 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
55289038914 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
55289038920 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
55887023130 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
55887023160 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
55887023190 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
58016069800 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
58016069830 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
58016069860 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
58016069890 COMBIVIR TABLET LAMIVUDINE/ZIDO W5L NRTI 
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VUDINE 
60760059504 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
60760059514 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
62682104801 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
66267050906 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
68030728301 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
68115009006 COMBIVIR TABLET LAMIVUDINE/ZIDO
VUDINE 
W5L NRTI 
68258915801 TRIZIVIR TABLET ABACAVIR/LAMIV
UDINE/ZIDOVUDIN
E 
W5L NRTI 
00074052260 KALETRA 100-25 MG 
TABLET 
RITONAVIR/LOPIN
AVIR 
W5M PI 
00074395646 KALETRA 400-100/5 ML 
ORAL SOLU 
RITONAVIR/LOPIN
AVIR 
W5M PI 
00074395977 KALETRA 133.3-33.3 MG 
SOFTGEL 
RITONAVIR/LOPIN
AVIR 
W5M PI 
00074679922 KALETRA 200-50 MG 
TABLET 
RITONAVIR/LOPIN
AVIR 
W5M PI 
35356011160 KALETRA 100-25 MG 
TABLET 
RITONAVIR/LOPIN
AVIR 
W5M PI 
35356011201 KALETRA 200-50 MG 
TABLET 
RITONAVIR/LOPIN
AVIR 
W5M PI 
35356011230 KALETRA 50-200 MG 
TABLET 
RITONAVIR/LOPIN
AVIR 
W5M PI 
52959096812 KALETRA 100-25 MG 
TABLET 
RITONAVIR/LOPIN
AVIR 
W5M PI 
54569514200 KALETRA SOFTGEL RITONAVIR/LOPIN
AVIR 
W5M PI 
54569552500 KALETRA ORAL 
SOLUTION 
RITONAVIR/LOPIN
AVIR 
W5M PI 
54569575200 KALETRA 200-50 MG 
TABLET 
RITONAVIR/LOPIN
AVIR 
W5M PI 
54868452400 KALETRA 133.3-33.3 MG 
SOFTGEL 
RITONAVIR/LOPIN
AVIR 
W5M PI 
54868556600 KALETRA 200-50 MG 
TABLET 
RITONAVIR/LOPIN
AVIR 
W5M PI 
55045348201 KALETRA 200-50 MG 
TABLET 
RITONAVIR/LOPIN
AVIR 
W5M PI 
55289093118 KALETRA SOFTGEL RITONAVIR/LOPIN W5M PI 
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AVIR 
55289094712 KALETRA 200-50 MG 
TABLET 
RITONAVIR/LOPIN
AVIR 
W5M PI 
00004038039 FUZEON 
CONVENIENCE KIT 
ENFUVIRTIDE W5N FI 
35356020660 FUZEON 
CONVENIENCE KIT 
ENFUVIRTIDE W5N FI 
54569578100 FUZEON 
CONVENIENCE KIT 
ENFUVIRTIDE W5N FI 
35356007006 TRUVADA TABLET EMTRICITABINE/T
ENOFOVIR 
W5O NRTI 
35356007030 TRUVADA TABLET EMTRICITABINE/T
ENOFOVIR 
W5O NRTI 
52959096903 TRUVADA TABLET EMTRICITABINE/T
ENOFOVIR 
W5O NRTI 
54569558800 TRUVADA TABLET EMTRICITABINE/T
ENOFOVIR 
W5O NRTI 
54868514100 TRUVADA TABLET EMTRICITABINE/T
ENOFOVIR 
W5O NRTI 
55045348103 TRUVADA TABLET EMTRICITABINE/T
ENOFOVIR 
W5O NRTI 
61958070101 TRUVADA TABLET EMTRICITABINE/T
ENOFOVIR 
W5O NRTI 
00597000201 APTIVUS 100 MG/ML 
SOLUTION 
TIPRANAVIR/VITA
MIN E TPGS 
W5P PI 
00597000302 APTIVUS 250 MG 
CAPSULE 
TIPRANAVIR W5P PI 
35356011301 PREZISTA 300 MG 
TABLET 
DARUNAVIR 
ETHANOLATE 
W5P PI 
35356011330 PREZISTA 300 MG 
TABLET 
DARUNAVIR 
ETHANOLATE 
W5P PI 
35356028460 PREZISTA 600 MG 
TABLET 
DARUNAVIR 
ETHANOLATE 
W5P PI 
54569581400 PREZISTA 300 MG 
TABLET 
DARUNAVIR 
ETHANOLATE 
W5P PI 
54868563100 PREZISTA 300 MG 
TABLET 
DARUNAVIR 
ETHANOLATE 
W5P PI 
59676056001 PREZISTA 300 MG 
TABLET 
DARUNAVIR 
ETHANOLATE 
W5P PI 
59676056101 PREZISTA 400 MG 
TABLET 
DARUNAVIR 
ETHANOLATE 
W5P PI 
59676056201 PREZISTA 600 MG 
TABLET 
DARUNAVIR 
ETHANOLATE 
W5P PI 
59676056301 PREZISTA 75 MG 
TABLET 
DARUNAVIR 
ETHANOLATE 
W5P PI 
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00069080760 SELZENTRY 150 MG 
TABLET 
MARAVIROC W5T CCR5 
00069080860 SELZENTRY 300 MG 
TABLET 
MARAVIROC W5T CCR5 
35356020860 SELZENTRY 150 MG 
TABLET 
MARAVIROC W5T CCR5 
35356020960 SELZENTRY 300 MG 
TABLET 
MARAVIROC W5T CCR5 
54868580900 SELZENTRY 300 MG 
TABLET 
MARAVIROC W5T CCR5 
00006022761 ISENTRESS 400 MG 
TABLET 
RALTEGRAVIR 
POTASSIUM 
W5U INSTI 
35356011006 ISENTRESS 400 MG 
TABLET 
RALTEGRAVIR 
POTASSIUM 
W5U INSTI 
35356011060 ISENTRESS 400 MG 
TABLET 
RALTEGRAVIR 
POTASSIUM 
W5U INSTI 
54569603400 ISENTRESS 400 MG 
TABLET 
RALTEGRAVIR 
POTASSIUM 
W5U INSTI 
54868011700 ISENTRESS 400 MG 
TABLET 
RALTEGRAVIR 
POTASSIUM 
W5U INSTI 
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Appendix B: CPT Codes used to identify HIV/AIDS 
TABLE A2: Current Procedural Terminology Codes used to identify HIV/AIDS 
CPT Code CPT Label 
86359 T cells, total count 
86360 T cells, total count, absolute CD4 and CD8, including ratio 
88180 T cells, total count, absolute CD4 count 
87901 Infectious agent genotype analysis by nucleic aceid (DNA 
or RNA); HIV 1, reverse transcriptase and protease 
87903 Infectious agent phenotype analysis by nucleic acid (DNA 
or RNA); with drug resistance tissue culture analysis; HIV 
1; first through 10 drugs tested 
87904 Infectious agent phenotype analysis by nucleic acid (DNA 
or RNA); with drug resistance tissue culture analysis; HIV 
1; each additional 1 through 5 drugs tested (listed 
separately in addition to the code for the primary 
procedure) to be used in conjunction with code 87903 
0023T Infectious agent drug susceptibility phenotype prediction 
using geontypic comparison to known 
genotypic/phenotypic database, HIV 1 
87999 CCR5 Co-receptor Trofile- test is used to determine 
whether a person's HIV strains use the CCR5 or CXCR4 
co-receptors, or both, to enter CD4 T-cells. CCR5 
antagonists such as maraviroc (Selzentry) should not be 
used by people with CXCR4-tropic or dual/mixed-tropic 
virus. 
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Appendix C: International Classification of Diseases, Ninth Revision, Clinical 
Modification codes used to identify HIV/AIDS 
 
TABLE A3: International Classification of Diseases, Ninth Revision, Clinical Modification 
codes used to identify HIV/AIDS 
ICD-9-CM ICD-9-CM Label AIDS 
Defining? 
042. AIDS with specified conditions   
042.0 AIDS with specified infections (no longer assigned)   
042.1 AIDS causing other specified infections (no longer assigned)   
042.2 AIDS with specified malignant neoplasms (no longer 
assigned) 
  
042.9 AIDS, unspecified (no longer assigned)   
043. HIV infection causing other specified conditions (no longer 
assigned) 
  
043.0 HIV infection causing lymphadenopathy (no longer 
assigned) 
  
043.1 HIV infection causing specified diseases of the CNS (no 
longer assigned) 
  
043.2 HIV infection causing other disorders involving the immune 
mechanism (no longer assigned) 
  
043.3 HIV infection causing other specified conditions (no longer 
assigned) 
  
043.9 AIDS related complex, unspecified (no longer assigned)   
044. Other HIV infection (no longer assigned)   
044.9 HIV infection, unspecified (no longer assigned)   
795.8 Positive serological or viral culture findings for HIV   
795.71 Nonspecified serological evidence of HIV   
V08. Asymptomatic HIV infection status   
112.4 Candidiasis of lung Yes 
112.84 Candidiasis of esophagus Yes 
180.  Malignant neoplasm of cervic uteri Yes 
180.0 Malignant neoplasm of cervic uteri, endocervix Yes 
180.1 Malignant neoplasm of cervic uteri, exocervix Yes 
180.8 Malignant neoplasm of cervic uteri, other specified sites of 
cervix 
Yes 
180.9 Malignant neoplasm of cervic uteri, unspecified Yes 
114. Coccidioidomycosis Yes 
114.0 Primary coccidioidomycosis, pulmonary Yes 
114.1 Primary extrapulmonary coccidioidomycosis Yes 
114.2 Coccidioidal meningitis Yes 
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114.3 Other forms of coccidioidomycosis Yes 
114.4 Chronic pulmonary coccidioidomycosis Yes 
114.5 Pulmonary coccidioidomycosis, unspecified Yes 
114.9 Coccidioidomycosis, unspecified Yes 
117.5 Cryptococcosis, extrapulmonary Yes 
078.5 Cytomegalovirus disease Yes 
115. - 
115.99 
Histoplasma capsulatum Yes 
176. Kaposi's Sarcoma Yes 
176.0 Kaposi's Sarcoma, skin Yes 
176.1 Kaposi's Sarcoma, soft tissue Yes 
176.2 Kaposi's Sarcoma, palate Yes 
176.3 Kaposi's Sarcoma, gastrointestinal sites Yes 
176.4 Kaposi's Sarcoma, lung Yes 
176.5 Kaposi's Sarcoma, lymph nodes Yes 
176.8 Kaposi's Sarcoma, other specified sites Yes 
176.9 Kaposi's Sarcoma, unspecified Yes 
200.2 Burkitt's tumor or lymphoma Yes 
200.8 Lymphosarcoma and reticulosarcoma, other named variants Yes 
031.2 Diseases due to other mycobacteria, pulmonary Yes 
202.8 Other lymphoma Yes 
031.2 Mycobacterial disease, disseminated Yes 
10.0 - 18.9 Mycobacterium tuberculosis, any site (pulmonary or 
extrapulmonary) 
Yes 
136.3 Pnuemocystis carinaii pneumonia Yes 
046.3 Progressive multifocal leukoencephalopathy Yes 
130.0 Meningoencephalitis due to taxoplasmosis Yes 
799.4 Cachexia Yes 
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Appendix D: Florida county median household income, rural or urban designation, 
and Agency for Health Care Administration county codes 
 
TABLE A4: Florida county median household income, rural or urban designation, and 
Agency for Health Care Administration county codes 
County Median Income Rural  versus 
Urban 
Medicaid 
County Code 
Calhoun County  29,642 R 7 
Dixie County  31,426 R 15 
Putnam County  33,711 U 54 
Holmes County  33,868 R 30 
Highlands County  33,902 R 28 
Suwannee County  34,157 R 61 
Washington County  35,090 R 67 
Levy County  35,294 R 38 
Gadsden County  35,423 R 20 
Hamilton County  35,632 R 24 
Taylor County  35,900 R 62 
Jackson County  36,442 R 32 
Madison County  36,682 R 40 
DeSoto County  37,226 R 14 
Hendry County  37,354 R 26 
Citrus County  37,807 U 9 
Franklin County  38,436 R 19 
Gulf County  38,574 R 23 
Okeechobee County  38,643 R 47 
Hardee County  38,865 R 25 
Columbia County  39,078 R 12 
Glades County  39,260 R 22 
Alachua County  39,345 U 1 
Liberty County  39,583 R 39 
Marion County  40,306 U 42 
Bradford County  40,519 U 4 
Union County  40,694 R 63 
Sumter County  41,010 U 60 
Gilchrist County  41,048 R 21 
Hernando County  42,457 U 27 
Leon County  42,889 U 37 
Miami-Dade County  42,969 U 13 
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Escambia County  43,148 U 17 
Volusia County  43,326 U 64 
Pasco County  43,690 U 51 
Jefferson County  44,011 R 33 
Polk County  44,043 U 53 
Charlotte County  44,639 U 8 
Lake County  44,837 U 35 
Pinellas County  44,838 U 52 
Walton County  46,159 R 66 
Bay County  46,240 R 3 
Baker County  46,315 R 2 
Osceola County  46,315 U 49 
Indian River County  46,550 U 31 
Lafayette County  46,551 R 34 
St. Lucie County  46,656 U 56 
Flagler County  47,573 U 18 
Manatee County  47,935 U 41 
Sarasota County  49,013 U 58 
Brevard County  49,114 U 5 
Duval County  49,135 U 16 
Hillsborough County  49,594 U 29 
Orange County  50,352 U 48 
Lee County  50,362 U 36 
Broward County  51,731 U 6 
Wakulla County  52,353 R 65 
Martin County  52,734 U 43 
Palm Beach County  53,538 U 50 
Okaloosa County  53,741 U 46 
Santa Rosa County  54,250 U 57 
Monroe County  54,946 R 44 
Nassau County  57,907 U 45 
Collier County  58,133 U 11 
Seminole County  58,313 U 59 
Clay County  60,352 U 10 
St. Johns County  63,630 U 55 
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Appendix E: Depression, anxiety or somatoform diagnoses, alcohol abuse and/or 
substance abuse, or severe mental illness diagnoses 
 
TABLE A5: Depression, anxiety or somatoform diagnoses (DEP_ANX), alcohol abuse 
and/or substance abuse (AASA), or severe mental illness (SMI) diagnoses  
Diagnosis Category Variable ICD-9 
Schizophrenia schizophrenia SMI 295.xx 
Major depressive affective disorder, single 
episode, with psychotic behavior 
depression SMI 296.24 
Major depressive affective disorder, recurrent, 
with psychotic behavior 
depression SMI 296.34 
Manic disorder, single episode bipolar 
disorder 
SMI 296.0x 
Bipolar affective disorder, manic bipolar 
disorder 
SMI 296.4x 
Bipolar affective disorder, mixed bipolar 
disorder 
SMI 296.6x 
Bipolar affective disorder depressed bipolar 
disorder 
SMI 296.5x 
Bipolar affective disorder, unspecified bipolar 
disorder 
SMI 296.7 
Manic-depressive psychosis, other bipolar 
disorder 
SMI 296.89 
Affective personality disorder, cyclothymic 
disorder 
bipolar 
disorder 
SMI 301.13 
Manic-depressive psychosis, unspecified bipolar 
disorder 
SMI 296.8 
Organic affective syndrome bipolar 
disorder 
SMI 293.83 
Unspecified affective psychosis bipolar 
disorder 
SMI 296.90 
Major depressive affective disorder single 
episode unspecified degree 
Depression DEP_ANX 296.20 
Major depressive affective disorder single 
episode mild degree 
Depression DEP_ANX 296.21 
Major depressive affective disorder single 
episode moderate degree 
Depression DEP_ANX 296.22 
Major depressive affective disorder single 
episode severe degree without psychotic 
behavior 
Depression DEP_ANX 296.23 
Major depressive affective disorder single 
episode in partial or unspecified remission 
Depression DEP_ANX 296.25 
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Major depressive affective disorder single 
episode in full remission 
Depression DEP_ANX 296.26 
Major depressive affective disorder recurrent 
episode unspecified degree 
Depression DEP_ANX 296.30 
Major depressive affective disorder recurrent 
episode mild degree 
Depression DEP_ANX 296.31 
Major depressive affective disorder recurrent 
episode moderate degree 
Depression DEP_ANX 296.32 
Major depressive affective disorder recurrent 
episode severe degree without psychotic 
behavior 
Depression DEP_ANX 296.33 
Major depressive affective disorder recurrent 
episode in partial or unspecified remission 
Depression DEP_ANX 296.35 
Major depressive affective disorder recurrent 
episode in full remission 
Depression DEP_ANX 296.36 
Neurotic depression Depression DEP_ANX 300.4 
Depressive disorder, not elsewhere classified Depression DEP_ANX 311 
Panic disorder without agoraphobia Anxiety DEP_ANX 300.01 
Panic disorder with agoraphobia Anxiety DEP_ANX 300.21 
Agoraphobia without a history of panic 
disorder 
Anxiety DEP_ANX 300.22 
Social phobia (social anxiety disorder) Anxiety DEP_ANX 300.23 
Obsessive-compulsive disorder Anxiety DEP_ANX 300.3 
Posttraumatic stress disorder Anxiety DEP_ANX 309.81 
Acute stress disorder Anxiety DEP_ANX 308.3 
Generalized anxiety disorder Anxiety DEP_ANX 300.02 
Anxiety disorder due to general medical 
condition 
Anxiety DEP_ANX 293.89 
Anxiety disorder not otherwise specified Anxiety DEP_ANX 300.00 
Somatization disorder Somatoform 
disorders 
DEP_ANX 300.81 
Undifferentiated somatoform disorder Somatoform 
disorders 
DEP_ANX 300.82 
Other somatoform disorders Somatoform 
disorders 
DEP_ANX 300.89 
Acute alcoholic intoxication in alcoholism 
unspecified drinking behavior 
Alcohol abuse AASA 303.00 
Acute alcoholic intoxication in alcoholism 
continuous drinking behavior 
Alcohol abuse AASA 303.01 
Acute alcoholic intoxication in alcoholism 
episodic drinking behavior 
Alcohol abuse AASA 303.02 
Acute alcoholic intoxication in alcoholism in 
remission 
Alcohol abuse AASA 303.03 
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Other and unspecified alcohol dependence 
unspecified drinking behavior 
Alcohol abuse AASA 303.90 
Other and unspecified alcohol dependence 
continuous drinking behavior 
Alcohol abuse AASA 303.91 
Other and unspecified alcohol dependence 
episodic drinking behavior 
Alcohol abuse AASA 303.92 
Other and unspecified alcohol dependence in 
remission 
Alcohol abuse AASA 303.93 
Opioid type dependence unspecified use Substance 
abuse  
AASA 304.00 
Opioid type dependence continuous use Substance 
abuse  
AASA 304.01 
Opioid type dependence episodic use Substance 
abuse  
AASA 304.02 
Opioid type dependence in remission Substance 
abuse  
AASA 304.03 
sedative, hypnotic or anxiolytic dependence 
unspecified use 
Substance 
abuse  
AASA 304.10 
sedative, hypnotic or anxiolytic dependence 
continuous use 
Substance 
abuse  
AASA 304.11 
sedative, hypnotic or anxiolytic dependence 
episodic use 
Substance 
abuse  
AASA 304.12 
sedative, hypnotic or anxiolytic dependence 
in remission 
Substance 
abuse  
AASA 304.13 
Cocaine dependence unspecified use Substance 
abuse  
AASA 304.20 
Cocaine dependence continuous use Substance 
abuse  
AASA 304.21 
Cocaine dependence episodic use Substance 
abuse  
AASA 304.22 
Cocaine dependence in remission Substance 
abuse  
AASA 304.23 
Cannabis dependence unspecified use Substance 
abuse  
AASA 304.30 
Cannabis dependence continuous use Substance 
abuse  
AASA 304.31 
Cannabis dependence episodic use Substance 
abuse  
AASA 304.32 
Cannabis dependence in remission Substance 
abuse  
AASA 304.33 
Amphetamine and other psychostimulant 
dependence unspecified use 
Substance 
abuse  
AASA 304.40 
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Amphetamine and other psychostimulant 
dependence continuous use 
Substance 
abuse  
AASA 304.41 
Amphetamine and other psychostimulant 
dependence episodic use 
Substance 
abuse  
AASA 304.42 
Amphetamine and other psychostimulant 
dependence in remission 
Substance 
abuse  
AASA 304.43 
Hallucinogen dependence unspecified use Substance 
abuse  
AASA 304.50 
Hallucinogen dependence continuous use Substance 
abuse  
AASA 304.51 
Hallucinogen dependence episodic use Substance 
abuse  
AASA 304.52 
Hallucinogen dependence in remission Substance 
abuse  
AASA 304.53 
Other specified drug dependence unspecified 
use 
Substance 
abuse  
AASA 304.60 
Other specified drug dependence continuous 
use 
Substance 
abuse  
AASA 304.61 
Other specified drug dependence episodic use Substance 
abuse  
AASA 304.62 
Other specified drug dependence in remission Substance 
abuse  
AASA 304.63 
Combinations of opioid type drug with any 
other drug dependence unspecified use 
Substance 
abuse  
AASA 304.70 
Combinations of opioid type drug with any 
other drug dependence continuous use 
Substance 
abuse  
AASA 304.71 
Combinations of opioid type drug with any 
other drug dependence episodic use 
Substance 
abuse  
AASA 304.72 
Combinations of opioid type drug with any 
other drug dependence in remission 
Substance 
abuse  
AASA 304.73 
Combinations of drug dependence excluding 
opioid type drug unspecified use 
Substance 
abuse  
AASA 304.80 
Combinations of drug dependence excluding 
opioid type drug continuous use 
Substance 
abuse  
AASA 304.81 
Combinations of drug dependence excluding 
opioid type drug episodic use 
Substance 
abuse  
AASA 304.82 
Combinations of drug dependence excluding 
opioid type drug in remission 
Substance 
abuse  
AASA 304.83 
Unspecified drug dependence  Substance 
abuse  
AASA 304.90 
Unspecified drug dependence continuous use Substance 
abuse  
AASA 304.91 
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Unspecified drug dependence episodic use Substance 
abuse  
AASA 304.92 
Unspecified drug dependence in remission Substance 
abuse  
AASA 304.93 
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Appendix F: Expenditure-predictive diagnosis groups and key comorbidities 
TABLE A6: Expenditure-predictive diagnosis groups and key comorbidities among 
previously ART naïve Medicaid-insured PLWHA (n=502) 
  Diagnosis Dx  ICD-9 Freq % 
COM1 Acute poliomyelitis 1 045 0 0.0% 
COM2 Viral hepatitis 1 070 75 14.9% 
COM3 Congenital syphilis 1 090 0 0.0% 
COM4 Early syphilis, symptomatic 1 091 0 0.0% 
COM5 Early syphilis, latent 1 092 0 0.0% 
COM6 Cardiovascular syphilis 1 093 0 0.0% 
COM7 Neurosyphilis 1 094 0 0.0% 
COM8 Other forms of late syphilis, with 
symptoms 
1 095 0 0.0% 
COM9 Late syphilis, latent 1 096 0 0.0% 
COM10 Other and unspecified syphilis 1 097 22 4.4% 
COM11 Toxoplasmosis 1 130 4 0.8% 
COM12 Nutritional Deficiencies 1 260-269 27 5.4% 
COM13 Disorders of fluid, electrolyte, and 
acid-base balance 
1 276 87 17.3% 
COM14 Chorioretinal inflammations, scars, 
and other disorders of choroid 
1 728 32 6.4% 
COM15 Symptoms concerning nutrition, 
metabolism, and development 
1 783 40 8.0% 
COM16 Cachexia / Wasting Disease 1 799.4 32 6.4% 
COM17 Hypertensive renal disease 1 403,404 23 4.6% 
COM18 Acute and chronic renal failure 1 584-588 67 13.3% 
COM19 Acute and subacute endocarditis 1 421 3 0.6% 
COM20 Symptoms involving digestive 
system 
1 787 185 36.9% 
COM21 Diseases due to other mycobacteria 2 031 0 0.0% 
COM22 Cryptococcosis 2 117.5 3 0.6% 
COM23 Pneumocystosis 2 136.3 20 4.0% 
COM24 Aplastic anemia 2 284 25 5.0% 
COM25 Purpura and other hemorrhagic 
conditions 
2 287 25 5.0% 
COM26 Diseases of white blood cells 2 288 58 11.6% 
COM27 Mental Retardation 2 317,318,319 4 0.8% 
COM28 Bacterial meningitis 2 320 1 0.2% 
COM29 Other cerebral degenerations 2 321 0 0.0% 
COM30 Meningitis of unspecified cause 2 322 2 0.4% 
COM31 Other cerebral degenerations 2 331 9 1.8% 
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COM32 Chorioretinal inflammations, scars, 
and other disorders of choroid 
2 363 15 3.0% 
COM33 Other diseases of pericardium 2 423 5 1.0% 
COM34 Acute, but ill-defined, 
cerebrovascular disease 
2 436 20 4.0% 
COM35 Viral pneumonia 2 480 6 1.2% 
COM36 Pneumococcal pneumonia  2 481 14 2.8% 
COM37 Other bacterial pneumonia 2 482 15 3.0% 
COM38 Pneumonia due to other specified 
organism 
2 483 3 0.6% 
COM39 Bronchopneumonia, organism 
unspecified 
 485 0 0.0% 
COM40 Pneumonia, organism unspecified 2 486 109 21.7% 
COM41 Pneumonia, organism unspecified 2 492 12 2.4% 
COM42 Emphysema 2 511 31 6.2% 
COM43 Pleurisy 2 518 90 17.9% 
COM44 Other diseases of the lung 2 578 42 8.4% 
COM45 Gastrointestinal hemorrhage 2 648 30 6.0% 
COM46 Other conditions in the mother 
complicating pregnancy 
2 707 20 4.0% 
COM47 Chronic ulcer of skin 2 781 33 6.6% 
COM48 Symptoms involving nervous and 
musculoskeletal systems 
3 046.3 2 0.4% 
COM49 Progressive multifocal 
leukoencephalopathy 
3 348.3 18 3.6% 
COM50 Unspecified encephalopathy 3 416.0 10 2.0% 
COM51 Primary pulmonary hypertension 3 428 35 7.0% 
COM52 Heart failure 3 512 4 0.8% 
COM53 Pneumothorax 3 514 18 3.6% 
COM54 Pulmonary congestion and 
hypostasis 
3 516 3 0.6% 
COM55 Other alveolar and parietoalveolar 
pneumonopathy 
3 560 18 3.6% 
COM56 Intestinal obstruction without 
mention of hernia 
3 730 10 2.0% 
COM57 Septicemia 4 038 33 6.6% 
COM58 Cytomegaloviral disease 4 078.5,484, 
573.1 
12 2.4% 
COM59 Malignant neoplasm of trachea, 
bronchus, and lung 
4 162 2 0.4% 
COM60 Intracranial and intraspinal abscess 4 324 2 0.4% 
COM61 Epilepsy 4 345 35 7.0% 
COM62 Inflammatory and toxic neuropathy 4 357 19 3.8% 
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COM63 Subarachnoid hemorrhage 4 430 3 0.6% 
COM64 Intracerebral hemorrhage 4 431 3 0.6% 
COM65 Bronchiectasis 4 494 1 0.2% 
COM66 Peritonitis 4 567 4 0.8% 
COM67 Hydronephrosis 4 591 9 1.8% 
COM69 Histoplasmosis 5 115 1 0.2% 
COM70 Lymphoid leukemia 5 204-206, 208 2 0.4% 
COM71 Diabetes with renal manifestations 5 250.4 11 2.2% 
COM72 Coagulation defects 5 286 12 2.4% 
COM73 Other paralytic syndromes 5 344 6 1.2% 
COM76 Polyarteritis nodosa and allied 
conditions 
5 446 1 0.2% 
COM77 Lymphosarcoma and 
reticulosarcoma 
6 200 4 0.8% 
Key comorbidities and diagnosis groups defined by Fakhraei, S.H., Kaelin, J.J., & 
Consiver, R. (2001). Comorbidity-Based Payment Methodology for Medicaid 
Enrollees with HIV/AIDS. Health Care Financing Review, 23(2), 53–69. 
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Appendix G: Institutional Review Board Approvals 
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